tetraphene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	tetraphene	go back to main search page
Accession:	CHEBI:51348	browse the term
Definition:	An angular ortho-fused polycyclic arene consisting of four fused benzene rings.
Synonyms:	related_synonym:	1,2-Benzanthracene; 1,2-Benzanthrazen; 2,3-benzphenanthrene; Benz[a]anthracene; Formula=C18H12; InChI=1S/C18H12/c1-2-7-15-12-18-16(11-14(15)6-1)10-9-13-5-3-4-8-17(13)18/h1-12H; InChIKey=DXBHBZVCASKNBY-UHFFFAOYSA-N; SMILES=c1ccc2cc3c(ccc4ccccc34)cc2c1; benzanthrene; naphthanthracene
	alt_id:	CHEBI:33088; CHEBI:34557
	xref:	Beilstein:1909298; CAS:56-55-3; Gmelin:244702; KEGG:C14317
	xref_mesh:	MESH:C030935
	xref:	PMID:25528193; PMID:25528488; PMID:26720419; PMID:7561049; Patent:DE481819; Patent:DE486766; Reaxys:1909298; Wikipedia:Tetraphene

show annotations for term's descendants Sort by:
Rat (1218) Mouse (1323) Human (1247) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1323)

tetraphene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

APOBEC1 complementation factor

decreases expression

benz(a)anthracene results in decreased expression of A1CF mRNA

NCBI chr19:31,846,156...31,929,765
Ensembl chr19:31,846,164...31,926,395

G

achalasia, adrenocortical insufficiency, alacrimia

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA

NCBI chr15:102,246,682...102,259,194
Ensembl chr15:102,246,687...102,259,206

G

aminoadipate-semialdehyde dehydrogenase

affects expression

benz(a)anthracene affects the expression of AASDH mRNA

NCBI chr 5:77,021,506...77,053,376
Ensembl chr 5:77,021,506...77,053,361

G

apoptosis-associated tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of AATK mRNA

NCBI chr11:119,898,137...119,938,009
Ensembl chr11:119,898,139...119,937,993

G

ATP-binding cassette, sub-family C member 3

increases expression

benz(a)anthracene results in increased expression of ABCC3 mRNA

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 5

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ABCC5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family C member 9

decreases expression

benz(a)anthracene results in decreased expression of ABCC9 mRNA

NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041

G

abhydrolase domain containing 15

increases expression

benz(a)anthracene results in increased expression of ABHD15 mRNA

NCBI chr11:77,405,943...77,411,454
Ensembl chr11:77,405,947...77,429,433

G

abhydrolase domain containing 6

increases expression

benz(a)anthracene results in increased expression of ABHD6 mRNA

NCBI chr14:14,413,000...14,466,885
Ensembl chr14:14,413,010...14,466,871

G

ABI family member 3 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA

NCBI chr16:56,298,179...56,510,498
Ensembl chr16:56,298,241...56,510,498

G

actin-binding LIM protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA

NCBI chr19:57,021,165...57,303,776
Ensembl chr19:57,021,165...57,303,351

G

BRISC complex subunit

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ABRAXAS2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:132,460,954...132,486,843
Ensembl chr 7:132,460,954...132,486,840

G

1-aminocyclopropane-1-carboxylate synthase (inactive)

increases expression

benz(a)anthracene results in increased expression of ACCS mRNA

NCBI chr 2:93,663,812...93,680,343
Ensembl chr 2:93,663,812...93,680,288

G

apoptotic chromatin condensation inducer 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ACIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:54,879,618...54,924,422
Ensembl chr14:54,879,618...54,924,388

G

acyl-coenzyme A amino acid N-acyltransferase 2

decreases expression

benz(a)anthracene results in decreased expression of ACNAT2 mRNA

NCBI chr 4:49,374,458...49,408,151
Ensembl chr 4:49,379,840...49,408,151

G

acyl-CoA thioesterase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA

NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145

G

acyl-Coenzyme A oxidase 1, palmitoyl

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ACOX1 mRNA; benz(a)anthracene results in increased expression of ACOX1 protein
benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]

NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871

G

acyl-Coenzyme A oxidase-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ACOXL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:127,680,717...127,968,172
Ensembl chr 2:127,680,796...127,965,793

G

proacrosin binding protein

affects expression

benz(a)anthracene affects the expression of ACRBP mRNA

NCBI chr 6:125,026,890...125,040,228
Ensembl chr 6:125,026,652...125,040,230

G

activin A receptor, type 1B

increases expression

benz(a)anthracene results in increased expression of ACVR1B mRNA

NCBI chr15:101,071,953...101,111,565
Ensembl chr15:101,071,948...101,111,565

G

a disintegrin and metallopeptidase domain 22

increases expression

benz(a)anthracene results in increased expression of ADAM22 mRNA

NCBI chr 5:8,122,353...8,418,312
Ensembl chr 5:8,122,352...8,418,160

G

ADAM-like, decysin 1

increases expression

benz(a)anthracene results in increased expression of ADAMDEC1 mRNA

NCBI chr14:68,800,829...68,819,535
Ensembl chr14:68,800,829...68,819,544

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:61,032,886...61,109,447
Ensembl chr10:61,032,891...61,109,217

G

adenylate cyclase 7

increases expression

benz(a)anthracene results in increased expression of ADCY7 mRNA

NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590

G

adducin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA

NCBI chr19:53,128,874...53,235,518
Ensembl chr19:53,128,874...53,235,830

G

adhesion G protein-coupled receptor E4

increases expression

benz(a)anthracene results in increased expression of ADGRE4 mRNA

NCBI chr17:56,056,984...56,160,662
Ensembl chr17:56,056,984...56,160,662

G

adhesion G protein-coupled receptor L4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA

NCBI chr 3:151,143,519...151,250,718
Ensembl chr 3:151,143,524...151,250,723

G

adrenomedullin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ADM mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adenosine A1 receptor

increases expression

benz(a)anthracene results in increased expression of ADORA1 mRNA

NCBI chr 1:134,126,953...134,163,195
Ensembl chr 1:134,126,963...134,163,169

G

adrenergic receptor, alpha 1b

decreases expression

benz(a)anthracene results in decreased expression of ADRA1B mRNA

NCBI chr11:43,665,432...43,792,076
Ensembl chr11:43,665,433...43,792,037

G

adrenergic receptor, beta 3

affects expression

benz(a)anthracene affects the expression of ADRB3 mRNA

NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644

G

apoptosis enhancing nuclease

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA

NCBI chr 7:78,545,675...78,560,957
Ensembl chr 7:78,545,602...78,560,957

G

ATP/GTP binding protein-like 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AGBL2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:90,613,029...90,664,781
Ensembl chr 2:90,613,071...90,664,781

G

argonaute RISC catalytic subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA

NCBI chr15:72,967,693...73,056,777
Ensembl chr15:72,967,693...73,056,784

G

argonaute RISC catalytic subunit 4

decreases expression

benz(a)anthracene results in decreased expression of AGO4 mRNA

NCBI chr 4:126,383,280...126,427,379
Ensembl chr 4:126,383,334...126,427,265

G

agouti related neuropeptide

increases expression

benz(a)anthracene results in increased expression of AGRP mRNA

NCBI chr 8:106,293,327...106,306,477
Ensembl chr 8:106,293,330...106,364,025

G

angiotensin II receptor, type 1a

increases expression

benz(a)anthracene results in increased expression of AGTR1A mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

S-adenosylhomocysteine hydrolase-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA

NCBI chr 6:29,768,378...29,912,309
Ensembl chr 6:29,768,010...29,912,309

G

AHNAK nucleoprotein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of AHNAK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA

PMID:26377693 PMID:27858113

NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278

G

AHNAK nucleoprotein 2

decreases expression

benz(a)anthracene results in decreased expression of AHNAK2 mRNA

NCBI chr12:112,738,631...112,766,278
Ensembl chr12:112,738,628...112,766,277

G

aryl-hydrocarbon receptor

affects response to substance
affects binding
increases activity
multiple interactions
increases response to substance

AHR affects the susceptibility to benz(a)anthracene
benz(a)anthracene binds to AHR protein
benz(a)anthracene results in increased activity of AHR protein
AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]
AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]
[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene co-treated with pyrene] results in increased activity of AHR protein; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with TNF protein] results in increased activity of AHR protein; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]
AHR results in increased susceptibility to benz(a)anthracene

PMID:1650214 PMID:1654865 PMID:1658612 PMID:2154949 PMID:3005314 More...

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aryl-hydrocarbon receptor repressor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AHRR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA

PMID:26377693 PMID:27858113

NCBI chr13:74,359,237...74,440,450
Ensembl chr13:74,359,237...74,440,450

G

allograft inflammatory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

apoptosis-inducing factor, mitochondrion-associated 3

increases expression

benz(a)anthracene results in increased expression of AIFM3 mRNA

NCBI chr16:17,307,418...17,325,349
Ensembl chr16:17,307,475...17,325,349

G

A kinase anchor protein 13

decreases expression

benz(a)anthracene results in decreased expression of AKAP13 mRNA

NCBI chr 7:75,105,271...75,404,357
Ensembl chr 7:75,105,282...75,404,357

G

A kinase anchor protein 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA

NCBI chr10:25,044,988...25,175,115
Ensembl chr10:25,044,988...25,183,768

G

A kinase anchor protein 8

increases expression

benz(a)anthracene results in increased expression of AKAP8 mRNA

NCBI chr17:32,522,646...32,540,212
Ensembl chr17:32,522,646...32,540,212

G

A kinase anchor protein 8-like

increases expression

benz(a)anthracene results in increased expression of AKAP8L mRNA

NCBI chr17:32,540,398...32,569,589
Ensembl chr17:32,540,398...32,569,581

G

aldo-keto reductase family 1, member B10

increases expression

benz(a)anthracene results in increased expression of AKR1B10 mRNA

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

aldo-keto reductase family 1, member C18

increases expression

benz(a)anthracene results in increased expression of AKR1C3 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldehyde dehydrogenase 1 family, member L1

decreases expression

benz(a)anthracene results in decreased expression of ALDH1L1 mRNA

NCBI chr 6:90,527,751...90,576,153
Ensembl chr 6:90,463,409...90,577,185

G

aldehyde dehydrogenase family 3, subfamily A1

increases expression

benz(a)anthracene results in increased expression of ALDH3A1 mRNA

NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247

G

ALG6 alpha-1,3-glucosyltransferase

increases expression

benz(a)anthracene results in increased expression of ALG6 mRNA

NCBI chr 4:99,603,833...99,651,697
Ensembl chr 4:99,603,901...99,651,697

G

ALK and LTK ligand 1

increases expression

benz(a)anthracene results in increased expression of ALKAL1 mRNA

NCBI chr 1:6,429,555...6,464,955
Ensembl chr 1:6,429,442...6,464,955

G

arachidonate 12-lipoxygenase

increases expression

benz(a)anthracene results in increased expression of ALOX12 mRNA

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 5-lipoxygenase

increases expression

benz(a)anthracene results in increased expression of ALOX5 mRNA

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

alkaline phosphatase, liver/bone/kidney

increases expression

benz(a)anthracene results in increased expression of ALPL mRNA

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

ALS2 C-terminal like

affects expression

benz(a)anthracene affects the expression of ALS2CL mRNA

NCBI chr 9:110,709,203...110,729,598
Ensembl chr 9:110,708,938...110,729,598

G

amidohydrolase domain containing 2

increases expression

benz(a)anthracene results in increased expression of AMDHD2 mRNA

NCBI chr17:24,374,807...24,382,752
Ensembl chr17:24,374,807...24,382,740

G

angiopoietin 2

increases expression

benz(a)anthracene results in increased expression of ANGPT2 mRNA

NCBI chr 8:18,740,279...18,791,578
Ensembl chr 8:18,740,279...18,791,578

G

angiopoietin-like 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

ankyrin 3, epithelial

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA

NCBI chr10:69,234,608...69,863,266
Ensembl chr10:69,234,603...69,863,268

G

ankyrin repeat domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA

NCBI chr17:66,272,698...66,386,242
Ensembl chr17:66,272,693...66,384,084

G

ankyrin repeat domain 16

affects expression

benz(a)anthracene affects the expression of ANKRD16 mRNA

NCBI chr 2:11,781,902...11,795,138
Ensembl chr 2:11,782,687...11,795,140

G

ankyrin repeat and zinc finger domain containing 1

increases expression

benz(a)anthracene results in increased expression of ANKZF1 mRNA

NCBI chr 1:75,168,794...75,176,031
Ensembl chr 1:75,168,795...75,176,031

G

acidic nuclear phosphoprotein 32 family member A

increases expression

benz(a)anthracene results in increased expression of ANP32A mRNA

NCBI chr 9:62,248,637...62,286,084
Ensembl chr 9:62,248,575...62,286,094

G

alanyl aminopeptidase, membrane

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA

NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807

G

annexin A10

increases expression

benz(a)anthracene results in increased expression of ANXA10 mRNA

NCBI chr 8:62,510,076...62,576,227
Ensembl chr 8:62,510,076...62,576,184

G

adaptor-related protein 5 complex, sigma 1 subunit

increases expression

benz(a)anthracene results in increased expression of AP5S1 mRNA

NCBI chr 2:131,052,280...131,055,434
Ensembl chr 2:131,048,998...131,055,434

G

adaptor-related protein complex 5, zeta 1 subunit

affects expression

benz(a)anthracene affects the expression of AP5Z1 mRNA

NCBI chr 5:142,448,960...142,464,471
Ensembl chr 5:142,449,699...142,464,465

G

amyloid beta precursor protein binding family B member 3

affects expression

benz(a)anthracene affects the expression of APBB3 mRNA

NCBI chr18:36,804,207...36,812,419
Ensembl chr18:36,804,207...36,812,419

G

apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3

increases expression

benz(a)anthracene results in increased expression of APOBEC3 mRNA

NCBI chr15:79,774,620...79,802,419
Ensembl chr15:79,775,860...79,800,107

G

apolipoprotein L 11b

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of APOL11B mRNA

NCBI chr15:77,518,151...77,527,486
Ensembl chr15:77,518,146...77,527,486

G

apolipoprotein L 9a

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of APOL9A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA

PMID:26377693 PMID:27858113

NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335

G

apolipoprotein L 9b

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of APOL9B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9B mRNA

PMID:26377693 PMID:27858113

NCBI chr15:77,613,248...77,620,582
Ensembl chr15:77,613,239...77,620,582

G

adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2

increases expression

benz(a)anthracene results in increased expression of APPL2 mRNA

NCBI chr10:83,435,897...83,484,741
Ensembl chr10:83,435,897...83,484,602

G

aquaporin 4

decreases expression

benz(a)anthracene results in decreased expression of AQP4 mRNA

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

androgen receptor

increases activity
multiple interactions

benz(a)anthracene results in increased activity of AR protein
benz(a)anthracene binds to and results in decreased activity of AR protein; benz(a)anthracene inhibits the reaction [Androgens results in increased activity of AR protein]

PMID:10771140 PMID:28377212

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

decreases expression

benz(a)anthracene results in decreased expression of ARAP2 mRNA

NCBI chr 5:62,759,788...62,923,874
Ensembl chr 5:62,759,788...62,923,502

G

amphiregulin

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AREG mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA
bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA]

PMID:22643241 PMID:27858113

NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291

G

arginine and glutamate rich 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ARGLU1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:8,716,307...8,741,818
Ensembl chr 8:8,715,075...8,740,521

G

Rho GTPase activating protein 20

decreases expression

benz(a)anthracene results in decreased expression of ARHGAP20 mRNA

NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156

G

Rho GTPase activating protein 23

decreases expression

benz(a)anthracene results in decreased expression of ARHGAP23 mRNA

NCBI chr11:97,295,183...97,393,228
Ensembl chr11:97,306,359...97,393,228

G

Rho GTPase activating protein 4

increases expression

benz(a)anthracene results in increased expression of ARHGAP4 mRNA

NCBI chr X:72,937,958...72,954,945
Ensembl chr X:72,935,048...72,965,476

G

Rho GTPase activating protein 45

increases expression

benz(a)anthracene results in increased expression of ARHGAP45 mRNA

NCBI chr10:79,852,505...79,867,305
Ensembl chr10:79,852,487...79,867,306

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA

NCBI chr 3:132,818,039...132,940,710
Ensembl chr 3:132,818,039...132,940,710

G

Rho guanine nucleotide exchange factor 40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA

NCBI chr14:52,222,158...52,243,704
Ensembl chr14:52,222,176...52,243,708

G

AT-rich interaction domain 4A

decreases expression

benz(a)anthracene results in decreased expression of ARID4A mRNA

NCBI chr12:71,061,314...71,146,125
Ensembl chr12:71,062,764...71,145,366

G

ariadne RBR E3 ubiquitin protein ligase 2

increases expression

benz(a)anthracene results in increased expression of ARIH2 mRNA

NCBI chr 9:108,480,141...108,531,917
Ensembl chr 9:108,480,141...108,526,585

G

ADP-ribosylation factor-like 5C

increases expression

benz(a)anthracene results in increased expression of ARL5C mRNA

NCBI chr11:97,880,404...97,887,109
Ensembl chr11:97,880,404...97,887,007

G

armadillo repeat containing 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA

NCBI chr 8:70,672,822...70,687,099
Ensembl chr 8:70,672,822...70,687,116

G

arrestin domain containing 2

affects expression

benz(a)anthracene affects the expression of ARRDC2 mRNA

NCBI chr 8:71,287,773...71,293,173
Ensembl chr 8:71,287,773...71,292,364

G

arrestin domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA

NCBI chr 7:68,386,742...68,398,986
Ensembl chr 7:68,386,743...68,398,989

G

ADP-ribosyltransferase 4

increases expression

benz(a)anthracene results in increased expression of ART4 mRNA

NCBI chr 6:136,825,449...136,834,598
Ensembl chr 6:136,825,449...136,834,731

G

adipocyte-related X-chromosome expressed sequence 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARXES2 mRNA

NCBI chr X:134,894,569...134,896,108
Ensembl chr X:134,894,573...134,896,104

G

activating signal cointegrator 1 complex subunit 3

decreases expression

benz(a)anthracene results in decreased expression of ASCC3 mRNA

NCBI chr10:50,468,756...50,727,300
Ensembl chr10:50,468,765...50,727,581

G

asialoglycoprotein receptor 1

decreases expression

benz(a)anthracene results in decreased expression of ASGR1 mRNA

NCBI chr11:69,939,735...69,948,721
Ensembl chr11:69,944,911...69,948,720

G

asialoglycoprotein receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA

NCBI chr11:69,983,470...69,997,013
Ensembl chr11:69,983,470...69,997,013

G

aspartate-beta-hydroxylase

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ASPH mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:9,449,085...9,669,344
Ensembl chr 4:9,448,069...9,669,344

G

ATPase family, AAA domain containing 2B

decreases expression

benz(a)anthracene results in decreased expression of ATAD2B mRNA

NCBI chr12:4,964,404...5,097,396
Ensembl chr12:4,967,353...5,097,394

G

autophagy related 16 like 2

affects expression

benz(a)anthracene affects the expression of ATG16L2 mRNA

NCBI chr 7:100,935,521...100,951,474
Ensembl chr 7:100,912,241...100,951,458

G

atos homolog A

increases expression

benz(a)anthracene results in increased expression of ATOSA mRNA

NCBI chr 9:74,860,162...74,939,750
Ensembl chr 9:74,860,151...74,939,746

G

ATPase, class VI, type 11A

increases expression

benz(a)anthracene results in increased expression of ATP11A mRNA

NCBI chr 8:12,807,016...12,918,728
Ensembl chr 8:12,807,014...12,918,728

G

ATPase type 13A3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA

NCBI chr16:30,131,241...30,207,674
Ensembl chr16:30,131,241...30,224,793

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ATP2A2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

ATPase, H+ transporting, lysosomal V0 subunit E2

decreases expression

benz(a)anthracene results in decreased expression of ATP6V0E2 mRNA

NCBI chr 6:48,514,503...48,518,735
Ensembl chr 6:48,514,549...48,518,735

G

arginine vasopressin receptor 1A

decreases expression

benz(a)anthracene results in decreased expression of AVPR1A mRNA

NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357

G

antizyme inhibitor 1

affects expression

benz(a)anthracene affects the expression of AZIN1 mRNA

NCBI chr15:38,487,674...38,523,506
Ensembl chr15:38,487,671...38,519,510

G

UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA

NCBI chr 4:40,804,602...40,855,711
Ensembl chr 4:40,804,602...40,854,005

G

UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5

decreases expression

benz(a)anthracene results in decreased expression of B4GALT5 mRNA

NCBI chr 2:167,140,364...167,191,155
Ensembl chr 2:167,140,364...167,191,103

G

bile acid-Coenzyme A: amino acid N-acyltransferase

decreases expression

benz(a)anthracene results in decreased expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BTB and CNC homology, basic leucine zipper transcription factor 2

increases expression

benz(a)anthracene results in increased expression of BACH2 mRNA

NCBI chr 4:32,238,413...32,586,109
Ensembl chr 4:32,238,804...32,586,108

G

BCL2-associated athanogene 3

decreases expression

benz(a)anthracene results in decreased expression of BAG3 mRNA

NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705

G

B cell scaffold protein with ankyrin repeats 1

increases expression

benz(a)anthracene results in increased expression of BANK1 mRNA

NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827

G

BTG3 associated nuclear protein

decreases expression

benz(a)anthracene results in decreased expression of BANP mRNA

NCBI chr 8:122,674,711...122,755,999
Ensembl chr 8:122,676,489...122,755,997

G

basic leucine zipper transcription factor, ATF-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA

NCBI chr12:85,733,494...85,755,861
Ensembl chr12:85,733,443...85,755,861

G

BCL2-associated X protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

BCL2 like 14

increases expression

benz(a)anthracene results in increased expression of BCL2L14 mRNA

NCBI chr 6:134,373,292...134,415,687
Ensembl chr 6:134,373,281...134,415,699

G

B cell leukemia/lymphoma 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

B cell CLL/lymphoma 6, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA

NCBI chr11:70,114,953...70,120,624
Ensembl chr11:70,114,954...70,120,624

G

B cell CLL/lymphoma 7B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA

NCBI chr 5:135,197,226...135,210,706
Ensembl chr 5:135,197,137...135,210,709

G

BCL2-associated transcription factor 1

increases expression

benz(a)anthracene results in increased expression of BCLAF1 mRNA

NCBI chr10:20,187,897...20,218,390
Ensembl chr10:20,188,215...20,220,359

G

BEN domain containing 3

increases expression

benz(a)anthracene results in increased expression of BEND3 mRNA

NCBI chr10:43,355,130...43,391,413
Ensembl chr10:43,354,827...43,391,392

G

beaded filament structural protein 2, phakinin

increases expression

benz(a)anthracene results in increased expression of BFSP2 mRNA

NCBI chr 9:103,302,123...103,357,608
Ensembl chr 9:103,302,123...103,357,619

G

basic helix-loop-helix family, member e40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA

NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886

G

baculoviral IAP repeat-containing 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

biogenesis of lysosomal organelles complex-1, subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA

NCBI chr19:44,127,685...44,134,909
Ensembl chr19:44,127,685...44,134,885

G

basic helix-loop-helix ARNT like 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of BMAL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333

G

BCL2 modifying factor

increases expression

benz(a)anthracene results in increased expression of BMF mRNA

NCBI chr 2:118,359,238...118,385,240
Ensembl chr 2:118,359,238...118,380,168

G

bone morphogenetic protein 7

decreases expression

benz(a)anthracene results in decreased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

bone morphogenetic protein receptor type 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

BMX non-receptor tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of BMX mRNA

NCBI chr X:162,975,838...163,041,189
Ensembl chr X:162,975,838...163,041,189

G

bromodomain and WD repeat domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of BRWD1 mRNA

NCBI chr16:95,793,289...95,883,905
Ensembl chr16:95,793,292...95,883,726

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA

NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047

G

BTG anti-proliferation factor 1

decreases expression

benz(a)anthracene results in decreased expression of BTG1 mRNA

NCBI chr10:96,452,863...96,458,675
Ensembl chr10:96,452,868...96,458,671

G

BTG anti-proliferation factor 2

increases expression

benz(a)anthracene results in increased expression of BTG2 mRNA

NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858

G

B and T lymphocyte associated

increases expression
multiple interactions

benz(a)anthracene results in increased expression of BTLA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA

PMID:26377693 PMID:27858113

NCBI chr16:45,043,121...45,073,258
Ensembl chr16:45,044,678...45,078,033

G

complement C2

decreases expression

benz(a)anthracene results in decreased expression of C2 mRNA

NCBI chr17:35,081,578...35,101,076
Ensembl chr17:35,081,580...35,117,241

G

C2 calcium-dependent domain containing 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of C2CD3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:100,021,440...100,119,366
Ensembl chr 7:100,021,440...100,119,359

G

complement component 5a receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA

NCBI chr 7:15,968,512...15,978,079
Ensembl chr 7:15,968,510...15,978,079

G

complement component 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA

NCBI chr15:5,017,232...5,093,230
Ensembl chr15:5,018,244...5,093,222

G

calcium binding protein 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA

NCBI chr 7:13,119,885...13,142,812
Ensembl chr 7:13,132,057...13,142,812

G

calcium channel, voltage-dependent, alpha 1I subunit

increases expression

benz(a)anthracene results in increased expression of CACNA1I mRNA

NCBI chr15:80,171,439...80,282,493
Ensembl chr15:80,171,439...80,282,480

G

calcyclin binding protein

decreases expression

benz(a)anthracene results in decreased expression of CACYBP mRNA

NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445

G

calcitonin receptor

increases expression

benz(a)anthracene results in increased expression of CALCR mRNA

NCBI chr 6:3,685,678...3,764,713
Ensembl chr 6:3,685,680...3,764,714

G

calcium/calmodulin-dependent protein kinase II gamma

increases expression

benz(a)anthracene results in increased expression of CAMK2G mRNA

NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156

G

calpain 11

increases expression

benz(a)anthracene results in increased expression of CAPN11 mRNA

NCBI chr17:45,941,117...45,970,400
Ensembl chr17:45,941,130...45,970,251

G

calcyphosphine 2

increases expression

benz(a)anthracene results in increased expression of CAPS2 mRNA

NCBI chr10:111,999,254...112,052,466
Ensembl chr10:111,999,526...112,052,460

G

carbonic anhydrase 14

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CAR14 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:95,805,080...95,812,443
Ensembl chr 3:95,805,080...95,812,003

G

caspase recruitment domain family, member 11

increases expression

benz(a)anthracene results in increased expression of CARD11 mRNA

NCBI chr 5:140,858,109...140,986,398
Ensembl chr 5:140,858,745...140,986,337

G

caveolin 1, caveolae protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

CBFA2/RUNX1 translocation partner 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA

NCBI chr 8:123,351,875...123,426,069
Ensembl chr 8:123,351,880...123,425,848

G

collagen and calcium binding EGF domains 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA

NCBI chr18:66,189,926...66,424,909
Ensembl chr18:66,178,373...66,435,812

G

coiled-coil domain containing 121

increases expression

benz(a)anthracene results in increased expression of CCDC121 mRNA

NCBI chr 5:31,643,205...31,645,820
Ensembl chr 5:31,643,084...31,645,820

G

coiled-coil domain containing 184

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA

NCBI chr15:98,065,687...98,068,015
Ensembl chr15:98,065,039...98,068,015

G

coiled coil domain containing 28B

increases expression

benz(a)anthracene results in increased expression of CCDC28B mRNA

NCBI chr 4:129,513,067...129,517,820
Ensembl chr 4:129,513,067...129,517,740

G

coiled-coil domain containing 30

increases expression

benz(a)anthracene results in increased expression of CCDC30 mRNA

NCBI chr 4:119,179,665...119,272,718
Ensembl chr 4:119,179,663...119,272,718

G

coiled-coil domain containing 39

increases expression

benz(a)anthracene results in increased expression of CCDC39 mRNA

NCBI chr 3:33,864,906...33,898,473
Ensembl chr 3:33,866,511...33,898,459

G

coiled-coil domain containing 68

affects expression

benz(a)anthracene affects the expression of CCDC68 mRNA

NCBI chr18:70,057,929...70,102,559
Ensembl chr18:70,058,497...70,102,555

G

coiled-coil domain containing 78

increases expression

benz(a)anthracene results in increased expression of CCDC78 mRNA

NCBI chr17:26,005,554...26,009,487
Ensembl chr17:26,005,554...26,009,487

G

coiled-coil domain containing 81

increases expression

benz(a)anthracene results in increased expression of CCDC81 mRNA

NCBI chr 7:89,515,356...89,552,837
Ensembl chr 7:89,515,356...89,552,837

G

coiled-coil domain containing 82

increases expression

benz(a)anthracene results in increased expression of CCDC82 mRNA

NCBI chr 9:13,246,573...13,292,867
Ensembl chr 9:13,246,536...13,292,867

G

C-C motif chemokine ligand 11

increases expression

benz(a)anthracene results in increased expression of CCL11 mRNA

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 2

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 27A

decreases expression

benz(a)anthracene results in decreased expression of CCL27A mRNA

NCBI chr 4:41,769,467...41,774,251
Ensembl chr 4:41,769,467...41,774,247

G

C-C motif chemokine ligand 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine ligand 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

cerebral cavernous malformation 2-like

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CCM2L mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:152,907,857...152,923,655
Ensembl chr 2:152,907,875...152,923,655

G

cyclin A2

multiple interactions
increases expression

AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein]

NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299

G

cyclin D1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin D2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA

NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156

G

cyclin G1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA

NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138

G

cyclin J-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CCNJL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA

PMID:26377693 PMID:27858113

NCBI chr11:43,419,576...43,477,826
Ensembl chr11:43,419,611...43,477,824

G

cyclin L1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CCNL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:65,853,333...65,869,451
Ensembl chr 3:65,853,572...65,865,670

G

cyclin L2

affects expression

benz(a)anthracene affects the expression of CCNL2 mRNA

NCBI chr 4:155,894,468...155,909,005
Ensembl chr 4:155,896,946...155,909,000

G

C-C motif chemokine receptor 3

increases expression

benz(a)anthracene results in increased expression of CCR3 mRNA

NCBI chr 9:123,817,799...123,831,729
Ensembl chr 9:123,822,009...123,831,726

G

C-C motif chemokine receptor 6

increases expression

benz(a)anthracene results in increased expression of CCR6 mRNA

NCBI chr17:8,454,875...8,477,353
Ensembl chr17:8,454,875...8,475,973

G

C-C motif chemokine receptor 7

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CCR7 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

CD151 antigen

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD151 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386

G

CD19 antigen

increases expression

benz(a)anthracene results in increased expression of CD19 mRNA

NCBI chr 7:126,007,620...126,016,401
Ensembl chr 7:126,007,622...126,014,061

G

CD200 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA

NCBI chr16:45,202,474...45,229,419
Ensembl chr16:45,202,498...45,229,416

G

CD209c antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD209C mRNA

NCBI chr 8:3,990,081...4,004,746
Ensembl chr 8:3,990,222...4,004,746

G

CD300C molecule 2

increases expression

benz(a)anthracene results in increased expression of CD300C2 mRNA

NCBI chr11:114,887,595...114,892,706
Ensembl chr11:114,887,547...114,895,058

G

CD300 molecule like family member F

increases expression

benz(a)anthracene results in increased expression of CD300LF mRNA

NCBI chr11:115,007,040...115,024,834
Ensembl chr11:115,007,040...115,024,818

G

CD34 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA

NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587

G

CD37 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA

NCBI chr 7:44,883,056...44,888,701
Ensembl chr 7:44,883,056...44,888,539

G

CD48 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA

NCBI chr 1:171,508,989...171,532,825
Ensembl chr 1:171,509,577...171,532,826

G

CD69 antigen

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD69 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399

G

CD79A antigen (immunoglobulin-associated alpha)

increases expression

benz(a)anthracene results in increased expression of CD79A mRNA

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

G

CD79B antigen

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD79B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA

PMID:26377693 PMID:27858113

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD84 antigen

increases expression

benz(a)anthracene results in increased expression of CD84 mRNA

NCBI chr 1:171,667,261...171,718,288
Ensembl chr 1:171,667,265...171,718,285

G

CD8 subunit beta 1

increases expression

benz(a)anthracene results in increased expression of CD8B1 mRNA

NCBI chr 6:71,299,772...71,314,476
Ensembl chr 6:71,299,772...71,314,478

G

CD99 antigen

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA

G

CDC14 cell division cycle 14B

increases expression

benz(a)anthracene results in increased expression of CDC14B mRNA

NCBI chr13:64,337,085...64,423,670
Ensembl chr13:64,337,082...64,423,104

G

cell division cycle 40

decreases expression

benz(a)anthracene results in decreased expression of CDC40 mRNA

NCBI chr10:40,707,617...40,759,139
Ensembl chr10:40,707,617...40,759,307

G

cadherin 1

decreases expression

benz(a)anthracene results in decreased expression of CDH1 mRNA

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA

NCBI chr 8:105,328,547...105,351,028
Ensembl chr 8:105,328,543...105,351,028

G

cadherin-related family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA

NCBI chr 9:107,869,656...107,876,880
Ensembl chr 9:107,869,696...107,876,883

G

cyclin dependent kinase 2

multiple interactions

benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein]

NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900

G

cyclin dependent kinase inhibitor 1A

increases expression
multiple interactions
decreases expression

benz(a)anthracene results in increased expression of CDKN1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA
benz(a)anthracene results in decreased expression of CDKN1A mRNA

PMID:22236718 PMID:26377693 PMID:27858113

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

CUGBP, Elav-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA

NCBI chr10:81,295,061...81,318,564
Ensembl chr10:81,295,061...81,318,543

G

cadherin, EGF LAG seven-pass G-type receptor 2

decreases expression

benz(a)anthracene results in decreased expression of CELSR2 mRNA

NCBI chr 3:108,298,164...108,323,416
Ensembl chr 3:108,298,167...108,323,383

G

centrosomal protein 162

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA

NCBI chr 9:87,071,626...87,137,589
Ensembl chr 9:87,071,630...87,137,589

G

centrosomal protein 70

increases expression

benz(a)anthracene results in increased expression of CEP70 mRNA

NCBI chr 9:99,065,640...99,205,569
Ensembl chr 9:99,125,420...99,182,457

G

centrosomal protein 85-like

decreases expression

benz(a)anthracene results in decreased expression of CEP85L mRNA

NCBI chr10:53,149,537...53,256,765
Ensembl chr10:53,149,539...53,256,043

G

centrosomal protein 95

increases expression

benz(a)anthracene results in increased expression of CEP95 mRNA

NCBI chr11:106,679,466...106,709,687
Ensembl chr11:106,680,078...106,710,756

G

carboxyesterase 2B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2B mRNA

NCBI chr 8:105,555,130...105,566,725
Ensembl chr 8:105,558,204...105,566,725

G

carboxylesterase 2C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 2E

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA

NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304

G

cilia and flagella associated protein 43

increases expression

benz(a)anthracene results in increased expression of CFAP43 mRNA

NCBI chr19:47,723,706...47,825,893
Ensembl chr19:47,725,296...47,907,726

G

cilia and flagella associated protein 65

increases expression

benz(a)anthracene results in increased expression of CFAP65 mRNA

NCBI chr 1:74,941,230...74,974,785
Ensembl chr 1:74,941,230...74,974,758

G

complement factor B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

cofilin 1, non-muscle

increases expression

benz(a)anthracene results in increased expression of CFL1 mRNA

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

cingulin

increases expression

benz(a)anthracene results in increased expression of CGN mRNA

NCBI chr 3:94,667,376...94,695,036
Ensembl chr 3:94,667,376...94,693,826

G

chromodomain helicase DNA binding protein 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CHD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:73,076,400...73,191,494
Ensembl chr 7:73,076,386...73,191,578

G

chitinase, acidic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA

NCBI chr 3:106,020,698...106,039,434
Ensembl chr 3:106,020,545...106,039,436

G

chitinase-like 4

increases expression

benz(a)anthracene results in increased expression of CHI3L4 mRNA

NCBI chr 3:106,108,807...106,126,795
Ensembl chr 3:106,108,806...106,126,823

G

choline kinase alpha

decreases expression

benz(a)anthracene results in decreased expression of CHKA mRNA

NCBI chr19:3,901,585...3,944,368
Ensembl chr19:3,901,773...3,944,369

G

choline kinase beta

increases expression

benz(a)anthracene results in increased expression of CHKB mRNA

NCBI chr15:89,310,552...89,314,130
Ensembl chr15:89,310,563...89,314,111

G

charged multivesicular body protein 4B

decreases expression

benz(a)anthracene results in decreased expression of CHMP4B mRNA

NCBI chr 2:154,498,949...154,536,703
Ensembl chr 2:154,493,625...154,536,705

G

cysteine and histidine rich domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of CHORDC1 mRNA

NCBI chr 9:18,203,563...18,225,296
Ensembl chr 9:18,203,421...18,228,738

G

chondroitin polymerizing factor 2

affects expression

benz(a)anthracene affects the expression of CHPF2 mRNA

NCBI chr 5:24,788,950...24,799,396
Ensembl chr 5:24,791,739...24,799,554

G

cholinergic receptor, nicotinic, alpha polypeptide 4

decreases expression

benz(a)anthracene results in decreased expression of CHRNA4 mRNA

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

G

carbohydrate sulfotransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA

NCBI chr 2:92,429,978...92,445,597
Ensembl chr 2:92,430,052...92,445,595

G

carbohydrate sulfotransferase 3

increases expression

benz(a)anthracene results in increased expression of CHST3 mRNA

NCBI chr10:60,017,349...60,057,936
Ensembl chr10:60,017,354...60,055,082

G

carbohydrate sulfotransferase 8

increases expression

benz(a)anthracene results in increased expression of CHST8 mRNA

NCBI chr 7:34,373,893...34,512,136
Ensembl chr 7:34,373,893...34,512,136

G

circadian associated repressor of transcription

increases expression

benz(a)anthracene results in increased expression of CIART mRNA

NCBI chr 3:95,785,812...95,790,012
Ensembl chr 3:95,785,815...95,789,563

G

calcium and integrin binding family member 3

decreases expression

benz(a)anthracene results in decreased expression of CIB3 mRNA

NCBI chr 8:72,958,180...72,966,892
Ensembl chr 8:72,958,179...72,966,840

G

ciliary microtubule associated protein 2

increases expression

benz(a)anthracene results in increased expression of CIMAP2 mRNA

NCBI chr 4:106,448,105...106,474,594
Ensembl chr 4:106,448,106...106,474,438

G

cold inducible RNA binding protein

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CIRBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA

PMID:26377693 PMID:27858113

NCBI chr10:80,001,824...80,008,620
Ensembl chr10:80,001,819...80,008,620

G

cytokine inducible SH2-containing protein

decreases expression

benz(a)anthracene results in decreased expression of CISH mRNA

NCBI chr 9:107,173,858...107,179,983
Ensembl chr 9:107,173,225...107,179,983

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA

NCBI chr10:17,598,452...17,601,422
Ensembl chr10:17,598,966...17,601,422

G

cytoskeleton associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA

NCBI chr 8:22,658,168...22,675,835
Ensembl chr 8:22,658,176...22,675,835

G

CLK4-associating serine/arginine rich protein

increases expression

benz(a)anthracene results in increased expression of SFRS16 mRNA

NCBI chr 7:19,314,963...19,338,442
Ensembl chr 7:19,314,960...19,338,411

G

claudin 1

decreases expression

benz(a)anthracene results in decreased expression of CLDN1 mRNA

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

claudin 17

decreases expression

benz(a)anthracene results in decreased expression of CLDN17 mRNA

NCBI chr16:88,302,695...88,303,866
Ensembl chr16:88,302,695...88,303,866

G

claudin 2

decreases expression

benz(a)anthracene results in decreased expression of CLDN2 mRNA

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

claudin domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of CLDND1 mRNA

NCBI chr16:58,548,269...58,554,610
Ensembl chr16:58,548,273...58,554,614

G

C-type lectin domain family 1, member a

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CLEC1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:129,403,647...129,428,963
Ensembl chr 6:129,401,735...129,428,963

G

C-type lectin domain family 2, member h

affects expression

benz(a)anthracene affects the expression of CLEC2D mRNA

NCBI chr 6:128,639,348...128,654,337
Ensembl chr 6:128,639,348...128,654,337

G

C-type lectin domain family 4, member a1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA

NCBI chr 6:122,898,807...122,911,578
Ensembl chr 6:122,898,807...122,911,578

G

C-type lectin domain family 4, member g

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA

NCBI chr 8:3,757,066...3,770,695
Ensembl chr 8:3,757,064...3,770,651

G

CAP-GLY domain containing linker protein family, member 4

increases expression

benz(a)anthracene results in increased expression of CLIP4 mRNA

NCBI chr17:72,076,674...72,171,205
Ensembl chr17:72,075,468...72,171,268

G

CDC-like kinase 1

affects expression

benz(a)anthracene affects the expression of CLK1 mRNA

NCBI chr 1:58,451,147...58,463,247
Ensembl chr 1:58,449,348...58,463,225

G

CDC-like kinase 2

increases expression

benz(a)anthracene results in increased expression of CLK2 mRNA

NCBI chr 3:89,072,102...89,084,394
Ensembl chr 3:89,072,102...89,084,228

G

CDC like kinase 4

increases expression

benz(a)anthracene results in increased expression of CLK4 mRNA

NCBI chr11:51,153,941...51,172,597
Ensembl chr11:51,152,557...51,172,593

G

calmin

increases expression

benz(a)anthracene results in increased expression of CLMN mRNA

NCBI chr12:104,729,373...104,831,335
Ensembl chr12:104,729,376...104,831,335

G

CXADR-like membrane protein

decreases expression

benz(a)anthracene results in decreased expression of CLMP mRNA

NCBI chr 9:40,596,975...40,696,849
Ensembl chr 9:40,597,258...40,696,615

G

clock circadian regulator

decreases expression

benz(a)anthracene results in decreased expression of CLOCK mRNA

NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639

G

calsyntenin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA

NCBI chr 9:97,326,448...97,915,433
Ensembl chr 9:97,326,448...97,915,234

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA

NCBI chr12:26,519,121...26,529,836
Ensembl chr12:26,519,203...26,529,836

G

centriolin

increases expression

benz(a)anthracene results in increased expression of CNTRL mRNA

NCBI chr 2:34,999,504...35,068,834
Ensembl chr 2:34,999,504...35,068,834

G

cordon-bleu WH2 repeat

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COBL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA

PMID:26377693 PMID:27858113

NCBI chr11:12,186,676...12,415,022
Ensembl chr11:12,186,608...12,414,960

G

collagen, type I, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type XX, alpha 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL20A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:180,626,629...180,659,338
Ensembl chr 2:180,628,328...180,660,156

G

collagen, type XXVII, alpha 1

decreases expression

benz(a)anthracene results in decreased expression of COL27A1 mRNA

NCBI chr 4:63,132,246...63,253,228
Ensembl chr 4:63,132,241...63,253,228

G

collagen, type II, alpha 1

decreases expression

benz(a)anthracene results in decreased expression of COL2A1 mRNA

NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576

G

collagen, type III, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 4

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL4A4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:82,426,140...82,564,570
Ensembl chr 1:82,426,144...82,564,570

G

collagen, type IV, alpha 6

decreases expression

benz(a)anthracene results in decreased expression of COL4A6 mRNA

NCBI chr X:139,948,399...140,257,091
Ensembl chr X:139,948,399...140,257,072

G

collagen, type V, alpha 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL5A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:20,681,353...20,726,363
Ensembl chr 9:20,681,346...20,726,363

G

COMM domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA

NCBI chr 2:18,677,246...18,681,042
Ensembl chr 2:18,677,234...18,681,042

G

coenzyme Q10B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA

NCBI chr 1:55,091,929...55,111,861
Ensembl chr 1:55,091,929...55,111,861

G

coenzyme Q8A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA

NCBI chr 1:179,992,803...180,023,585
Ensembl chr 1:179,992,803...180,027,167

G

coronin, actin binding protein 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA

NCBI chr 4:46,536,937...46,601,929
Ensembl chr 4:46,536,937...46,602,202

G

complexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA

NCBI chr13:54,455,447...54,531,736
Ensembl chr13:54,519,162...54,531,730

G

copine IV

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA

NCBI chr 9:104,443,900...104,911,747
Ensembl chr 9:104,424,485...104,911,743

G

copine V

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CPNE5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:29,375,495...29,456,764
Ensembl chr17:29,374,530...29,457,141

G

carnitine palmitoyltransferase 1c

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA

NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275

G

complement receptor 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CR2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

crumbs family member 2

decreases expression

benz(a)anthracene results in decreased expression of CRB2 mRNA

NCBI chr 2:37,666,238...37,689,115
Ensembl chr 2:37,666,261...37,689,115

G

CREB/ATF bZIP transcription factor

affects expression

benz(a)anthracene affects the expression of CREBZF mRNA

NCBI chr 7:90,091,942...90,097,590
Ensembl chr 7:90,091,937...90,097,202

G

cysteine-rich protein 3

decreases expression

benz(a)anthracene results in decreased expression of CRIP3 mRNA

NCBI chr17:46,735,058...46,742,706
Ensembl chr17:46,739,852...46,742,702

G

v-crk avian sarcoma virus CT10 oncogene homolog

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CRK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA

PMID:26377693 PMID:27858113

NCBI chr11:75,570,020...75,599,254
Ensembl chr11:75,570,085...75,597,734

G

colorectal neoplasia differentially expressed, non-protein coding

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CRNDE mRNA
benz(a)anthracene results in increased expression of CRNDE mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:93,052,661...93,082,739
Ensembl chr 8:93,038,763...93,084,336

G

cryptochrome circadian regulator 2

increases expression

benz(a)anthracene results in increased expression of CRY2 mRNA

NCBI chr 2:92,233,991...92,264,426
Ensembl chr 2:92,233,991...92,264,388

G

colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)

decreases expression

benz(a)anthracene results in decreased expression of CSF2RA mRNA

NCBI chr19:61,205,629...61,221,141
Ensembl chr19:61,212,395...61,216,867

G

colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)

increases expression

benz(a)anthracene results in increased expression of CSF2RB2 mRNA

NCBI chr15:78,166,707...78,189,921
Ensembl chr15:78,166,707...78,189,921

G

cystatin 8 (cystatin-related epididymal spermatogenic)

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CST8 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:148,640,759...148,647,516
Ensembl chr 2:148,640,705...148,647,515

G

CSA-conditional, T cell activation-dependent protein

increases expression

benz(a)anthracene results in increased expression of CSTAD mRNA

NCBI chr 2:30,485,056...30,498,957
Ensembl chr 2:30,485,052...30,498,955

G

cleavage stimulation factor, 3' pre-RNA, subunit 3

decreases expression

benz(a)anthracene results in decreased expression of CSTF3 mRNA

NCBI chr 2:104,420,829...104,495,770
Ensembl chr 2:104,420,868...104,495,774

G

cytotoxic T lymphocyte-associated protein 2 beta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CTLA2B mRNA

NCBI chr13:61,043,165...61,045,269
Ensembl chr13:61,043,164...61,045,261

G

cullin 9

increases expression

benz(a)anthracene results in increased expression of CUL9 mRNA

NCBI chr17:46,811,535...46,857,314
Ensembl chr17:46,811,498...46,857,314

G

cutA divalent cation tolerance homolog-like

affects expression

benz(a)anthracene affects the expression of CUTAL mRNA

NCBI chr 2:34,764,408...34,782,145
Ensembl chr 2:34,764,408...34,782,144

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CXCL12 mRNA
bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA]

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 15

multiple interactions
increases expression

[benz(a)anthracene co-treated with TNF protein] results in increased expression of CXCL8 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL5 mRNA
benz(a)anthracene results in increased expression of CXCL8 mRNA

PMID:23396138 PMID:25433334 PMID:27858113

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine receptor 5

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CXCR5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:44,423,084...44,437,741
Ensembl chr 9:44,423,084...44,473,174

G

C-X-C motif chemokine receptor 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA

NCBI chr 9:123,635,542...123,640,819
Ensembl chr 9:123,635,540...123,640,825

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA

NCBI chr 8:89,423,506...89,478,574
Ensembl chr 8:89,423,675...89,478,573

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression
multiple interactions
decreases expression

benz(a)anthracene results in increased expression of CYP17A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA
benz(a)anthracene results in decreased expression of CYP17A1 mRNA

PMID:23358148 PMID:26377693 PMID:27858113

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity
increases metabolic processing

[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 protein; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; Cadmium Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; CYP1A1 gene polymorphism affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; lead nitrate inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Mercuric Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; sodium arsenite inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]
benz(a)anthracene results in increased expression of CYP1A1 mRNA; benz(a)anthracene results in increased expression of CYP1A1 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]]; NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; Dactinomycin promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; resveratrol inhibits the reaction [[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA]

PMID:1358564 PMID:1521541 PMID:1846074 PMID:1934297 PMID:2052000 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression
affects response to substance
decreases activity

[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]
[chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA
benz(a)anthracene results in increased expression of CYP1A2 mRNA
CYP1A2 protein affects the susceptibility to benz(a)anthracene
benz(a)anthracene results in decreased activity of CYP1A2 protein
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]

PMID:7750161 PMID:8961944 PMID:9783729 PMID:11162773 PMID:17253728 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression
increases stability

[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 protein; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CYP1B1 mRNA; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]
benz(a)anthracene results in increased expression of CYP1B1 mRNA; benz(a)anthracene results in increased expression of CYP1B1 protein
[benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Progesterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
benz(a)anthracene results in increased stability of CYP1B1 protein
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]

PMID:7505439 PMID:8022408 PMID:8674863 PMID:9783729 PMID:10037446 More...

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 21, subfamily a, polypeptide 1

decreases expression

benz(a)anthracene results in decreased expression of CYP21A1 mRNA

NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

benz(a)anthracene results in increased expression of CYP2E1 mRNA

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily j, polypeptide 5

decreases expression

benz(a)anthracene results in decreased expression of CYP2J5 mRNA

NCBI chr 4:96,517,010...96,552,391
Ensembl chr 4:96,517,010...96,552,391

G

cytochrome P450, family 2, subfamily j, polypeptide 9

decreases expression

benz(a)anthracene results in decreased expression of CYP2J9 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 3, subfamily a, polypeptide 59

decreases expression

benz(a)anthracene results in decreased expression of CYP3A59 mRNA

NCBI chr 5:146,016,018...146,051,788
Ensembl chr 5:146,016,067...146,050,097

G

cystin 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CYS1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:24,715,832...24,731,794
Ensembl chr12:24,715,832...24,731,812

G

DNA segment, Chr 5, ERATO Doi 605, expressed

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of D5ERTD605E mRNA

NCBI chr 5:147,355,430...147,359,854
Ensembl chr 5:147,355,399...147,359,860

G

dishevelled-binding antagonist of beta-catenin 2

increases expression

benz(a)anthracene results in increased expression of DACT2 mRNA

NCBI chr17:14,415,492...14,424,595
Ensembl chr17:14,415,314...14,424,566

G

differentiation antagonizing non-protein coding RNA

decreases expression

benz(a)anthracene results in decreased expression of DANCR mRNA

NCBI chr 5:74,253,780...74,254,998
Ensembl chr 5:74,253,357...74,284,805

G

aspartyl-tRNA synthetase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA

NCBI chr 1:128,291,444...128,345,153
Ensembl chr 1:128,291,444...128,345,105

G

D site albumin promoter binding protein

increases expression
multiple interactions

benz(a)anthracene results in increased expression of DBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627

G

DDB1 and CUL4 associated factor 12-like 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DCAF12L2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:43,454,334...43,457,214
Ensembl chr X:43,454,335...43,457,219

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA

NCBI chr12:83,567,145...83,588,768
Ensembl chr12:83,567,240...83,588,694

G

DCC netrin 1 receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA

NCBI chr18:71,386,703...72,484,299
Ensembl chr18:71,386,705...72,484,140

G

doublecortin domain containing 2a

decreases expression

benz(a)anthracene results in decreased expression of DCDC2A mRNA

NCBI chr13:25,239,126...25,394,689
Ensembl chr13:25,239,987...25,394,689

G

decorin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA

NCBI chr 3:145,464,447...145,600,032
Ensembl chr 3:145,464,430...145,600,032

G

damage specific DNA binding protein 2

increases expression

benz(a)anthracene results in increased expression of DDB2 mRNA

NCBI chr 2:91,041,924...91,067,465
Ensembl chr 2:91,041,917...91,067,327

G

dopa decarboxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA

NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA

NCBI chr 7:92,506,734...92,523,455
Ensembl chr 7:92,506,733...92,523,455

G

DNA-damage-inducible transcript 4-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA

NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094

G

DEAD box helicase 17

decreases expression

benz(a)anthracene results in decreased expression of DDX17 mRNA

NCBI chr15:79,411,897...79,430,976
Ensembl chr15:79,411,937...79,430,942

G

DEAD box helicase 25

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA

NCBI chr 9:35,453,144...35,469,766
Ensembl chr 9:35,447,943...35,469,824

G

DEAD box helicase 5

affects expression
multiple interactions

benz(a)anthracene affects the expression of DDX5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:106,671,181...106,680,011
Ensembl chr11:106,671,181...106,680,011

G

DENN domain containing 1C

increases expression

benz(a)anthracene results in increased expression of DENND1C mRNA

NCBI chr17:57,373,051...57,385,518
Ensembl chr17:57,372,905...57,385,514

G

diacylglycerol O-acyltransferase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA

NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926

G

diacylglycerol kinase, theta

increases expression

benz(a)anthracene results in increased expression of DGKQ mRNA

NCBI chr 5:108,794,910...108,808,696
Ensembl chr 5:108,794,559...108,817,538

G

dehydrogenase/reductase 7B

decreases expression

benz(a)anthracene results in decreased expression of DHRS7B mRNA

NCBI chr11:60,721,457...60,749,249
Ensembl chr11:60,721,457...60,751,021

G

DExH-box helicase 34

increases expression

benz(a)anthracene results in increased expression of DHX34 mRNA

NCBI chr 7:15,931,145...15,956,005
Ensembl chr 7:15,931,072...15,955,962

G

DEAH-box helicase 35

increases expression

benz(a)anthracene results in increased expression of DHX35 mRNA

NCBI chr 2:158,636,674...158,700,141
Ensembl chr 2:158,636,727...158,700,134

G

DExH-box helicase 58

decreases expression

benz(a)anthracene results in decreased expression of DHX58 mRNA

NCBI chr11:100,585,710...100,595,165
Ensembl chr11:100,585,710...100,595,097

G

diaphanous related formin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DIAP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:37,976,654...38,068,573
Ensembl chr18:37,976,654...38,068,529

G

death inducer-obliterator 1

affects expression
multiple interactions

benz(a)anthracene affects the expression of DIDO1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:180,299,757...180,351,886
Ensembl chr 2:180,299,757...180,351,792

G

deiodinase, iodothyronine, type II

decreases expression

benz(a)anthracene results in decreased expression of DIO2 mRNA

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

divergent protein kinase domain 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA

NCBI chr 2:26,518,469...26,526,509
Ensembl chr 2:26,518,469...26,526,509

G

DIRAS family, GTP-binding RAS-like 2

decreases expression

benz(a)anthracene results in decreased expression of DIRAS2 mRNA

NCBI chr13:52,658,411...52,685,390
Ensembl chr13:52,658,416...52,685,315

G

dentin matrix protein 1

increases expression

benz(a)anthracene results in increased expression of DMP1 mRNA

NCBI chr 5:104,345,441...104,361,968
Ensembl chr 5:104,350,479...104,361,968

G

dynein axonemal assembly factor 4

increases expression

benz(a)anthracene results in increased expression of DNAAF4 mRNA

NCBI chr 9:72,863,574...72,880,971
Ensembl chr 9:72,866,067...72,880,346

G

dynein, axonemal, heavy chain 10

increases expression

benz(a)anthracene results in increased expression of DNAH10 mRNA

NCBI chr 5:124,802,149...124,911,372
Ensembl chr 5:124,802,149...124,911,372

G

dynein, axonemal, heavy chain 2

increases expression

benz(a)anthracene results in increased expression of DNAH2 mRNA

NCBI chr11:69,311,635...69,439,934
Ensembl chr11:69,311,635...69,439,936

G

dynein, axonemal, heavy chain 7A

increases expression

benz(a)anthracene results in increased expression of DNAH7A mRNA

NCBI chr 1:53,436,154...53,746,456
Ensembl chr 1:53,436,165...53,745,943

G

dynein, axonemal, heavy chain 8

increases expression

benz(a)anthracene results in increased expression of DNAH8 mRNA

NCBI chr17:30,845,909...31,094,736
Ensembl chr17:30,843,328...31,096,339

G

DnaJ heat shock protein family (Hsp40) member A1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DNAJA1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149

G

DnaJ heat shock protein family (Hsp40) member A4

decreases expression

benz(a)anthracene results in decreased expression of DNAJA4 mRNA

NCBI chr 9:54,606,132...54,623,601
Ensembl chr 9:54,606,157...54,623,599

G

DnaJ heat shock protein family (Hsp40) member B1

decreases expression

benz(a)anthracene results in decreased expression of DNAJB1 mRNA

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA

NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939

G

DnaJ heat shock protein family (Hsp40) member C21

decreases expression

benz(a)anthracene results in decreased expression of DNAJC21 mRNA

NCBI chr15:10,446,849...10,470,685
Ensembl chr15:10,446,842...10,470,602

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA

NCBI chr 4:132,262,859...132,281,053
Ensembl chr 4:132,262,861...132,281,053

G

dedicator of cytokinesis 6

increases expression

benz(a)anthracene results in increased expression of DOCK6 mRNA

NCBI chr 9:21,711,476...21,764,006
Ensembl chr 9:21,711,156...21,763,931

G

docking protein 3

increases expression

benz(a)anthracene results in increased expression of DOK3 mRNA

NCBI chr13:55,671,044...55,678,158
Ensembl chr13:55,671,044...55,677,109

G

DOT1 like histone lysine methyltransferase

increases expression

benz(a)anthracene results in increased expression of DOT1L mRNA

NCBI chr10:80,590,935...80,631,295
Ensembl chr10:80,591,040...80,631,295

G

dopamine receptor D1

multiple interactions

[Particulate Matter results in increased abundance of benz(a)anthracene] which results in decreased expression of DRD1 mRNA

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

G

dystonin

decreases expression

benz(a)anthracene results in decreased expression of DST mRNA

NCBI chr 1:33,946,969...34,347,743
Ensembl chr 1:33,947,306...34,347,742

G

denticleless E3 ubiquitin protein ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA

NCBI chr 1:191,269,468...191,307,656
Ensembl chr 1:191,269,468...191,307,656

G

deltex 4, E3 ubiquitin ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA

NCBI chr19:12,443,700...12,479,509
Ensembl chr19:12,443,702...12,478,818

G

Dppa2 upstream binding RNA

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DUBR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DUBR mRNA

PMID:26377693 PMID:27858113

NCBI chr16:50,547,114...50,553,136
Ensembl chr16:50,530,719...50,555,103

G

dual specificity phosphatase 2

increases expression

benz(a)anthracene results in increased expression of DUSP2 mRNA

NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296

G

dishevelled segment polarity protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DVL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:20,335,694...20,352,763
Ensembl chr16:20,335,732...20,352,760

G

dynein 2 intermediate chain 1

increases expression

benz(a)anthracene results in increased expression of DYNC2I1 mRNA

NCBI chr12:116,169,881...116,226,665
Ensembl chr12:116,169,882...116,226,642

G

DAZ interacting protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA

NCBI chr14:119,112,927...119,162,947
Ensembl chr14:119,112,932...119,162,872

G

enoyl Coenzyme A hydratase domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of ECHDC2 mRNA

NCBI chr 4:108,022,630...108,036,505
Ensembl chr 4:108,022,634...108,036,505

G

extracellular matrix protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA

NCBI chr 3:95,641,459...95,646,880
Ensembl chr 3:95,641,459...95,646,881

G

endothelin 1

increases expression

benz(a)anthracene results in increased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

estrogen-induced osteoclastogenesis regulator 1

increases expression

benz(a)anthracene results in increased expression of EEIG1 mRNA

NCBI chr 2:32,425,344...32,459,763
Ensembl chr 2:32,425,344...32,459,768

G

EF-hand calcium binding domain 12

increases expression

benz(a)anthracene results in increased expression of EFCAB12 mRNA

NCBI chr 6:115,787,695...115,815,177
Ensembl chr 6:115,787,857...115,815,373

G

EF hand domain family, member B

increases expression

benz(a)anthracene results in increased expression of EFHB mRNA

NCBI chr17:53,705,077...53,770,362
Ensembl chr17:53,705,917...53,770,349

G

ephrin B1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA

NCBI chr X:98,179,667...98,192,628
Ensembl chr X:98,179,736...98,192,597

G

epidermal growth factor

multiple interactions

AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

EGF-like domain 7

increases expression

benz(a)anthracene results in increased expression of EGFL7 mRNA

NCBI chr 2:26,471,095...26,482,694
Ensembl chr 2:26,470,026...26,483,132

G

epidermal growth factor receptor

multiple interactions

AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

EH domain binding protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of EHBP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:21,955,825...22,237,086
Ensembl chr11:21,955,828...22,292,292

G

EH-domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA

NCBI chr19:6,326,926...6,350,126
Ensembl chr19:6,326,755...6,350,126

G

EH-domain containing 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EHD4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:119,919,958...119,985,028
Ensembl chr 2:119,919,656...119,985,087

G

eukaryotic translation initiation factor 2 alpha kinase 4

increases expression

benz(a)anthracene results in increased expression of EIF2AK4 mRNA

NCBI chr 2:118,219,065...118,305,715
Ensembl chr 2:118,219,099...118,305,715

G

eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked

increases expression

benz(a)anthracene results in increased expression of EIF2S3Y mRNA

NCBI chr Y:1,010,562...1,049,136
Ensembl chr Y:1,010,543...1,028,847

G

eukaryotic translation initiation factor 3, subunit J1

decreases expression

benz(a)anthracene results in decreased expression of EIF3J mRNA

NCBI chr 2:121,859,061...121,884,113
Ensembl chr 2:121,859,027...121,887,079

G

ELOVL fatty acid elongase 1

increases expression

benz(a)anthracene results in increased expression of ELOVL1 mRNA

NCBI chr 4:118,285,321...118,290,150
Ensembl chr 4:118,285,290...118,290,150

G

endomucin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA

NCBI chr 3:137,046,824...137,136,830
Ensembl chr 3:137,046,828...137,137,946

G

echinoderm microtubule associated protein like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA

NCBI chr12:108,337,265...108,505,835
Ensembl chr12:108,337,216...108,505,876

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

decreases expression

benz(a)anthracene results in decreased expression of ENPP3 mRNA

NCBI chr10:24,649,712...24,712,093
Ensembl chr10:24,648,304...24,718,721

G

erythrocyte membrane protein band 4.1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of EPB41 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:131,650,724...131,802,824
Ensembl chr 4:131,650,724...131,802,632

G

Eph receptor A1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EPHA1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:42,335,421...42,350,249
Ensembl chr 6:42,335,421...42,350,202

G

epoxide hydrolase 1, microsomal

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]
benz(a)anthracene results in increased expression of EPHX1 protein

PMID:2208584 PMID:8961944 PMID:27858113

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

EPM2A interacting protein 1

increases expression

benz(a)anthracene results in increased expression of EPM2AIP1 mRNA

NCBI chr 9:111,100,913...111,108,161
Ensembl chr 9:111,100,997...111,108,161

G

erythropoietin receptor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EPOR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:21,870,193...21,874,915
Ensembl chr 9:21,870,193...21,874,802

G

EPS8-like 1

increases expression

benz(a)anthracene results in increased expression of EPS8L1 mRNA

NCBI chr 7:4,463,636...4,483,486
Ensembl chr 7:4,463,673...4,483,486

G

erb-b2 receptor tyrosine kinase 2

decreases expression

benz(a)anthracene results in decreased expression of ERBB2 mRNA

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

excision repair cross-complementing rodent repair deficiency, complementation group 1

increases expression

benz(a)anthracene results in increased expression of ERCC1 mRNA

NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449

G

ermin, ERM-like protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA

NCBI chr 2:57,874,920...57,942,962
Ensembl chr 2:57,935,125...57,942,876

G

estrogen receptor 1 (alpha)

multiple interactions
increases activity
decreases expression
increases phosphorylation
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA; benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]; fulvestrant inhibits the reaction [benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]]
benz(a)anthracene results in increased activity of ESR1 protein
benz(a)anthracene results in decreased expression of ESR1 protein
benz(a)anthracene results in increased phosphorylation of ESR1 protein
benz(a)anthracene results in increased expression of ESR1 mRNA

PMID:11922773 PMID:12441364 PMID:18634860 PMID:21783948 PMID:25012808

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

electron transfer flavoprotein beta subunit lysine methyltransferase

increases expression

benz(a)anthracene results in increased expression of ETFBKMT mRNA

NCBI chr 6:149,042,980...149,052,669
Ensembl chr 6:149,041,347...149,052,669

G

E26 avian leukemia oncogene 1, 5' domain

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]

NCBI chr 9:32,547,501...32,669,116
Ensembl chr 9:32,547,517...32,669,116

G

ets variant 5

increases expression

benz(a)anthracene results in increased expression of ETV5 mRNA

NCBI chr16:22,200,063...22,258,320
Ensembl chr16:22,200,059...22,258,469

G

eva-1 homolog A, regulator of programmed cell death

increases expression

benz(a)anthracene results in increased expression of EVA1A mRNA

NCBI chr 6:82,018,058...82,070,079
Ensembl chr 6:82,018,024...82,070,080

G

Ewing sarcoma breakpoint region 1

increases expression

benz(a)anthracene results in increased expression of EWSR1 mRNA

NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266

G

exocyst complex component 3-like

increases expression

benz(a)anthracene results in increased expression of EXOC3L mRNA

NCBI chr 8:106,016,555...106,024,258
Ensembl chr 8:106,016,556...106,022,733

G

exocyst complex component 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA

NCBI chr 6:33,226,025...33,950,914
Ensembl chr 6:33,226,020...33,950,914

G

exocyst complex component 6B

decreases expression

benz(a)anthracene results in decreased expression of EXOC6B mRNA

NCBI chr 6:84,595,468...85,046,524
Ensembl chr 6:84,595,469...85,046,495

G

exosome component 7

increases expression

benz(a)anthracene results in increased expression of EXOSC7 mRNA

NCBI chr 9:122,942,310...122,965,194
Ensembl chr 9:122,942,280...122,965,194

G

fatty acid binding protein 1, liver

increases expression

benz(a)anthracene results in increased expression of FABP1 mRNA

NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007

G

fatty acid binding protein 12

increases expression

benz(a)anthracene results in increased expression of FABP12 mRNA

NCBI chr 3:10,309,269...10,366,575
Ensembl chr 3:10,309,269...10,366,243

G

family with sequence similarity 107, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA

NCBI chr14:14,152,166...14,173,503
Ensembl chr14:14,151,750...14,173,499

G

family with sequence similarity 110, member D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA

NCBI chr 4:133,978,413...133,993,528
Ensembl chr 4:133,978,421...133,981,417

G

family with sequence similarity 133, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA

NCBI chr 5:3,593,833...3,620,548
Ensembl chr 5:3,593,833...3,620,238

G

family with sequence similarity 135, member A

increases expression

benz(a)anthracene results in increased expression of FAM135A mRNA

NCBI chr 1:24,049,824...24,139,444
Ensembl chr 1:24,050,174...24,139,422

G

family with sequence similarity 13, member C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA

NCBI chr10:70,274,981...70,394,566
Ensembl chr10:70,276,311...70,394,566

G

family with sequence similarity 193, member B

affects expression

benz(a)anthracene affects the expression of FAM193B mRNA

NCBI chr13:55,687,129...55,718,920
Ensembl chr13:55,687,129...55,718,933

G

FAM20B, glycosaminoglycan xylosylkinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA

NCBI chr 1:156,506,127...156,547,204
Ensembl chr 1:156,506,102...156,546,656

G

family with sequence similarity 76, member B

increases expression

benz(a)anthracene results in increased expression of FAM76B mRNA

NCBI chr 9:13,738,490...13,766,033
Ensembl chr 9:13,739,012...13,766,283

G

FERM, ARH/RhoGEF and pleckstrin domain protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FARP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:121,272,563...121,521,156
Ensembl chr14:121,272,612...121,521,156

G

Fas-activated serine/threonine kinase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of FASTK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:24,646,036...24,650,280
Ensembl chr 5:24,643,438...24,650,285

G

F-box and leucine-rich repeat protein 12

increases expression

benz(a)anthracene results in increased expression of FBXL12 mRNA

NCBI chr 9:20,549,045...20,556,064
Ensembl chr 9:20,529,414...20,556,063

G

F-box and leucine-rich repeat protein 13

increases expression

benz(a)anthracene results in increased expression of FBXL13 mRNA

NCBI chr 5:21,688,845...21,850,696
Ensembl chr 5:21,688,845...21,850,632

G

F-box and leucine-rich repeat protein 20

increases expression

benz(a)anthracene results in increased expression of FBXL20 mRNA

NCBI chr11:97,973,380...98,042,014
Ensembl chr11:97,973,382...98,041,229

G

Fc receptor, IgE, low affinity II, alpha polypeptide

increases expression
multiple interactions

benz(a)anthracene results in increased expression of FCER2A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:3,730,280...3,744,174
Ensembl chr 8:3,731,737...3,744,175

G

Fc fragment of IgM receptor

increases expression

benz(a)anthracene results in increased expression of FCMR mRNA

NCBI chr 1:130,793,514...130,808,528
Ensembl chr 1:130,793,406...130,808,528

G

Fc receptor-like A

increases expression

benz(a)anthracene results in increased expression of FCRLA mRNA

NCBI chr 1:170,745,163...170,755,169
Ensembl chr 1:170,745,145...170,755,152

G

FYVE, RhoGEF and PH domain containing 6

decreases expression

benz(a)anthracene results in decreased expression of FGD6 mRNA

NCBI chr10:93,871,862...93,981,201
Ensembl chr10:93,871,863...93,981,201

G

fibroblast growth factor 7

increases expression

benz(a)anthracene results in increased expression of FGF7 mRNA

NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105

G

fibroblast growth factor 9

increases expression

benz(a)anthracene results in increased expression of FGF9 mRNA

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

FGFR1 oncogene partner 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FGFR1OP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:146,479,401...146,500,696
Ensembl chr 6:146,478,701...146,500,696

G

fibrinogen gamma chain

increases expression

benz(a)anthracene results in increased expression of FGG mRNA

NCBI chr 3:82,915,031...82,922,363
Ensembl chr 3:82,915,031...82,922,356

G

fin bud initiation factor homolog (zebrafish)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA

NCBI chr 2:110,191,270...110,193,338
Ensembl chr 2:110,191,262...110,193,528

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA

NCBI chr10:41,064,168...41,179,237
Ensembl chr10:41,064,168...41,179,256

G

fidgetin-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA

NCBI chr11:11,737,429...11,758,962
Ensembl chr11:11,737,431...11,758,962

G

functional intergenic repeating RNA element

decreases expression

benz(a)anthracene results in decreased expression of FIRRE mRNA

NCBI chr X:49,651,997...49,724,198
Ensembl chr X:49,644,621...49,724,249

G

FK506 binding protein 1a

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FKBP1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612

G

flightless I actin binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA

NCBI chr11:60,604,969...60,618,089
Ensembl chr11:60,604,949...60,618,089

G

FMS-like tyrosine kinase 3 ligand

increases expression

benz(a)anthracene results in increased expression of FLT3L mRNA

NCBI chr 7:44,780,607...44,785,914
Ensembl chr 7:44,779,212...44,785,856

G

flavin containing monooxygenase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA

NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569

G

fructosamine 3 kinase

decreases expression

benz(a)anthracene results in decreased expression of FN3K mRNA

NCBI chr11:121,325,779...121,341,316
Ensembl chr11:121,325,739...121,341,317

G

formin binding protein 4

increases expression

benz(a)anthracene results in increased expression of FNBP4 mRNA

NCBI chr 2:90,575,793...90,611,365
Ensembl chr 2:90,575,714...90,611,365

G

fibronectin type III domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA

NCBI chr17:7,957,401...8,046,158
Ensembl chr17:7,957,401...8,046,134

G

folate receptor beta

decreases expression

benz(a)anthracene results in decreased expression of FOLR2 mRNA

NCBI chr 7:101,489,195...101,506,397
Ensembl chr 7:101,489,195...101,506,401

G

forkhead box A2

decreases expression

benz(a)anthracene results in decreased expression of FOXA2 mRNA

NCBI chr 2:147,884,797...147,888,889
Ensembl chr 2:147,884,797...147,888,889

G

forkhead box F1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA

NCBI chr 8:121,811,100...121,814,883
Ensembl chr 8:121,811,125...121,814,883

G

forkhead box Q1

decreases expression

benz(a)anthracene results in decreased expression of FOXQ1 mRNA

NCBI chr13:31,742,153...31,744,959
Ensembl chr13:31,740,117...31,744,959

G

forkhead box S1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA

NCBI chr 2:152,773,818...152,775,128
Ensembl chr 2:152,773,818...152,775,128

G

Fraser extracellular matrix complex subunit 1

decreases expression

benz(a)anthracene results in decreased expression of FRAS1 mRNA

NCBI chr 5:96,518,622...96,932,592
Ensembl chr 5:96,521,814...96,932,587

G

Fras1 related extracellular matrix protein 1

decreases expression

benz(a)anthracene results in decreased expression of FREM1 mRNA

NCBI chr 4:82,816,157...82,970,743
Ensembl chr 4:82,816,164...82,970,576

G

FSHD region gene 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FRG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:41,842,218...41,870,179
Ensembl chr 8:41,850,496...41,870,111

G

FERM domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA

NCBI chr 6:97,263,828...97,594,618
Ensembl chr 6:97,263,828...97,594,502

G

fascin actin-bundling protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA

NCBI chr 6:28,427,888...28,438,621
Ensembl chr 6:28,427,788...28,438,621

G

fused in sarcoma

increases expression

benz(a)anthracene results in increased expression of FUS mRNA

NCBI chr 7:127,565,276...127,581,204
Ensembl chr 7:127,566,629...127,584,873

G

frizzled class receptor 4

increases expression

benz(a)anthracene results in increased expression of FZD4 mRNA

NCBI chr 7:89,053,574...89,062,341
Ensembl chr 7:89,053,563...89,062,342

G

frizzled class receptor 6

increases expression

benz(a)anthracene results in increased expression of FZD6 mRNA

NCBI chr15:38,869,673...38,901,587
Ensembl chr15:38,869,429...38,901,583

G

growth factor receptor bound protein 2-associated protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GAB3 mRNA

NCBI chr X:74,032,151...74,128,511
Ensembl chr X:74,010,449...74,129,064

G

gamma-aminobutyric acid type B receptor subunit 1

increases expression

benz(a)anthracene results in increased expression of GABBR1 mRNA

NCBI chr17:37,356,888...37,385,197
Ensembl chr17:37,356,858...37,385,959

G

growth arrest and DNA-damage-inducible 45 alpha

increases expression

benz(a)anthracene metabolite results in increased expression of GADD45A protein; benz(a)anthracene results in increased expression of GADD45A mRNA

PMID:22236718 PMID:31051210

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

growth arrest and DNA-damage-inducible 45 gamma

decreases expression

benz(a)anthracene results in decreased expression of GADD45G mRNA

NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504

G

polypeptide N-acetylgalactosaminyltransferase 15

decreases expression

benz(a)anthracene results in decreased expression of GALNT15 mRNA

NCBI chr14:31,750,739...31,784,161
Ensembl chr14:31,750,946...31,784,154

G

growth arrest specific 1

decreases expression

benz(a)anthracene results in decreased expression of GAS1 mRNA

NCBI chr13:60,322,219...60,325,179
Ensembl chr13:60,322,219...60,325,179

G

growth arrest specific 5

increases expression

benz(a)anthracene results in increased expression of GAS5 mRNA

NCBI chr 1:160,862,171...160,866,109
Ensembl chr 1:160,861,793...160,866,118

G

growth arrest specific 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA

NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490

G

golgi associated kinase 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA

NCBI chr 3:79,791,795...79,853,585
Ensembl chr 3:79,791,840...79,853,587

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA

NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014

G

1,4-alpha-glucan branching enzyme 1

decreases expression

benz(a)anthracene results in decreased expression of GBE1 mRNA

NCBI chr16:70,110,837...70,366,608
Ensembl chr16:70,110,837...70,366,604

G

guanylate binding protein 11

decreases expression

benz(a)anthracene results in decreased expression of GBP11 mRNA

NCBI chr 5:105,470,892...105,494,342
Ensembl chr 5:105,470,908...105,494,338

G

guanylate-binding protein 9

decreases expression

benz(a)anthracene results in decreased expression of GBP6 mRNA

NCBI chr 5:105,224,331...105,258,255
Ensembl chr 5:105,225,496...105,287,405

G

GRIP and coiled-coil domain containing 2

increases expression

benz(a)anthracene results in increased expression of GCC2 mRNA

NCBI chr10:58,091,240...58,141,421
Ensembl chr10:58,091,319...58,141,421

G

glucagon receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA

NCBI chr11:120,420,011...120,429,815
Ensembl chr11:120,421,525...120,429,812

G

glial cells missing homolog 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA

NCBI chr 9:77,959,240...77,972,906
Ensembl chr 9:77,959,206...77,972,906

G

growth differentiation factor 10

increases expression

benz(a)anthracene results in increased expression of GDF10 mRNA

NCBI chr14:33,645,544...33,658,471
Ensembl chr14:33,645,544...33,659,940

G

growth differentiation factor 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

glial cell line derived neurotrophic factor

increases expression

benz(a)anthracene results in increased expression of GDNF mRNA

NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056

G

glial cell line derived neurotrophic factor family receptor alpha 4

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GFRA4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:130,881,552...130,885,008
Ensembl chr 2:130,881,552...130,885,008

G

gap junction protein, alpha 5

decreases expression

benz(a)anthracene results in decreased expression of GJA5 mRNA

NCBI chr 3:96,939,718...96,960,950
Ensembl chr 3:96,812,009...96,984,732

G

gap junction protein, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA

NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235

G

gap junction protein, gamma 2

decreases expression

benz(a)anthracene results in decreased expression of GJC2 mRNA

NCBI chr11:59,066,390...59,074,039
Ensembl chr11:59,066,394...59,074,039

G

gastrokine 2

increases expression

benz(a)anthracene results in increased expression of GKN2 mRNA

NCBI chr 6:87,350,347...87,356,476
Ensembl chr 6:87,350,339...87,356,479

G

GLIS family zinc finger 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA

NCBI chr16:4,412,217...4,443,076
Ensembl chr16:4,412,577...4,442,788

G

glycosyltransferase 8 domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of GLT8D1 mRNA

NCBI chr14:30,723,137...30,733,948
Ensembl chr14:30,723,357...30,733,948

G

glycosyltransferase 8 domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of GLT8D2 mRNA

NCBI chr10:82,486,262...82,529,846
Ensembl chr10:82,486,267...82,526,484

G

geminin

increases expression
multiple interactions

benz(a)anthracene results in increased expression of GMNN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA

PMID:26377693 PMID:27858113

NCBI chr13:24,935,828...24,954,222
Ensembl chr13:24,935,828...24,945,906

G

gon-4 like

decreases expression

benz(a)anthracene results in decreased expression of GON4L mRNA

NCBI chr 3:88,742,531...88,817,406
Ensembl chr 3:88,742,535...88,817,410

G

glycerophosphocholine phosphodiesterase 1

increases expression

benz(a)anthracene results in increased expression of GPCPD1 mRNA

NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649

G

glycerol-3-phosphate dehydrogenase 1 (soluble)

multiple interactions
increases activity

benz(a)anthracene inhibits the reaction [Dehydroepiandrosterone results in increased activity of GPD1 protein]
benz(a)anthracene results in increased activity of GPD1 protein

NCBI chr15:99,615,468...99,622,895
Ensembl chr15:99,615,396...99,622,886

G

GPI-anchored HDL-binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA

NCBI chr15:75,468,479...75,470,062
Ensembl chr15:75,468,477...75,471,330

G

G protein-coupled receptor 174

increases expression

benz(a)anthracene results in increased expression of GPR174 mRNA

NCBI chr X:106,299,484...106,340,377
Ensembl chr X:106,299,484...106,340,375

G

G protein-coupled receptor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA

NCBI chr 7:18,946,463...18,958,101
Ensembl chr 7:18,946,463...18,958,099

G

GPRIN family member 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GPRIN3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:59,317,988...59,403,291
Ensembl chr 6:59,324,211...59,403,279

G

glutathione peroxidase 6

increases expression

benz(a)anthracene results in increased expression of GPX6 mRNA

NCBI chr13:21,479,635...21,503,795
Ensembl chr13:21,496,295...21,503,794

G

GRAM domain containing 1A

increases expression

benz(a)anthracene results in increased expression of GRAMD1A mRNA

NCBI chr 7:30,829,552...30,855,374
Ensembl chr 7:30,829,552...30,855,321

G

GRAM domain containing 1C

decreases expression

benz(a)anthracene results in decreased expression of GRAMD1C mRNA

NCBI chr16:43,800,713...43,883,757
Ensembl chr16:43,800,713...43,883,708

G

growth factor receptor bound protein 10

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GRB10 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:11,880,499...11,987,428
Ensembl chr11:11,880,508...11,988,683

G

gene regulated by estrogen in breast cancer protein

increases expression
multiple interactions

benz(a)anthracene results in increased expression of GREB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:16,720,616...16,851,395
Ensembl chr12:16,720,616...16,850,887

G

galectin-related inter-fiber protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA

NCBI chr 5:140,548,872...140,553,280
Ensembl chr 5:140,548,874...140,550,826

G

G protein-coupled receptor kinase 3

increases expression

benz(a)anthracene results in increased expression of GRK3 mRNA

NCBI chr 5:113,058,344...113,163,518
Ensembl chr 5:113,058,348...113,163,657

G

gastrin releasing peptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA

NCBI chr18:66,005,826...66,019,670
Ensembl chr18:66,005,891...66,019,667

G

gamma-secretase activating protein

increases expression

benz(a)anthracene results in increased expression of GSAP mRNA

NCBI chr 5:21,380,767...21,518,423
Ensembl chr 5:21,391,253...21,520,130

G

gasdermin A2

increases expression

benz(a)anthracene results in increased expression of GSDMA2 mRNA

NCBI chr11:98,537,569...98,548,791
Ensembl chr11:98,537,585...98,548,790

G

glutathione S-transferase, alpha 2 (Yc2)

increases expression
increases activity
multiple interactions

benz(a)anthracene results in increased expression of GSTA2 mRNA
benz(a)anthracene results in increased activity of GSTA2 protein
1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of GSTA2 mRNA]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

glutathione S-transferase, alpha 3

increases expression

benz(a)anthracene results in increased expression of GSTA2 mRNA

NCBI chr 1:21,310,837...21,335,885
Ensembl chr 1:21,310,813...21,335,885

G

gene trap ROSA 26, Philippe Soriano

decreases expression

benz(a)anthracene results in decreased expression of GT(ROSA)26SOR mRNA

NCBI chr 6:113,044,389...113,054,205
Ensembl chr 6:113,043,843...113,055,336

G

general transcription factor IIIC, polypeptide 2, beta

increases expression

benz(a)anthracene results in increased expression of GTF3C2 mRNA

NCBI chr 5:31,313,350...31,337,488
Ensembl chr 5:31,313,349...31,337,488

G

GTP binding protein 2

increases expression

benz(a)anthracene results in increased expression of GTPBP2 mRNA

NCBI chr17:46,470,153...46,480,294
Ensembl chr17:46,471,958...46,480,296

G

GTPase, very large interferon inducible 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GVIN1 mRNA

NCBI chr 7:105,755,742...105,814,547
Ensembl chr 7:105,755,763...105,814,533

G

granzyme A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

histocompatibility 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA

NCBI chr 2:152,511,292...152,550,590
Ensembl chr 2:152,511,381...152,550,590

G

H1.2 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA

NCBI chr13:23,922,790...23,923,514
Ensembl chr13:23,922,791...23,924,350

G

H1.4 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA

NCBI chr13:23,805,760...23,806,541
Ensembl chr13:23,804,612...23,806,541

G

histocompatibility 2, class II, locus Mb2

increases expression

benz(a)anthracene results in increased expression of H2-DMB2 mRNA

NCBI chr17:34,362,203...34,370,527
Ensembl chr17:34,362,281...34,370,529

G

histocompatibility 2, class II antigen E beta2

increases expression

benz(a)anthracene results in increased expression of H2-EB2 mRNA

NCBI chr17:34,544,477...34,560,384
Ensembl chr17:34,544,639...34,560,386

G

histocompatibility 2, M region locus 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of H2-M2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H2-M2 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

histocompatibility 2, O region alpha locus

increases expression
multiple interactions

benz(a)anthracene results in increased expression of H2-OA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OA mRNA

PMID:26377693 PMID:27858113

NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208

G

histocompatibility 2, O region beta locus

increases expression
multiple interactions

benz(a)anthracene results in increased expression of H2-OB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OB mRNA

PMID:26377693 PMID:27858113

NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388

G

histocompatibility 2, Q region locus 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-Q10 mRNA

NCBI chr17:35,780,986...35,785,460
Ensembl chr17:35,780,986...35,785,460

G

H2A.X variant histone

increases expression

benz(a)anthracene metabolite results in increased expression of H2AX protein

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

H2B clustered histone 27

increases expression

benz(a)anthracene results in increased expression of H2BC27 mRNA

NCBI chr11:58,839,737...58,840,198
Ensembl chr11:58,839,746...58,840,359

G

H3 clustered histone 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H3C15 mRNA

NCBI chr13:23,728,222...23,729,124
Ensembl chr13:23,728,222...23,729,482

G

H4 clustered histone 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H4C3 mRNA

NCBI chr 3:96,170,250...96,170,633
Ensembl chr 3:96,168,998...96,170,627

G

hydroxyacylglutathione hydrolase-like

increases expression

benz(a)anthracene results in increased expression of HAGHL mRNA

NCBI chr17:25,998,817...26,004,560
Ensembl chr17:25,998,817...26,004,647

G

HAUS augmin-like complex, subunit 4

increases expression

benz(a)anthracene results in increased expression of HAUS4 mRNA

NCBI chr14:54,779,242...54,792,446
Ensembl chr14:54,779,242...54,792,073

G

HAUS augmin-like complex, subunit 5

increases expression

benz(a)anthracene results in increased expression of HAUS5 mRNA

NCBI chr 7:30,353,133...30,364,419
Ensembl chr 7:30,353,136...30,364,419

G

hemolytic complement

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HC mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:34,873,341...34,958,518
Ensembl chr 2:34,873,343...34,951,450

G

hemopoietic cell kinase

increases expression

benz(a)anthracene results in increased expression of HCK mRNA

NCBI chr 2:152,950,388...152,993,361
Ensembl chr 2:152,950,388...152,993,361

G

histone deacetylase 10

increases expression

benz(a)anthracene results in increased expression of HDAC10 mRNA

NCBI chr15:89,007,506...89,012,903
Ensembl chr15:89,007,510...89,012,903

G

HEAT repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA

NCBI chr13:12,410,256...12,453,774
Ensembl chr13:12,409,908...12,455,170

G

helicase with zinc finger 2, transcriptional coactivator

decreases expression

benz(a)anthracene results in decreased expression of HELZ2 mRNA

NCBI chr 2:180,869,408...180,883,851
Ensembl chr 2:180,869,408...180,883,820

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

increases expression

benz(a)anthracene results in increased expression of HERC1 mRNA

NCBI chr 9:66,257,694...66,416,057
Ensembl chr 9:66,257,732...66,416,057

G

hect domain and RLD 3

increases expression

benz(a)anthracene results in increased expression of HERC3 mRNA

NCBI chr 6:58,808,440...58,897,383
Ensembl chr 6:58,808,450...58,897,383

G

hes family bHLH transcription factor 2

increases expression

benz(a)anthracene results in increased expression of HES2 mRNA

NCBI chr 4:152,243,324...152,246,926
Ensembl chr 4:152,243,324...152,246,926

G

hypermethylated in cancer 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA

NCBI chr11:75,052,203...75,059,970
Ensembl chr11:75,055,391...75,060,345

G

hypoxia inducible lipid droplet associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA

NCBI chr 6:29,272,487...29,275,448
Ensembl chr 6:29,272,487...29,275,445

G

hexokinase domain containing 1

increases expression

benz(a)anthracene results in increased expression of HKDC1 mRNA

NCBI chr10:62,218,916...62,259,490
Ensembl chr10:62,218,916...62,258,270

G

hepatic leukemia factor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HLF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA

PMID:26377693 PMID:27858113

NCBI chr11:90,227,361...90,281,745
Ensembl chr11:90,227,362...90,281,721

G

hemicentin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA

NCBI chr 1:150,438,251...150,869,568
Ensembl chr 1:150,438,275...150,869,186

G

high mobility group box 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

high-mobility group high mobility group box 1, pseudogene 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1-PS7 mRNA

NCBI chr 7:41,670,149...41,671,427
Ensembl chr 7:41,670,260...41,670,907

G

high mobility group nucleosomal binding domain 2

increases expression

benz(a)anthracene results in increased expression of HMGN2 mRNA

NCBI chr 4:133,692,050...133,695,302
Ensembl chr 4:133,692,049...133,695,961

G

high-mobility group nucleosome binding domain 5

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HMGN5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:108,048,143...108,056,986
Ensembl chr X:108,048,140...108,057,010

G

histamine N-methyltransferase

decreases expression

benz(a)anthracene results in decreased expression of HNMT mRNA

NCBI chr 2:23,892,923...23,939,756
Ensembl chr 2:23,892,922...23,939,406

G

heterogeneous nuclear ribonucleoprotein A2/B1

increases expression

benz(a)anthracene results in increased expression of HNRNPA2B1 mRNA

NCBI chr 6:51,437,414...51,448,054
Ensembl chr 6:51,437,912...51,446,874

G

heterogeneous nuclear ribonucleoprotein C

decreases expression

benz(a)anthracene results in decreased expression of HNRNPC mRNA

NCBI chr14:52,310,834...52,341,462
Ensembl chr14:52,310,834...52,341,485

G

heterogeneous nuclear ribonucleoprotein D-like

increases expression

benz(a)anthracene results in increased expression of HNRNPDL mRNA

NCBI chr 5:100,181,436...100,187,769
Ensembl chr 5:100,181,436...100,187,523

G

heterogeneous nuclear ribonucleoprotein F

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA

NCBI chr 6:117,877,301...117,902,583
Ensembl chr 6:117,877,285...117,902,583

G

heterogeneous nuclear ribonucleoprotein H1

decreases expression

benz(a)anthracene results in decreased expression of HNRNPH1 mRNA

NCBI chr11:50,266,084...50,277,355
Ensembl chr11:50,267,817...50,277,355

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA

NCBI chr19:42,743,629...42,770,013
Ensembl chr19:42,743,544...42,768,417

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7

increases expression

benz(a)anthracene results in increased expression of HSD3B7 mRNA

NCBI chr 7:127,399,830...127,402,973
Ensembl chr 7:127,399,776...127,402,974

G

heat shock protein 1A

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HSPA1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA

PMID:26377693 PMID:27858113

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 8

decreases expression

benz(a)anthracene results in decreased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 1 (chaperonin)

decreases expression

benz(a)anthracene results in decreased expression of HSPD1 mRNA

NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402

G

HIV-1 Tat interactive protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA

NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723

G

HIV TAT specific factor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HTATSF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:56,098,930...56,112,543
Ensembl chr X:56,098,943...56,112,543

G

hormonally upregulated Neu-associated kinase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HUNK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA

PMID:26377693 PMID:27858113

NCBI chr16:90,182,550...90,296,443
Ensembl chr16:90,182,901...90,296,441

G

hyaluronoglucosaminidase 1

decreases expression

benz(a)anthracene results in decreased expression of HYAL1 mRNA

NCBI chr 9:107,454,149...107,458,898
Ensembl chr 9:107,454,126...107,458,909

G

islet cell autoantigen 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA

NCBI chr 6:8,630,527...8,778,531
Ensembl chr 6:8,630,527...8,778,488

G

icos ligand

increases expression

benz(a)anthracene results in increased expression of ICOSL mRNA

NCBI chr10:77,904,921...77,915,359
Ensembl chr10:77,905,136...77,919,747

G

inhibitor of DNA binding 1, HLH protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

iduronidase, alpha-L

increases expression

benz(a)anthracene results in increased expression of IDUA mRNA

NCBI chr 5:108,808,197...108,833,312
Ensembl chr 5:108,808,197...108,832,423

G

immediate early response 3

increases expression

benz(a)anthracene results in increased expression of IER3 mRNA

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

immediate early response 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA

NCBI chr 1:154,972,113...154,975,382
Ensembl chr 1:154,972,107...154,975,382

G

intermediate filament family orphan 1

increases expression

benz(a)anthracene results in increased expression of IFFO1 mRNA

NCBI chr 6:125,122,167...125,138,746
Ensembl chr 6:125,122,204...125,138,745

G

interferon activated gene 203

decreases expression

benz(a)anthracene results in decreased expression of IFI203 mRNA

NCBI chr 1:173,747,966...173,770,432
Ensembl chr 1:173,747,973...173,770,238

G

interferon activated gene 211

decreases expression

benz(a)anthracene results in decreased expression of MNDA mRNA

NCBI chr 1:173,723,907...173,740,650
Ensembl chr 1:173,723,911...173,740,612

G

interferon, alpha-inducible protein 27 like 2A

decreases expression

benz(a)anthracene results in decreased expression of IFI27L2A mRNA

NCBI chr12:103,400,132...103,409,939
Ensembl chr12:103,408,426...103,409,939

G

interferon, alpha-inducible protein 27 like 2B

decreases expression

benz(a)anthracene results in decreased expression of IFI27L1 mRNA

NCBI chr12:103,417,157...103,423,482
Ensembl chr12:103,417,157...103,423,482

G

interferon-induced protein 44

decreases expression

benz(a)anthracene results in decreased expression of IFI44 mRNA

NCBI chr 3:151,436,559...151,455,580
Ensembl chr 3:151,436,559...151,455,597

G

interferon induced protein with tetratricpeptide repeats 1B like 1

decreases expression

benz(a)anthracene results in decreased expression of IFIT1 mRNA

NCBI chr19:34,570,288...34,640,382
Ensembl chr19:34,570,291...34,579,356

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

benz(a)anthracene results in decreased expression of IFIT3 mRNA

NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131

G

interferon induced transmembrane protein 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IFITM6 mRNA

NCBI chr 7:140,595,725...140,596,805
Ensembl chr 7:140,595,612...140,597,837

G

insulin-like growth factor binding protein 5

decreases expression

benz(a)anthracene results in decreased expression of IGFBP5 mRNA

NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043

G

IGF-like family receptor 1

affects expression

benz(a)anthracene affects the expression of IGFLR1 mRNA

NCBI chr 7:30,264,852...30,267,387
Ensembl chr 7:30,264,852...30,267,387

G

Immunoglobulin heavy chain (gamma polypeptide)

decreases expression

benz(a)anthracene results in decreased expression of IGHG mRNA

G

immunoglobulin heavy constant mu

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IGHM mRNA

NCBI chr12:113,382,446...113,386,350
Ensembl chr12:113,382,178...113,386,350

G

immunoglobulin heavy variable 1-77

increases expression

benz(a)anthracene results in increased expression of IGHV1-77 mRNA

NCBI chr12:115,825,487...115,825,780
Ensembl chr12:115,825,487...115,825,975

G

immunoglobulin kappa variable 3-4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IGKV3-4 mRNA

NCBI chr 6:70,648,773...70,649,361
Ensembl chr 6:70,648,772...70,649,361

G

immunoglobulin lambda variable 1

increases expression

benz(a)anthracene results in increased expression of IGLV1 mRNA

NCBI chr16:18,903,767...18,904,210
Ensembl chr16:18,903,767...18,904,250

G

immunoglobulin superfamily, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA

NCBI chr 3:101,284,306...101,370,375
Ensembl chr 3:101,284,399...101,370,375

G

immunoglobulin superfamily, member 6

increases expression

benz(a)anthracene results in increased expression of IGSF6 mRNA

NCBI chr 7:120,663,290...120,673,753
Ensembl chr 7:120,663,290...120,673,795

G

interferon inducible GTPase 1

decreases expression

benz(a)anthracene results in decreased expression of IIGP1 mRNA

NCBI chr18:60,506,688...60,525,706
Ensembl chr18:60,509,099...60,525,706

G

IKAROS family zinc finger 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA

NCBI chr10:128,466,708...128,505,668
Ensembl chr10:128,466,712...128,505,227

G

interleukin 18 receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA

NCBI chr 1:40,504,712...40,540,014
Ensembl chr 1:40,504,712...40,540,014

G

interleukin 1 alpha

increases expression

benz(a)anthracene results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

decreases expression

benz(a)anthracene results in decreased expression of IL1B mRNA

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 4 induced 1

increases expression

benz(a)anthracene results in increased expression of IL4I1 mRNA

NCBI chr 7:44,485,712...44,490,233
Ensembl chr 7:44,465,811...44,490,233

G

interleukin 6

increases secretion
increases expression
multiple interactions

benz(a)anthracene results in increased secretion of IL6 protein
benz(a)anthracene results in increased expression of IL6 mRNA
[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased secretion of IL6 protein; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Curcumin inhibits the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA]; RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of IL6 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased secretion of IL6 protein]

PMID:8156173 PMID:22643241 PMID:23396138 PMID:25433334

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 7 receptor

increases expression

benz(a)anthracene results in increased expression of IL7R mRNA

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

interleukin enhancer binding factor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA

NCBI chr 3:90,383,421...90,395,686
Ensembl chr 3:90,383,433...90,395,686

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ILRUN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA

PMID:26377693 PMID:27858113

NCBI chr17:27,970,206...28,039,516
Ensembl chr17:27,970,209...28,039,622

G

InaF motif containing 2

decreases expression

benz(a)anthracene results in decreased expression of INAFM2 mRNA

NCBI chr 2:118,576,239...118,579,291
Ensembl chr 2:118,576,239...118,579,291

G

inka box actin regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA

NCBI chr 3:105,611,915...105,628,158
Ensembl chr 3:105,611,915...105,628,158

G

INO80 complex subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA

NCBI chr 6:83,098,746...83,102,100
Ensembl chr 6:83,098,746...83,102,412

G

inositol polyphosphate 5-phosphatase K

increases expression

benz(a)anthracene results in increased expression of INPP5K mRNA

NCBI chr11:75,519,893...75,539,691
Ensembl chr11:75,521,814...75,539,697

G

integrator complex subunit 6 like

increases expression

benz(a)anthracene results in increased expression of INTS6L mRNA

NCBI chr X:55,500,180...55,553,201
Ensembl chr X:55,500,217...55,553,203

G

IQ motif containing E

increases expression

benz(a)anthracene results in increased expression of IQCE mRNA

NCBI chr 5:140,648,308...140,688,158
Ensembl chr 5:140,647,582...140,688,133

G

IQ motif and Sec7 domain 3

increases expression

benz(a)anthracene results in increased expression of IQSEC3 mRNA

NCBI chr 6:121,349,886...121,450,697
Ensembl chr 6:121,349,892...121,450,637

G

inositol 1,4,5-triphosphate receptor associated 2

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA
benz(a)anthracene results in increased expression of IRAG2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:145,061,357...145,120,655
Ensembl chr 6:145,061,379...145,120,660

G

interferon regulatory factor 2 binding protein 2

decreases expression

benz(a)anthracene results in decreased expression of IRF2BP2 mRNA

NCBI chr 8:127,315,035...127,320,725
Ensembl chr 8:127,315,035...127,320,725

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA

NCBI chr12:86,927,477...86,931,588
Ensembl chr12:86,927,475...86,931,572

G

interferon regulatory factor 7

decreases expression

benz(a)anthracene results in decreased expression of IRF7 mRNA

NCBI chr 7:140,843,096...140,846,412
Ensembl chr 7:140,842,619...140,846,394

G

ISG15 ubiquitin-like modifier

decreases expression

benz(a)anthracene results in decreased expression of ISG15 mRNA

NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253

G

integrin alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA

NCBI chr13:115,094,615...115,238,500
Ensembl chr13:115,089,632...115,238,500

G

integrin alpha 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ITGA2 mRNA
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]

NCBI chr13:114,969,617...115,068,588
Ensembl chr13:114,969,617...115,068,636

G

integrin alpha 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA

NCBI chr10:128,769,633...128,794,155
Ensembl chr10:128,769,645...128,794,155

G

integrin beta 1 (fibronectin receptor beta)

decreases expression

benz(a)anthracene results in decreased expression of ITGB1 mRNA

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

G

inter alpha-trypsin inhibitor, heavy chain 4

increases expression

benz(a)anthracene results in increased expression of ITIH4 mRNA

NCBI chr14:30,608,433...30,623,943
Ensembl chr14:30,608,433...30,624,310

G

inositol 1,4,5-triphosphate receptor interacting protein-like 2

decreases expression

benz(a)anthracene results in decreased expression of ITPRIPL2 mRNA

NCBI chr 7:118,084,334...118,091,198
Ensembl chr 7:118,084,334...118,091,198

G

intersectin 1 (SH3 domain protein 1A)

decreases expression

benz(a)anthracene results in decreased expression of ITSN1 mRNA

NCBI chr16:91,526,198...91,717,479
Ensembl chr16:91,526,169...91,717,485

G

IZUMO family member 4

affects expression

benz(a)anthracene affects the expression of IZUMO4 mRNA

NCBI chr10:80,537,858...80,541,216
Ensembl chr10:80,538,018...80,541,207

G

jade family PHD finger 1

decreases expression

benz(a)anthracene results in decreased expression of JADE1 mRNA

NCBI chr 3:41,510,169...41,571,299
Ensembl chr 3:41,510,166...41,571,299

G

Janus kinase 3

increases expression

benz(a)anthracene results in increased expression of JAK3 mRNA

NCBI chr 8:72,129,027...72,143,221
Ensembl chr 8:72,128,940...72,143,219

G

jun proto-oncogene

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA

NCBI chr 4:98,643,129...98,706,295
Ensembl chr 4:98,643,135...98,705,774

G

kazrin, periplakin interacting protein

increases expression

benz(a)anthracene results in increased expression of KAZN mRNA

NCBI chr 4:141,829,701...142,801,231
Ensembl chr 4:141,829,701...142,205,056

G

potassium voltage-gated channel, Isk-related subfamily, gene 3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of KCNE3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:99,825,714...99,834,076
Ensembl chr 7:99,825,709...99,834,076

G

KCNQ1 overlapping transcript 1

decreases expression

benz(a)anthracene results in decreased expression of KCNQ1OT1 mRNA

NCBI chr 7:142,766,848...142,850,284
Ensembl chr 7:142,731,402...142,850,327

G

potassium channel tetramerisation domain containing 12b

increases expression

benz(a)anthracene results in increased expression of KCTD12B mRNA

NCBI chr X:152,468,150...152,479,382
Ensembl chr X:152,468,150...152,479,387

G

kinesin family member 21B

increases expression

benz(a)anthracene results in increased expression of KIF21B mRNA

NCBI chr 1:136,059,128...136,105,739
Ensembl chr 1:136,059,127...136,105,736

G

kinesin family member 26B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA

NCBI chr 1:178,356,690...178,766,765
Ensembl chr 1:178,356,690...178,766,765

G

kinesin family member C2

affects expression

benz(a)anthracene affects the expression of KIFC2 mRNA

NCBI chr15:76,543,984...76,552,396
Ensembl chr15:76,544,058...76,552,396

G

KIT proto-oncogene receptor tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of KIT mRNA

NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382

G

kit ligand

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of KITL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA

PMID:26377693 PMID:27858113

NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278

G

Kruppel-like transcription factor 12

decreases expression

benz(a)anthracene results in decreased expression of KLF12 mRNA

NCBI chr14:100,103,617...100,719,681
Ensembl chr14:100,108,068...100,522,115

G

Kruppel-like transcription factor 5

decreases expression

benz(a)anthracene results in decreased expression of KLF5 mRNA

NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472

G

kelch domain containing 8B

affects expression

benz(a)anthracene affects the expression of KLHDC8B mRNA

NCBI chr 9:108,324,834...108,338,780
Ensembl chr 9:108,324,835...108,338,780

G

kelch domain containing 9

increases expression

benz(a)anthracene results in increased expression of KLHDC9 mRNA

NCBI chr 1:171,186,017...171,188,366
Ensembl chr 1:171,186,014...171,188,366

G

kelch-like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA

NCBI chr 5:65,264,894...65,325,490
Ensembl chr 5:65,264,882...65,325,531

G

kelch-like 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA

NCBI chr16:19,765,242...19,801,766
Ensembl chr16:19,765,246...19,801,787

G

kallikrein 1-related peptidase b24

decreases expression

benz(a)anthracene results in decreased expression of KLK1B24 mRNA

NCBI chr 7:43,837,658...43,841,879
Ensembl chr 7:43,837,660...43,841,879

G

kallikrein 1-related peptidase b27

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLK1B27 mRNA

NCBI chr 7:43,701,714...43,706,136
Ensembl chr 7:43,701,714...43,706,136

G

kallikrein 1-related peptidase b5

decreases expression

benz(a)anthracene results in decreased expression of KLK1B5 mRNA

NCBI chr 7:43,865,898...43,870,127
Ensembl chr 7:43,865,369...43,870,127

G

killer cell lectin-like receptor, subfamily A, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA1 mRNA

NCBI chr 6:130,340,881...130,363,837
Ensembl chr 6:130,340,880...130,363,837

G

killer cell lectin-like receptor, subfamily A, member 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA15 mRNA

G

killer cell lectin-like receptor, subfamily A, member 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA16 mRNA

G

killer cell lectin-like receptor subfamily A, member 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA22 mRNA

G

killer cell lectin-like receptor, subfamily A, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA4 mRNA

NCBI chr 6:130,020,693...130,044,242
Ensembl chr 6:130,020,694...130,044,234

G

killer cell lectin-like receptor, subfamily A, member 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KLRA8 mRNA

NCBI chr 6:130,092,189...130,106,861
Ensembl chr 6:130,092,189...130,106,861

G

killer cell lectin-like receptor, subfamily D, member 1

increases expression

benz(a)anthracene results in increased expression of KLRD1 mRNA

NCBI chr 6:129,565,055...129,575,738
Ensembl chr 6:129,568,745...129,575,738

G

lysine (K)-specific methyltransferase 2D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA

NCBI chr15:98,729,550...98,771,958
Ensembl chr15:98,729,550...98,769,085

G

lysine methyltransferase 5A

decreases expression

benz(a)anthracene results in decreased expression of KMT5A mRNA

NCBI chr 5:124,577,980...124,600,371
Ensembl chr 5:124,577,993...124,600,371

G

lysine methyltransferase 5B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA

NCBI chr19:3,816,436...3,868,303
Ensembl chr19:3,817,421...3,868,303

G

KRAB-A domain containing 1

increases expression

benz(a)anthracene results in increased expression of KRBA1 mRNA

NCBI chr 6:48,371,577...48,396,789
Ensembl chr 6:48,372,520...48,396,715

G

keratin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA

NCBI chr11:100,022,585...100,026,775
Ensembl chr11:100,022,584...100,026,754

G

keratin 31

increases expression

benz(a)anthracene results in increased expression of KRT31 mRNA

NCBI chr11:99,937,472...99,941,377
Ensembl chr11:99,937,472...99,941,377

G

keratin associated protein 19-5

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of KRTAP19-4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KRTAP19-4 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:88,692,856...88,693,337
Ensembl chr16:88,692,856...88,693,345

G

keratin associated protein 20-20

decreases expression

benz(a)anthracene results in decreased expression of KRTAP20-2 mRNA

NCBI chr16:88,948,027...88,948,191
Ensembl chr16:88,947,974...88,948,438

G

keratinocyte associated protein 3

decreases expression

benz(a)anthracene results in decreased expression of KRTCAP3 mRNA

NCBI chr 5:31,409,050...31,410,541
Ensembl chr 5:31,409,035...31,410,546

G

kynurenine aminotransferase 1

decreases expression

benz(a)anthracene results in decreased expression of KYAT1 mRNA

NCBI chr 2:30,075,136...30,096,307
Ensembl chr 2:30,075,136...30,095,859

G

laminin, alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA

NCBI chr17:68,004,129...68,129,640
Ensembl chr17:68,004,254...68,129,642

G

LIM and SH3 protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA

NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590

G

Leber congenital amaurosis 5-like

increases expression

benz(a)anthracene results in increased expression of LCA5L mRNA

NCBI chr16:95,959,605...95,993,450
Ensembl chr16:95,959,607...95,993,471

G

ligand dependent nuclear receptor corepressor-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of LCORL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:45,854,523...46,015,213
NCBI chr 5:45,877,009...45,884,920
Ensembl chr 5:45,854,523...46,014,957

G

left right determination factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of LEFTY1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:180,762,587...180,765,966
Ensembl chr 1:180,762,587...180,765,965

G

leukocyte receptor cluster (LRC) member 8

increases expression

benz(a)anthracene results in increased expression of LENG8 mRNA

NCBI chr 7:4,140,014...4,151,176
Ensembl chr 7:4,140,038...4,151,176

G

Leo1, Paf1/RNA polymerase II complex component

decreases expression

benz(a)anthracene results in decreased expression of LEO1 mRNA

NCBI chr 9:75,348,072...75,373,714
Ensembl chr 9:75,348,806...75,373,714

G

leptin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

lectin, galactose binding, soluble 1

increases expression

benz(a)anthracene results in increased expression of LGALS1 mRNA

NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665

G

lectin, galactose binding, soluble 4

affects expression

benz(a)anthracene affects the expression of LGALS4 mRNA

NCBI chr 7:28,533,559...28,541,128
Ensembl chr 7:28,533,279...28,541,133

G

lipoma HMGIC fusion partner-like 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA

NCBI chr 5:22,951,052...23,480,595
Ensembl chr 5:22,951,057...23,480,595

G

Lck interacting transmembrane adaptor 1

affects expression

benz(a)anthracene affects the expression of LIME1 mRNA

NCBI chr 2:181,023,028...181,025,421
Ensembl chr 2:181,021,871...181,025,421

G

lysosomal acid lipase A

decreases expression

benz(a)anthracene results in decreased expression of LIPA mRNA

NCBI chr19:34,469,716...34,504,874
Ensembl chr19:34,469,718...34,504,874

G

lipin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA

NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967

G

LRAT domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of LRATD1 mRNA

NCBI chr12:14,197,599...14,202,039
Ensembl chr12:14,196,831...14,202,055

G

low density lipoprotein-related protein 12

increases expression

benz(a)anthracene results in increased expression of LRP12 mRNA

NCBI chr15:39,733,985...39,807,417
Ensembl chr15:39,733,985...39,807,390

G

leucine rich repeat containing 36

increases expression

benz(a)anthracene results in increased expression of LRRC36 mRNA

NCBI chr 8:106,140,230...106,190,718
Ensembl chr 8:106,140,203...106,190,718

G

leucine rich repeat containing 45

affects expression

benz(a)anthracene affects the expression of LRRC45 mRNA

NCBI chr11:120,604,779...120,611,954
Ensembl chr11:120,604,751...120,611,954

G

leucine rich repeat containing 71

increases expression

benz(a)anthracene results in increased expression of LRRC71 mRNA

NCBI chr 3:87,644,227...87,655,930
Ensembl chr 3:87,644,230...87,655,932

G

leucine rich repeat containing 75B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA

NCBI chr10:75,385,953...75,396,532
Ensembl chr10:75,385,957...75,396,164

G

leucine-rich repeat kinase 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of LRRK1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:65,908,493...66,038,089
Ensembl chr 7:65,876,660...66,038,098

G

leucine rich repeat neuronal 4

decreases expression

benz(a)anthracene results in decreased expression of LRRN4 mRNA

NCBI chr 2:132,710,436...132,735,930
Ensembl chr 2:132,710,225...132,722,811

G

leucine-rich repeats and transmembrane domains 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of LRTM2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:119,292,094...119,315,009
Ensembl chr 6:119,292,094...119,307,727

G

LSM family member 14B

increases expression

benz(a)anthracene results in increased expression of LSM14B mRNA

NCBI chr 2:179,666,770...179,677,254
Ensembl chr 2:179,666,780...179,677,258

G

leukocyte specific transcript 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA

NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415

G

leukotriene C4 synthase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA

NCBI chr11:50,127,288...50,129,378
Ensembl chr11:50,127,288...50,129,443

G

LUC7-like 3 (S. cerevisiae)

decreases expression

benz(a)anthracene results in decreased expression of LUC7L3 mRNA

NCBI chr11:94,181,899...94,213,196
Ensembl chr11:94,178,716...94,212,814

G

lumican

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA

NCBI chr10:97,401,363...97,408,565
Ensembl chr10:97,400,990...97,408,565

G

lymphocyte antigen 6 family member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA

NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880

G

lymphocyte antigen 6 family member C1

decreases expression

benz(a)anthracene results in decreased expression of LY6C1 mRNA

NCBI chr15:74,915,867...74,920,690
Ensembl chr15:74,915,867...74,920,679

G

lymphocyte antigen 6 family member G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6G mRNA

NCBI chr15:75,027,110...75,030,977
Ensembl chr15:75,027,089...75,030,975

G

lymphatic vessel endothelial hyaluronan receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA

NCBI chr 7:110,449,814...110,462,160
Ensembl chr 7:110,449,814...110,462,446

G

lysozyme-like 4

increases expression

benz(a)anthracene results in increased expression of LYZL4 mRNA

NCBI chr 9:121,406,907...121,471,187
Ensembl chr 9:121,406,909...121,471,162

G

leucine-zipper-like transcriptional regulator, 1

increases expression

benz(a)anthracene results in increased expression of LZTR1 mRNA

NCBI chr16:17,326,124...17,344,197
Ensembl chr16:17,326,552...17,344,197

G

leucine zipper, putative tumor suppressor family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA

NCBI chr 2:130,474,685...130,484,764
Ensembl chr 2:130,474,759...130,484,723

G

MAGE family member H1

increases expression

benz(a)anthracene results in increased expression of MAGEH1 mRNA

NCBI chr X:151,819,162...151,820,559
Ensembl chr X:151,819,162...151,820,571

G

membrane associated guanylate kinase, WW and PDZ domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA

NCBI chr 3:103,920,575...104,127,722
Ensembl chr 3:103,920,575...104,127,690

G

magnesium transporter 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MAGT1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:105,011,690...105,055,408
Ensembl chr X:105,011,690...105,055,512

G

MALT1 paracaspase

increases expression

benz(a)anthracene results in increased expression of MALT1 mRNA

NCBI chr18:65,564,010...65,612,138
Ensembl chr18:65,564,009...65,612,138

G

mesencephalic astrocyte-derived neurotrophic factor

decreases expression

benz(a)anthracene results in decreased expression of MANF mRNA

NCBI chr 9:106,765,952...106,769,137
Ensembl chr 9:106,715,511...106,769,178

G

monoamine oxidase A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

mitogen-activated protein kinase kinase kinase 14

increases expression

benz(a)anthracene results in increased expression of MAP3K14 mRNA

NCBI chr11:103,110,590...103,158,227
Ensembl chr11:103,110,588...103,158,298

G

mitogen-activated protein kinase kinase kinase kinase 2

increases expression

benz(a)anthracene results in increased expression of MAP4K2 mRNA

NCBI chr19:6,391,023...6,405,649
Ensembl chr19:6,391,165...6,405,645

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA

NCBI chr 1:39,939,806...40,065,470
Ensembl chr 1:39,940,073...40,065,470

G

mitogen-activated protein kinase 14

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

mitogen-activated protein kinase 8 interacting protein 3

affects expression

benz(a)anthracene affects the expression of MAPK8IP3 mRNA

NCBI chr17:25,116,480...25,155,951
Ensembl chr17:25,111,127...25,155,942

G

membrane associated ring-CH-type finger 1

increases expression

benz(a)anthracene results in increased expression of MARCHF1 mRNA

NCBI chr 8:66,070,558...66,925,761
Ensembl chr 8:66,070,552...66,924,289

G

macrophage receptor with collagenous structure

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA

NCBI chr 1:120,402,267...120,432,753
Ensembl chr 1:120,402,267...120,432,753

G

MARVEL (membrane-associating) domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA

NCBI chr 8:110,674,541...110,688,837
Ensembl chr 8:110,674,546...110,688,835

G

methionine adenosyltransferase 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA

NCBI chr14:40,826,969...40,846,385
Ensembl chr14:40,826,992...40,846,369

G

methionine adenosyltransferase 2A

decreases expression

benz(a)anthracene results in decreased expression of MAT2A mRNA

NCBI chr 6:72,409,779...72,416,539
Ensembl chr 6:72,409,782...72,416,541

G

MAP3K12 binding inhibitory protein 1

increases expression

benz(a)anthracene results in increased expression of MBIP mRNA

NCBI chr12:56,375,091...56,392,681
Ensembl chr12:56,375,088...56,392,679

G

membrane bound O-acyltransferase domain containing 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MBOAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:24,881,401...25,014,399
Ensembl chr12:24,880,878...25,014,396

G

melanoma cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA

NCBI chr 9:44,045,958...44,054,024
Ensembl chr 9:44,045,766...44,054,024

G

minichromosome maintenance complex component 6

increases expression

benz(a)anthracene results in increased expression of MCM6 mRNA

NCBI chr 1:128,259,312...128,287,442
Ensembl chr 1:128,259,327...128,287,401

G

mucolipin 3

increases expression

benz(a)anthracene results in increased expression of MCOLN3 mRNA

NCBI chr 3:145,799,032...145,847,563
Ensembl chr 3:145,823,205...145,847,561

G

mast cell protease 1

increases expression

benz(a)anthracene results in increased expression of MCPT1 mRNA

NCBI chr14:56,255,421...56,257,848
Ensembl chr14:56,255,428...56,257,841

G

transformed mouse 3T3 cell double minute 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

transformed mouse 3T3 cell double minute 4

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MDM4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:132,913,843...132,958,325
Ensembl chr 1:132,887,222...132,958,299

G

midasin AAA ATPase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA

NCBI chr 4:32,656,867...32,775,217
Ensembl chr 4:32,657,119...32,775,217

G

MDS1 and EVI1 complex locus

decreases expression

benz(a)anthracene results in decreased expression of MECOM mRNA

NCBI chr 3:30,005,445...30,563,937
Ensembl chr 3:30,005,445...30,602,157

G

maternally expressed 3

affects expression

benz(a)anthracene affects the expression of MEG3 mRNA

NCBI chr12:109,506,879...109,538,163
Ensembl chr12:109,506,877...109,538,165

G

multiple EGF-like-domains 6

increases expression

benz(a)anthracene results in increased expression of MEGF6 mRNA

NCBI chr 4:154,255,156...154,360,178
Ensembl chr 4:154,255,187...154,360,170

G

meiosis specific with OB domains

decreases expression

benz(a)anthracene results in decreased expression of MEIOB mRNA

NCBI chr17:25,023,275...25,058,762
Ensembl chr17:25,023,263...25,058,762

G

mesoderm posterior 1

increases expression

benz(a)anthracene results in increased expression of MESP1 mRNA

NCBI chr 7:79,441,989...79,443,338
Ensembl chr 7:79,441,989...79,443,536

G

methyltransferase like 18

increases expression

benz(a)anthracene results in increased expression of METTL18 mRNA

NCBI chr 1:163,822,458...163,824,812
Ensembl chr 1:163,822,458...163,824,812

G

microfibrillar-associated protein 1B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MFAP1B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP1B mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:121,292,147...121,304,504
Ensembl chr 2:121,290,716...121,304,548

G

microfibrillar-associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA

NCBI chr 4:140,737,735...140,743,284
Ensembl chr 4:140,737,729...140,743,295

G

microfibrillar-associated protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA

NCBI chr11:61,376,257...61,379,536
Ensembl chr11:61,376,257...61,379,726

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

benz(a)anthracene results in increased expression of MFSD2A mRNA

NCBI chr 4:122,840,643...122,855,844
Ensembl chr 4:122,840,643...122,854,981

G

mannoside acetylglucosaminyltransferase 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MGAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:69,230,932...69,233,547
Ensembl chr12:69,230,931...69,233,544

G

monoglyceride lipase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA

NCBI chr 6:88,701,397...88,805,342
Ensembl chr 6:88,701,394...88,805,342

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA

NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995

G

MIA SH3 domain ER export factor 3

decreases expression

benz(a)anthracene results in decreased expression of MIA3 mRNA

NCBI chr 1:183,107,091...183,151,091
Ensembl chr 1:183,107,682...183,150,894

G

microtubule associated monooxygenase, calponin and LIM domain containing 1

increases expression

benz(a)anthracene results in increased expression of MICAL1 mRNA

NCBI chr10:41,351,693...41,363,026
Ensembl chr10:41,352,310...41,363,028

G

mitotic deacetylase associated SANT domain protein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MIDEAS mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA

PMID:26377693 PMID:27858113

NCBI chr12:84,195,942...84,265,679
Ensembl chr12:84,195,950...84,265,655

G

Mir17 host gene (non-protein coding)

affects expression

benz(a)anthracene affects the expression of MIR17HG mRNA

NCBI chr14:115,281,822...115,284,160
Ensembl chr14:115,278,211...115,284,162

G

microRNA 181d

increases expression

benz(a)anthracene results in increased expression of MIR181D mRNA

NCBI chr 8:84,905,345...84,905,416
Ensembl chr 8:84,905,345...84,905,416

G

microRNA 200c

increases expression

benz(a)anthracene results in increased expression of MIR200C mRNA

NCBI chr 6:124,695,285...124,695,353
Ensembl chr 6:124,695,285...124,695,353

G

microRNA 22

increases expression

benz(a)anthracene results in increased expression of MIR22 mRNA

NCBI chr11:75,354,542...75,354,636
Ensembl chr11:75,354,542...75,354,636

G

microRNA 221

increases expression

benz(a)anthracene results in increased expression of MIR221 mRNA

NCBI chr X:19,012,533...19,012,627
Ensembl chr X:19,012,533...19,012,627

G

microRNA 23b

increases expression

benz(a)anthracene results in increased expression of MIR23B mRNA

NCBI chr13:63,448,298...63,448,371
Ensembl chr13:63,448,298...63,448,371

G

microRNA 33

decreases expression

benz(a)anthracene results in decreased expression of MIR33A mRNA

NCBI chr15:82,082,323...82,082,391
Ensembl chr15:82,082,323...82,082,391

G

miRNA containing gene

decreases expression

benz(a)anthracene results in decreased expression of MIRG mRNA

NCBI chr12:109,701,415...109,715,892
Ensembl chr12:109,696,198...109,715,898

G

microRNA let7b

increases expression

benz(a)anthracene results in increased expression of MIRLET7B mRNA

NCBI chr15:85,591,520...85,591,604
Ensembl chr15:85,591,520...85,591,604

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of MKI67 protein; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA

PMID:27858113 PMID:38237855

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

McKusick-Kaufman syndrome

decreases expression

benz(a)anthracene results in decreased expression of MKKS mRNA

NCBI chr 2:136,715,700...136,733,422
Ensembl chr 2:136,715,700...136,733,309

G

melanophilin

increases expression

benz(a)anthracene results in increased expression of MLPH mRNA

NCBI chr 1:90,842,750...90,878,864
Ensembl chr 1:90,842,807...90,878,864

G

monocyte to macrophage differentiation-associated 2

decreases expression

benz(a)anthracene results in decreased expression of MMD2 mRNA

NCBI chr 5:142,549,229...142,594,886
Ensembl chr 5:142,548,113...142,594,555

G

matrix metallopeptidase 14 (membrane-inserted)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MMP2 mRNA
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 8

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MMP8 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486

G

multimerin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA

NCBI chr14:34,097,461...34,126,244
Ensembl chr14:34,097,422...34,126,244

G

microrchidia 4

decreases expression

benz(a)anthracene results in decreased expression of MORC4 mRNA

NCBI chr X:138,722,384...138,772,440
Ensembl chr X:138,722,381...138,772,426

G

macrophage expressed gene 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA

NCBI chr19:12,438,134...12,442,649
Ensembl chr19:12,438,143...12,442,649

G

M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)

decreases expression

benz(a)anthracene results in decreased expression of MPHOSPH10 mRNA

NCBI chr 7:64,026,289...64,041,984
Ensembl chr 7:64,026,275...64,042,016

G

myoregulin

decreases expression

benz(a)anthracene results in decreased expression of MRLN mRNA

NCBI chr10:70,040,494...70,055,541
Ensembl chr10:70,040,494...70,055,541

G

mitochondrial ribosomal protein S6

decreases expression

benz(a)anthracene results in decreased expression of MRPS6 mRNA

NCBI chr16:91,855,224...91,909,115
Ensembl chr16:91,855,158...91,909,115

G

membrane-spanning 4-domains, subfamily A, member 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MS4A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:11,227,043...11,243,513
Ensembl chr19:11,227,039...11,243,605

G

membrane-spanning 4-domains, subfamily A, member 4A

increases expression

benz(a)anthracene results in increased expression of MS4A4A mRNA

NCBI chr19:11,352,827...11,370,682
Ensembl chr19:11,352,887...11,370,154

G

membrane-spanning 4-domains, subfamily A, member 4C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A4C mRNA

NCBI chr19:11,382,081...11,404,610
Ensembl chr19:11,382,134...11,404,610

G

membrane-spanning 4-domains, subfamily A, member 8A

increases expression

benz(a)anthracene results in increased expression of MS4A8A mRNA

NCBI chr19:11,044,835...11,058,467
Ensembl chr19:11,044,835...11,058,466

G

mesothelin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MSLN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA

PMID:26377693 PMID:27858113

NCBI chr17:25,967,587...25,973,352
Ensembl chr17:25,967,587...25,973,352

G

macrophage scavenger receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA

NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714

G

cytochrome c oxidase I, mitochondrial

decreases expression

benz(a)anthracene results in decreased expression of COX1 mRNA

NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872

G

NADH dehydrogenase 4L, mitochondrial

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA

NCBI chr MT:9,877...10,173
Ensembl chr MT:9,877...10,173

G

NADH dehydrogenase 6, mitochondrial

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ND6 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA

PMID:26377693 PMID:27858113

NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MTHFD1L mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA

PMID:26377693 PMID:27858113

NCBI chr10:3,918,282...4,117,081
Ensembl chr10:3,923,118...4,117,081

G

myotubularin related protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA

NCBI chr 7:63,937,443...63,990,556
Ensembl chr 7:63,937,401...63,990,554

G

metaxin 3

decreases expression

benz(a)anthracene results in decreased expression of MTX3 mRNA

NCBI chr13:92,981,251...92,994,738
Ensembl chr13:92,981,268...92,994,738

G

mucin 4

increases expression

benz(a)anthracene results in increased expression of MUC4 mRNA

NCBI chr16:32,555,089...32,602,786
Ensembl chr16:32,555,015...32,602,754

G

major urinary protein 19

decreases expression

benz(a)anthracene results in decreased expression of MUP19 mRNA

NCBI chr 4:61,696,561...61,700,597
Ensembl chr 4:61,696,561...61,700,506

G

major urinary protein 2

decreases expression

benz(a)anthracene results in decreased expression of MUP2 mRNA

NCBI chr 4:60,135,913...60,139,977
Ensembl chr 4:60,135,932...60,154,289

G

major urinary protein 6

decreases expression

benz(a)anthracene results in decreased expression of MUP6 mRNA

NCBI chr 4:60,003,481...60,007,274
Ensembl chr 4:59,964,294...60,007,274

G

major urinary protein 9

decreases expression

benz(a)anthracene results in decreased expression of MUP9 mRNA

NCBI chr 4:60,374,045...60,378,084
Ensembl chr 4:60,374,045...60,377,951

G

MX dynamin-like GTPase 2

decreases expression

benz(a)anthracene results in decreased expression of MX2 mRNA

NCBI chr16:97,337,281...97,362,101
Ensembl chr16:97,336,508...97,362,100

G

myeloid-associated differentiation marker

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MYADM mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:3,337,563...3,347,871
Ensembl chr 7:3,337,605...3,348,958

G

myosin IG

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MYO1G mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA

PMID:26377693 PMID:27858113

NCBI chr11:6,456,548...6,470,960
Ensembl chr11:6,456,548...6,470,965

G

myomesin family, member 3

decreases expression

benz(a)anthracene results in decreased expression of MYOM3 mRNA

NCBI chr 4:135,486,688...135,542,882
Ensembl chr 4:135,487,026...135,542,875

G

nucleosome assembly protein 1-like 4

decreases expression

benz(a)anthracene results in decreased expression of NAP1L4 mRNA

NCBI chr 7:143,067,316...143,103,698
Ensembl chr 7:143,067,316...143,102,843

G

N-acetyltransferase 8 (GCN5-related)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA

NCBI chr 6:85,807,369...85,813,839
Ensembl chr 6:85,807,370...85,809,064

G

N-acetyltransferase 8B, pseudogene

decreases expression

benz(a)anthracene results in decreased expression of NAT8B mRNA

NCBI chr 6:85,909,539...85,910,364
Ensembl chr 6:85,909,663...85,910,361

G

neurobeachin like 1

decreases expression

benz(a)anthracene results in decreased expression of NBEAL1 mRNA

NCBI chr 1:60,217,910...60,377,487
Ensembl chr 1:60,219,758...60,377,487

G

non-SMC condensin I complex, subunit H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA

NCBI chr 2:126,945,729...126,975,857
Ensembl chr 2:126,945,729...126,975,874

G

nuclear cap binding protein subunit 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NCBP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:31,767,364...31,777,290
Ensembl chr16:31,767,331...31,780,599

G

nuclear cap binding subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA

NCBI chr11:72,937,443...72,974,405
Ensembl chr11:72,938,609...72,980,143

G

neutral cholesterol ester hydrolase 1

increases expression

benz(a)anthracene results in increased expression of NCEH1 mRNA

NCBI chr 3:27,237,153...27,299,112
Ensembl chr 3:27,237,114...27,338,757

G

NDC80 kinetochore complex component

decreases expression

benz(a)anthracene results in decreased expression of NDC80 mRNA

NCBI chr17:71,803,095...71,833,852
Ensembl chr17:71,803,095...71,833,852

G

NADPH dependent diflavin oxidoreductase 1

decreases expression

benz(a)anthracene results in decreased expression of NDOR1 mRNA

NCBI chr 2:25,134,825...25,145,458
Ensembl chr 2:25,134,833...25,146,034
Ensembl chr 2:25,134,833...25,146,034
Ensembl chr 2:25,134,833...25,146,034

G

nuclear paraspeckle assembly transcript 1 (non-protein coding)

affects expression

benz(a)anthracene affects the expression of NEAT1 mRNA

NCBI chr19:5,874,736...5,895,508
Ensembl chr19:5,874,736...5,897,132

G

nebulin

decreases expression

benz(a)anthracene results in decreased expression of NEB mRNA

NCBI chr 2:52,026,652...52,228,810
Ensembl chr 2:52,026,659...52,268,486

G

N-terminal EF-hand calcium binding protein 1

decreases expression

benz(a)anthracene results in decreased expression of NECAB1 mRNA

NCBI chr 4:14,952,245...15,149,804
Ensembl chr 4:14,952,245...15,149,794

G

nectin cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA

NCBI chr 9:43,655,251...43,718,758
Ensembl chr 9:43,655,281...43,743,955

G

neural precursor cell expressed, developmentally down-regulated gene 9

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of NEDD9 mRNA

NCBI chr13:41,463,392...41,640,836
Ensembl chr13:41,463,057...41,640,838

G

nuclear envelope integral membrane protein 2

increases expression

benz(a)anthracene results in increased expression of NEMP2 mRNA

NCBI chr 1:52,669,850...52,691,078
Ensembl chr 1:52,669,862...52,691,078

G

neuraminidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA

NCBI chr 1:87,501,749...87,525,567
Ensembl chr 1:87,437,611...87,525,567

G

nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA

NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286

G

nuclear factor, erythroid derived 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA

NCBI chr15:103,156,640...103,166,809
Ensembl chr15:103,156,639...103,166,830

G

nuclear factor, interleukin 3, regulated

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NFIL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:53,121,245...53,136,914
Ensembl chr13:53,121,245...53,135,109

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, delta

increases expression

benz(a)anthracene results in increased expression of NFKBID mRNA

NCBI chr 7:30,121,156...30,128,173
Ensembl chr 7:30,121,157...30,128,171

G

nuclear factor related to kappa B binding protein

increases expression

benz(a)anthracene results in increased expression of NFRKB mRNA

NCBI chr 9:31,297,476...31,332,629
Ensembl chr 9:31,297,488...31,332,629

G

nerve growth factor receptor (TNFR superfamily, member 16)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA

NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561

G

non-homologous end joining factor 1

decreases expression

benz(a)anthracene results in decreased expression of NHEJ1 mRNA

NCBI chr 1:75,006,505...75,101,870
Ensembl chr 1:75,006,298...75,101,844

G

NHERF family PDZ scaffold protein 1

increases expression

benz(a)anthracene results in increased expression of NHERF1 mRNA

NCBI chr11:115,054,138...115,072,009
Ensembl chr11:115,054,167...115,072,007

G

NHL repeat containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA

NCBI chr19:56,536,682...56,591,935
Ensembl chr19:56,536,693...56,591,935

G

natural killer tumor recognition sequence

affects expression
multiple interactions

benz(a)anthracene affects the expression of NKTR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:121,542,244...121,585,908
Ensembl chr 9:121,548,235...121,585,909

G

NLR family, CARD domain containing 5

decreases expression

benz(a)anthracene results in decreased expression of NLRC5 mRNA

NCBI chr 8:95,160,963...95,253,900
Ensembl chr 8:95,160,984...95,253,900

G

nitric oxide synthase trafficker

decreases expression

benz(a)anthracene results in decreased expression of NOSTRIN mRNA

NCBI chr 2:68,966,144...69,019,674
Ensembl chr 2:68,966,144...69,019,674

G

notch 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA

NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675

G

NADPH oxidase organizer 1

increases expression

benz(a)anthracene results in increased expression of NOXO1 mRNA

NCBI chr17:24,915,208...24,919,504
Ensembl chr17:24,915,208...24,919,503

G

nephronophthisis 1 (juvenile) homolog (human)

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NPHP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:127,582,652...127,630,833
Ensembl chr 2:127,582,652...127,630,817

G

natriuretic peptide receptor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA

NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373

G

neuropeptide Y receptor Y1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA

NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444

G

NAD(P)H dehydrogenase, quinone 1

increases activity
multiple interactions
increases expression

benz(a)anthracene results in increased activity of NQO1 protein
1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased expression of NQO1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]

PMID:7587946 PMID:9029048 PMID:17253728

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA

NCBI chr11:98,658,758...98,666,233
Ensembl chr11:98,658,758...98,666,159

G

nuclear receptor subfamily 1, group D, member 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of NR1D2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:4,230,549...4,265,639
Ensembl chr14:4,230,569...4,265,642

G

nuclear receptor subfamily 1, group H, member 5

decreases expression

benz(a)anthracene results in decreased expression of NR1H5 mRNA

NCBI chr 3:102,846,974...102,871,607
Ensembl chr 3:102,846,974...102,871,449

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

nuclear receptor binding protein 2

decreases expression

benz(a)anthracene results in decreased expression of NRBP2 mRNA

NCBI chr15:75,957,364...75,963,539
Ensembl chr15:75,957,367...75,963,476

G

neuronal cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA

NCBI chr12:44,375,568...44,651,977
Ensembl chr12:44,375,668...44,648,747

G

neuregulin 4

increases expression

benz(a)anthracene results in increased expression of NRG4 mRNA

NCBI chr 9:55,127,506...55,190,937
Ensembl chr 9:55,127,506...55,234,128

G

nuclear receptor-binding SET-domain protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NSD1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:55,357,595...55,466,138
Ensembl chr13:55,357,595...55,466,138

G

neuron specific gene family member 2

increases expression

benz(a)anthracene results in increased expression of NSG2 mRNA

NCBI chr11:31,949,678...32,009,211
Ensembl chr11:31,950,463...32,009,202

G

neutral sphingomyelinase (N-SMase) activation associated factor

increases expression

benz(a)anthracene results in increased expression of NSMAF mRNA

NCBI chr 4:6,396,207...6,454,840
Ensembl chr 4:6,396,207...6,454,271

G

5'-nucleotidase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA

NCBI chr14:30,853,046...30,861,081
Ensembl chr14:30,853,010...30,861,081

G

neurotrophin 3

increases expression

benz(a)anthracene results in increased expression of NTF3 mRNA

NCBI chr 6:126,078,375...126,143,703
Ensembl chr 6:126,078,375...126,143,873

G

netrin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA

NCBI chr11:68,100,190...68,277,652
Ensembl chr11:68,100,190...68,291,649

G

nudix hydrolase 13

increases expression

benz(a)anthracene results in increased expression of NUDT13 mRNA

NCBI chr14:20,344,709...20,367,652
Ensembl chr14:20,344,765...20,367,646

G

nuclear FMR1 interacting protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NUFIP2 mRNA

NCBI chr11:77,576,566...77,608,792
Ensembl chr11:77,576,981...77,632,747

G

nuclear protein transcription regulator 1

increases expression

benz(a)anthracene results in increased expression of NUPR1 mRNA

NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033

G

nuclear RNA export factor 1

affects expression

benz(a)anthracene affects the expression of NXF1 mRNA

NCBI chr19:8,734,467...8,748,274
Ensembl chr19:8,734,437...8,748,286

G

neurexophilin and PC-esterase domain family, member 2

decreases expression

benz(a)anthracene results in decreased expression of NXPE2 mRNA

NCBI chr 9:48,229,303...48,264,749
Ensembl chr 9:48,229,306...48,264,754

G

neurexophilin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NXPH3 mRNA

NCBI chr11:95,400,671...95,405,380
Ensembl chr11:95,400,671...95,405,396

G

2'-5' oligoadenylate synthetase 1B

decreases expression

benz(a)anthracene results in decreased expression of OAS1B mRNA

NCBI chr 5:120,950,700...120,962,228
Ensembl chr 5:120,950,700...120,962,228

G

2'-5' oligoadenylate synthetase 2

decreases expression

benz(a)anthracene results in decreased expression of OAS2 mRNA

NCBI chr 5:120,868,398...120,887,949
Ensembl chr 5:120,868,398...120,887,918

G

O-GlcNAcase

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OGA mRNA
benz(a)anthracene results in decreased expression of OGA mRNA

PMID:26377693 PMID:27858113

NCBI chr19:45,738,698...45,772,274
Ensembl chr19:45,738,698...45,772,276

G

O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)

affects expression

benz(a)anthracene affects the expression of OGT mRNA

NCBI chr X:100,683,617...100,727,957
Ensembl chr X:100,683,666...100,727,957

G

olfactory receptor family 13 subfamily L member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OR13L2 mRNA

NCBI chr 3:97,317,533...97,318,495
Ensembl chr 3:97,314,766...97,329,336

G

olfactory receptor family 2 subfamily A member 54

decreases expression

benz(a)anthracene results in decreased expression of OR2A54 mRNA

NCBI chr 6:43,092,678...43,093,610
Ensembl chr 6:43,083,303...43,094,737

G

olfactory receptor family 55 subfamily B member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OR55B4 mRNA

NCBI chr 7:102,133,321...102,137,514
Ensembl chr 7:102,131,238...102,137,520

G

orosomucoid 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ORM3 mRNA

NCBI chr 4:63,274,107...63,277,748
Ensembl chr 4:63,274,399...63,277,748

G

oxysterol binding protein-like 3

increases expression

benz(a)anthracene results in increased expression of OSBPL3 mRNA

NCBI chr 6:50,270,307...50,433,334
Ensembl chr 6:50,270,310...50,433,181

G

purinergic receptor P2X, ligand-gated ion channel, 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of P2RX7 mRNA

NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495

G

proliferation-associated 2G4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PA2G4 mRNA

NCBI chr10:128,393,635...128,401,803
Ensembl chr10:128,393,635...128,401,856

G

poly(A)binding protein nuclear 1-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PABPN1L mRNA

NCBI chr 8:123,346,210...123,349,474
Ensembl chr 8:123,346,210...123,349,478

G

phenylalanine hydroxylase

decreases expression

benz(a)anthracene results in decreased expression of PAH mRNA

NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998

G

p21 (RAC1) activated kinase 3

decreases expression

benz(a)anthracene results in decreased expression of PAK3 mRNA

NCBI chr X:142,301,370...142,580,792
Ensembl chr X:142,301,587...142,580,792

G

palladin, cytoskeletal associated protein

decreases expression

benz(a)anthracene results in decreased expression of PALLD mRNA

NCBI chr 8:61,964,465...62,355,741
Ensembl chr 8:61,964,467...62,355,724

G

palmdelphin

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PALMD mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PALMD mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:116,711,911...116,762,896
Ensembl chr 3:116,711,907...116,762,636

G

PAN2 poly(A) specific ribonuclease subunit

affects expression

benz(a)anthracene affects the expression of PAN2 mRNA

NCBI chr10:128,135,106...128,157,227
Ensembl chr10:128,139,204...128,157,227

G

pantothenate kinase 3

decreases expression

benz(a)anthracene results in decreased expression of PANK3 mRNA

NCBI chr11:35,660,322...35,682,112
Ensembl chr11:35,660,311...35,682,112

G

pantothenate kinase 4

increases expression

benz(a)anthracene results in increased expression of PANK4 mRNA

NCBI chr 4:155,048,580...155,065,395
Ensembl chr 4:155,048,580...155,065,395

G

poly (A) polymerase alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PAPOLA mRNA

NCBI chr12:105,750,926...105,805,208
Ensembl chr12:105,750,953...105,805,203

G

progestin and adipoQ receptor family member VII

increases expression

benz(a)anthracene results in increased expression of PAQR7 mRNA

NCBI chr 4:134,224,315...134,237,548
Ensembl chr 4:134,224,008...134,237,546

G

prostate androgen-regulated mucin-like protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PARM1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PARM1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:91,665,559...91,771,870
Ensembl chr 5:91,665,474...91,774,753

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage

benz(a)anthracene results in increased cleavage of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

PAX3 and PAX7 binding protein 1

increases expression

benz(a)anthracene results in increased expression of PAXBP1 mRNA

NCBI chr16:90,810,925...90,841,267
Ensembl chr16:90,810,925...90,841,431

G

PDZ binding kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PBK mRNA

NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271

G

pre B cell leukemia homeobox 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PBX1 mRNA

NCBI chr 1:167,946,933...168,259,898
Ensembl chr 1:167,946,933...168,259,839

G

protocadherin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PCDH17 mRNA

NCBI chr14:84,680,626...84,775,005
Ensembl chr14:84,681,003...84,776,442

G

protocadherin alpha subfamily C, 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PCDHAC2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHAC2 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:37,276,731...37,320,716
Ensembl chr18:37,276,556...37,320,710

G

protocadherin gamma subfamily A, 9

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PCDHGA9 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHGA9 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:37,869,989...37,974,916
Ensembl chr18:37,869,989...37,974,923

G

piccolo (presynaptic cytomatrix protein)

increases expression

benz(a)anthracene results in increased expression of PCLO mRNA

NCBI chr 5:14,564,924...14,913,479
Ensembl chr 5:14,564,932...14,913,473

G

Purkinje cell protein 2 (L7)

increases expression

benz(a)anthracene results in increased expression of PCP2 mRNA

NCBI chr 8:3,673,369...3,675,547
Ensembl chr 8:3,673,371...3,675,545

G

Purkinje cell protein 4-like 1

increases expression

benz(a)anthracene results in increased expression of PCP4L1 mRNA

NCBI chr 1:171,000,833...171,023,837
Ensembl chr 1:171,000,831...171,023,837

G

proprotein convertase subtilisin/kexin type 4

increases expression

benz(a)anthracene results in increased expression of PCSK4 mRNA

NCBI chr10:80,157,117...80,165,583
Ensembl chr10:80,157,117...80,165,332

G

phosphate cytidylyltransferase 2, ethanolamine

decreases expression

benz(a)anthracene results in decreased expression of PCYT2 mRNA

NCBI chr11:120,500,888...120,508,784
Ensembl chr11:120,500,913...120,508,762

G

phosphodiesterase 4A, cAMP specific

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PDE4A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PDE4A mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:21,076,998...21,124,544
Ensembl chr 9:21,073,005...21,124,544

G

phosphodiesterase 5A, cGMP-specific

decreases expression

benz(a)anthracene results in decreased expression of PDE5A mRNA

NCBI chr 3:122,522,822...122,653,023
Ensembl chr 3:122,522,596...122,653,023

G

phosphodiesterase 6C, cGMP specific, cone, alpha prime

decreases expression

benz(a)anthracene results in decreased expression of PDE6C mRNA

NCBI chr19:38,121,220...38,172,391
Ensembl chr19:38,121,229...38,172,406

G

phosphodiesterase 9A

increases expression

benz(a)anthracene results in increased expression of PDE9A mRNA

NCBI chr17:31,605,079...31,695,284
Ensembl chr17:31,605,184...31,695,284

G

platelet derived growth factor receptor, beta polypeptide

increases expression

benz(a)anthracene results in increased expression of PDGFRB mRNA

NCBI chr18:61,178,194...61,218,139
Ensembl chr18:61,178,222...61,218,133

G

protein disulfide isomerase associated 2

increases expression

benz(a)anthracene results in increased expression of PDIA2 mRNA

NCBI chr17:26,414,973...26,418,108
Ensembl chr17:26,414,973...26,418,061

G

PDZ and LIM domain 5

decreases expression

benz(a)anthracene results in decreased expression of PDLIM5 mRNA

NCBI chr 3:141,945,346...142,101,480
Ensembl chr 3:141,945,351...142,101,454

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PEBP1 mRNA

NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690

G

platelet/endothelial cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PECAM1 mRNA

NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454

G

period circadian clock 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER1 mRNA

NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786

G

period circadian clock 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PER2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:91,343,699...91,387,028
Ensembl chr 1:91,343,704...91,387,046

G

period circadian clock 3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PER3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:151,081,475...151,129,167
Ensembl chr 4:151,088,109...151,129,122

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2

increases expression

benz(a)anthracene results in increased expression of PFKFB2 mRNA

NCBI chr 1:130,616,780...130,656,990
Ensembl chr 1:130,616,919...130,656,990
Ensembl chr 1:130,616,919...130,656,990

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PFKFB3 mRNA

NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888

G

post-GPI attachment to proteins 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PGAP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PGAP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:101,859,153...101,887,771
Ensembl chr 7:101,859,415...101,887,774

G

progesterone receptor

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of PGR mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of PGR mRNA]

NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612

G

PH domain containing endocytic trafficking adaptor 2

increases expression

benz(a)anthracene results in increased expression of PHETA2 mRNA

NCBI chr15:82,223,148...82,229,911
Ensembl chr15:82,223,143...82,229,944

G

PHD finger protein 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHF19 mRNA

NCBI chr 2:34,783,764...34,804,365
Ensembl chr 2:34,783,769...34,804,038

G

PHD finger protein 20-like 1

decreases expression

benz(a)anthracene results in decreased expression of PHF20L1 mRNA

NCBI chr15:66,449,354...66,519,821
Ensembl chr15:66,449,409...66,519,825

G

PHD finger protein 21A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PHF21A mRNA

NCBI chr 2:92,014,096...92,195,011
Ensembl chr 2:92,014,451...92,195,011

G

pleckstrin homology like domain, family A, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLDA3 mRNA

NCBI chr 1:135,693,823...135,696,872
Ensembl chr 1:135,693,857...135,696,874

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLPP1 mRNA

NCBI chr 1:106,099,599...106,321,975
Ensembl chr 1:106,099,482...106,321,980

G

phosphotyrosine interaction domain containing 1

increases expression

benz(a)anthracene results in increased expression of PID1 mRNA

NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901

G

polymeric immunoglobulin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIGR mRNA

NCBI chr 1:130,754,421...130,779,986
Ensembl chr 1:130,754,421...130,779,986

G

phosphatidylinositol glycan anchor biosynthesis, class T

increases expression

benz(a)anthracene results in increased expression of PIGT mRNA

NCBI chr 2:164,339,461...164,350,221
Ensembl chr 2:164,339,440...164,350,221

G

PIH1 domain containing 2

increases expression

benz(a)anthracene results in increased expression of PIH1D2 mRNA

NCBI chr 9:50,528,621...50,536,300
Ensembl chr 9:50,528,621...50,536,300

G

paired immunoglobin-like type 2 receptor alpha

increases expression

benz(a)anthracene results in increased expression of PILRA mRNA

NCBI chr 5:137,820,214...137,834,540
Ensembl chr 5:137,820,214...137,834,543

G

proviral integration site 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIM1 mRNA

NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086

G

PICALM interacting mitotic regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIMREG mRNA

NCBI chr11:71,932,867...71,938,197
Ensembl chr11:71,932,858...71,938,196

G

PIN2/TERF1 interacting, telomerase inhibitor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PINX1 mRNA

NCBI chr14:64,097,728...64,157,311
Ensembl chr14:64,097,813...64,157,308

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIP4P1 mRNA

NCBI chr14:51,164,672...51,168,306
Ensembl chr14:51,163,525...51,168,313

G

phosphatidylserine decarboxylase, pseudogene 3

affects expression

benz(a)anthracene affects the expression of PISD-PS3 mRNA

G

PITPNM family member 3

increases expression

benz(a)anthracene results in increased expression of PITPNM3 mRNA

NCBI chr11:71,938,354...72,026,715
Ensembl chr11:71,938,354...72,026,604

G

protein kinase inhibitor, gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKIG mRNA

NCBI chr 2:163,500,306...163,568,078
Ensembl chr 2:163,500,306...163,568,078

G

protein kinase N3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PKN3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKN3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:29,967,657...29,981,031
Ensembl chr 2:29,967,696...29,981,034

G

phospholipase A2, group IID

increases expression

benz(a)anthracene results in increased expression of PLA2G2D mRNA

NCBI chr 4:138,503,046...138,509,363
Ensembl chr 4:138,503,046...138,509,357

G

phospholipase A2, group VI

increases expression

benz(a)anthracene results in increased expression of PLA2G6 mRNA

NCBI chr15:79,170,428...79,212,915
Ensembl chr15:79,170,428...79,212,590

G

phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)

increases expression

benz(a)anthracene results in increased expression of PLA2G7 mRNA

NCBI chr17:43,879,009...43,923,093
Ensembl chr17:43,878,989...43,923,092

G

placenta-specific 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLAC8 mRNA

NCBI chr 5:100,699,455...100,720,119
Ensembl chr 5:100,701,591...100,720,111

G

plasminogen activator, tissue

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PLAT mRNA

NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860

G

phospholipase C, beta 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PLCB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:134,628,084...135,317,178
Ensembl chr 2:134,627,987...135,317,178

G

phospholipase C, delta 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCD4 mRNA

NCBI chr 1:74,581,175...74,605,137
Ensembl chr 1:74,582,047...74,606,953

G

pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 8

decreases expression

benz(a)anthracene results in decreased expression of PLEKHA8 mRNA

NCBI chr 6:54,571,883...54,622,808
Ensembl chr 6:54,572,096...54,622,824

G

pleckstrin homology domain containing, family D (with coiled-coil domains) member 1

increases expression

benz(a)anthracene results in increased expression of PLEKHD1 mRNA

NCBI chr12:80,739,375...80,770,990
Ensembl chr12:80,739,365...80,770,988

G

pleckstrin homology domain containing, family G (with RhoGef domain) member 6

increases expression

benz(a)anthracene results in increased expression of PLEKHG6 mRNA

NCBI chr 6:125,339,614...125,358,578
Ensembl chr 6:125,339,623...125,357,756

G

polo like kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK2 mRNA

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

polo like kinase 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK5 mRNA

NCBI chr10:80,192,293...80,201,323
Ensembl chr10:80,192,293...80,201,323

G

phospholipid phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PPAP2A mRNA

NCBI chr13:112,937,311...113,004,428
Ensembl chr13:112,937,326...113,004,428

G

phospholipid scramblase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLSCR2 mRNA

NCBI chr 9:92,157,655...92,179,805
Ensembl chr 9:92,157,655...92,179,805

G

plexin A2

decreases expression

benz(a)anthracene results in decreased expression of PLXNA2 mRNA

NCBI chr 1:194,302,020...194,499,177
Ensembl chr 1:194,300,526...194,499,177

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PMAIP1 mRNA

NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636

G

peripheral myelin protein 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PMP22 mRNA

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

PNN interacting serine/arginine-rich

affects expression

benz(a)anthracene affects the expression of PNISR mRNA

NCBI chr 4:21,846,621...21,876,475
Ensembl chr 4:21,847,583...21,876,475

G

paraneoplastic antigen MA2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PNMA2 mRNA

NCBI chr14:67,139,038...67,157,512
Ensembl chr14:67,148,619...67,158,472

G

pinin

decreases expression

benz(a)anthracene results in decreased expression of PNN mRNA

NCBI chr12:59,113,705...59,120,803
Ensembl chr12:59,113,670...59,120,784

G

polymerase (DNA directed), gamma 2, accessory subunit

increases expression

benz(a)anthracene results in increased expression of POLG2 mRNA

NCBI chr11:106,659,030...106,670,363
Ensembl chr11:106,659,079...106,670,363

G

polymerase (DNA directed), eta (RAD 30 related)

increases expression

benz(a)anthracene results in increased expression of POLH mRNA

NCBI chr17:46,482,281...46,513,567
Ensembl chr17:46,482,281...46,513,571

G

polymerase (DNA directed), kappa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POLK mRNA

NCBI chr13:96,617,195...96,679,087
Ensembl chr13:96,617,198...96,679,087

G

polymerase (DNA directed), mu

increases expression

benz(a)anthracene results in increased expression of POLM mRNA

NCBI chr11:5,777,860...5,788,831
Ensembl chr11:5,777,860...5,788,016

G

polymerase (RNA) I polypeptide B

decreases expression

benz(a)anthracene results in decreased expression of POLR1B mRNA

NCBI chr 2:128,942,891...128,969,980
Ensembl chr 2:128,942,915...128,968,514

G

paraoxonase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PON2 mRNA

NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455

G

POU domain, class 2, associating factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of POU2AF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POU2AF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:51,124,990...51,151,379
Ensembl chr 9:51,125,008...51,151,380

G

peroxisome proliferator activated receptor alpha

increases expression

benz(a)anthracene results in increased expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

decreases expression

benz(a)anthracene results in decreased expression of PPARGC1A mRNA

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

PTPRF interacting protein, binding protein 1 (liprin beta 1)

decreases expression

benz(a)anthracene results in decreased expression of PPFIBP1 mRNA

NCBI chr 6:146,788,107...146,933,523
Ensembl chr 6:146,789,985...146,933,523

G

peptidyl-prolyl isomerase G (cyclophilin G)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PPIG mRNA

NCBI chr 2:69,553,152...69,584,356
Ensembl chr 2:69,552,889...69,584,356

G

protoporphyrinogen oxidase

affects expression

benz(a)anthracene affects the expression of PPOX mRNA

NCBI chr 1:171,104,564...171,108,955
Ensembl chr 1:171,103,563...171,108,760

G

protein phosphatase 1, regulatory subunit 3C

decreases expression

benz(a)anthracene results in decreased expression of PPP1R3C mRNA

NCBI chr19:36,709,131...36,714,004
Ensembl chr19:36,709,131...36,714,053

G

protein phosphatase 4, regulatory subunit 4

increases expression

benz(a)anthracene results in increased expression of PPP4R4 mRNA

NCBI chr12:103,498,509...103,580,098
Ensembl chr12:103,498,542...103,580,090

G

protein kinase, AMP-activated, gamma 3 non-catalytic subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRKAG3 mRNA

NCBI chr 1:74,778,062...74,788,623
Ensembl chr 1:74,778,081...74,788,380

G

protein kinase C, beta

increases expression

benz(a)anthracene results in increased expression of PRKCB mRNA

NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625

G

protein kinase C, delta

multiple interactions

[rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; PRKCD protein affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with benz(a)anthracene]

NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167

G

protein kinase C, epsilon

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRKCE mRNA

NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347

G

prolactin

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

prolactin receptor

decreases expression

benz(a)anthracene results in decreased expression of PRLR mRNA

NCBI chr15:10,177,324...10,349,276
Ensembl chr15:10,177,324...10,349,266

G

proline dehydrogenase

increases expression

benz(a)anthracene results in increased expression of PRODH mRNA

NCBI chr16:17,889,593...17,907,147
Ensembl chr16:17,878,221...17,908,067

G

proline and serine rich 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PROSER2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PROSER2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:6,103,304...6,135,100
Ensembl chr 2:6,102,418...6,135,022

G

protein Z, vitamin K-dependent plasma glycoprotein

increases expression

benz(a)anthracene results in increased expression of PROZ mRNA

NCBI chr 8:13,110,583...13,126,026
Ensembl chr 8:13,110,914...13,126,026

G

PRP38 pre-mRNA processing factor 38 (yeast) domain containing B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PRPF38B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF38B mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:108,810,121...108,819,055
Ensembl chr 3:108,810,121...108,819,043

G

pre-mRNA processing factor 39

increases expression

benz(a)anthracene results in increased expression of PRPF39 mRNA

NCBI chr12:65,083,094...65,110,160
Ensembl chr12:65,083,107...65,110,160

G

pre-mRNA processing factor 40B

increases expression

benz(a)anthracene results in increased expression of PRPF40B mRNA

NCBI chr15:99,192,957...99,214,899
Ensembl chr15:99,192,968...99,214,899

G

pre-mRNA processing factor 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF4B mRNA

NCBI chr13:35,058,803...35,090,047
Ensembl chr13:35,059,285...35,090,047

G

proline rich 5 like

increases expression

benz(a)anthracene results in increased expression of PRR5L mRNA

NCBI chr 2:101,543,455...101,713,428
Ensembl chr 2:101,544,630...101,713,372

G

proline rich 7 (synaptic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRR7 mRNA

NCBI chr13:55,612,080...55,620,968
Ensembl chr13:55,612,080...55,620,967

G

proline rich Gla (G-carboxyglutamic acid) 3 (transmembrane)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRRG3 mRNA

NCBI chr X:71,005,769...71,016,328
Ensembl chr X:71,006,230...71,016,328

G

serine protease 12 neurotrypsin (motopsin)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS12 mRNA

NCBI chr 3:123,240,562...123,300,251
Ensembl chr 3:123,240,562...123,300,246

G

serine protease 23

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS23 mRNA

NCBI chr 7:89,156,988...89,176,399
Ensembl chr 7:89,156,991...89,176,395

G

pregnancy-specific beta-1-glycoprotein 23

decreases expression

benz(a)anthracene results in decreased expression of PSG23 mRNA

NCBI chr 7:18,340,268...18,350,426
Ensembl chr 7:18,340,268...18,350,426

G

PC4 and SFRS1 interacting protein 1

decreases expression

benz(a)anthracene results in decreased expression of PSIP1 mRNA

NCBI chr 4:83,373,917...83,404,700
Ensembl chr 4:83,373,917...83,404,696

G

proline/serine-rich coiled-coil 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PSRC1 mRNA

NCBI chr 3:108,291,120...108,295,547
Ensembl chr 3:108,291,155...108,295,547

G

polypyrimidine tract binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTBP1 mRNA

NCBI chr10:79,690,502...79,700,269
Ensembl chr10:79,690,261...79,700,605

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

prothymosin alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTMA mRNA

NCBI chr 1:86,454,442...86,458,434
Ensembl chr 1:86,454,448...86,458,434

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

benz(a)anthracene results in decreased expression of PTPN5 mRNA

NCBI chr 7:46,727,543...46,783,774
Ensembl chr 7:46,727,543...46,783,432

G

protein tyrosine phosphatase, non-receptor type 6

increases expression

benz(a)anthracene results in increased expression of PTPN6 mRNA

NCBI chr 6:124,697,670...124,715,672
Ensembl chr 6:124,697,670...124,715,677

G

protein tyrosine phosphatase, non-receptor type 9

decreases expression

benz(a)anthracene results in decreased expression of PTPN9 mRNA

NCBI chr 9:56,902,252...56,970,092
Ensembl chr 9:56,902,207...56,970,091

G

protein tyrosine phosphatase receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTPRB mRNA

NCBI chr10:116,111,407...116,225,443
Ensembl chr10:116,111,428...116,225,440

G

protein tyrosine phosphatase receptor type G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PTPRG mRNA

NCBI chr14:10,227,722...10,916,341
Ensembl chr14:10,227,722...10,916,220

G

PWWP domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PWWP4B mRNA

NCBI chr X:72,180,829...72,193,071
Ensembl chr X:72,180,838...72,193,056

G

RAB11 family interacting protein 1 (class I)

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RAB11FIP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RAB11FIP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:27,628,801...27,664,707
Ensembl chr 8:27,628,801...27,664,674

G

RAB44, member RAS oncogene family

increases expression

benz(a)anthracene results in increased expression of RAB44 mRNA

NCBI chr17:29,333,102...29,367,966
Ensembl chr17:29,333,119...29,367,954

G

rabaptin, RAB GTPase binding effector protein 2

affects expression

benz(a)anthracene affects the expression of RABEP2 mRNA

NCBI chr 7:126,027,596...126,045,079
Ensembl chr 7:126,027,931...126,048,417

G

RAD51 recombinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA

NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926

G

retinoic acid induced 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAI2 mRNA

NCBI chr X:160,500,032...160,562,490
Ensembl chr X:160,500,065...160,562,492

G

Ral GTPase activating protein, alpha subunit 2 (catalytic)

increases expression

benz(a)anthracene results in increased expression of RALGAPA2 mRNA

NCBI chr 2:146,079,326...146,354,174
Ensembl chr 2:146,081,799...146,354,264

G

receptor (calcitonin) activity modifying protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAMP3 mRNA

NCBI chr11:6,608,507...6,627,478
Ensembl chr11:6,608,521...6,627,475

G

Rap1 GTPase-activating protein

increases expression

benz(a)anthracene results in increased expression of RAP1GAP mRNA

NCBI chr 4:137,391,549...137,457,172
Ensembl chr 4:137,392,037...137,457,172

G

Ras association (RalGDS/AF-6) and pleckstrin homology domains 1

increases expression

benz(a)anthracene results in increased expression of RAPH1 mRNA

NCBI chr 1:60,509,997...60,606,233
Ensembl chr 1:60,521,451...60,606,263

G

retinoic acid receptor, alpha

increases expression

benz(a)anthracene results in increased expression of RARA mRNA

NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768

G

RASD family, member 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RASD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:75,940,572...75,950,741
Ensembl chr 8:75,940,572...75,950,741

G

RasGEF domain family, member 1C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGEF1C mRNA

NCBI chr11:49,791,996...49,871,050
Ensembl chr11:49,792,662...49,871,821

G

RAS, guanyl releasing protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGRP3 mRNA

NCBI chr17:75,742,849...75,836,049
Ensembl chr17:75,742,891...75,836,049

G

RAS-like, family 11, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RASL11A mRNA

NCBI chr 5:146,781,881...146,784,536
Ensembl chr 5:146,781,881...146,784,537

G

Ras association (RalGDS/AF-6) domain family member 4

decreases expression

benz(a)anthracene results in decreased expression of RASSF4 mRNA

NCBI chr 6:116,609,969...116,650,797
Ensembl chr 6:116,609,969...116,650,913

G

retinoblastoma binding protein 6, ubiquitin ligase

increases expression

benz(a)anthracene results in increased expression of RBBP6 mRNA

NCBI chr 7:122,568,980...122,601,780
Ensembl chr 7:122,564,909...122,601,780

G

RNA binding motif protein 15B

decreases expression

benz(a)anthracene results in decreased expression of RBM15B mRNA

NCBI chr 9:106,758,127...106,764,274
Ensembl chr 9:106,758,117...106,764,627

G

RNA binding motif protein 26

increases expression

benz(a)anthracene results in increased expression of RBM26 mRNA

NCBI chr14:105,344,187...105,418,475
Ensembl chr14:105,344,187...105,414,763

G

RNA binding motif (RNP1, RRM) protein 3

decreases expression

benz(a)anthracene results in decreased expression of RBM3 mRNA

NCBI chr X:8,005,214...8,012,119
Ensembl chr X:8,005,214...8,012,119

G

RNA binding motif protein 33

affects expression

benz(a)anthracene affects the expression of RBM33 mRNA

NCBI chr 5:28,521,817...28,624,242
Ensembl chr 5:28,522,119...28,624,237

G

RNA binding motif protein 39

increases expression

benz(a)anthracene results in increased expression of RBM39 mRNA

NCBI chr 2:155,989,159...156,022,649
Ensembl chr 2:155,989,159...156,022,158

G

RNA binding motif protein, X chromosome

increases expression

benz(a)anthracene results in increased expression of RBMX mRNA

NCBI chr X:56,428,708...56,438,405
Ensembl chr X:56,428,890...56,438,396

G

retinol binding protein 1, cellular

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RBP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RBP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:98,305,014...98,328,604
Ensembl chr 9:98,305,014...98,328,628

G

recombination signal binding protein for immunoglobulin kappa J region-like

increases expression

benz(a)anthracene results in increased expression of RBPJL mRNA

NCBI chr 2:164,244,996...164,257,368
Ensembl chr 2:164,245,061...164,257,368

G

retinol dehydrogenase 5

increases expression

benz(a)anthracene results in increased expression of RDH5 mRNA

NCBI chr10:128,749,457...128,755,906
Ensembl chr10:128,749,462...128,758,757

G

receptor accessory protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP1 mRNA

NCBI chr 6:71,684,413...71,787,694
Ensembl chr 6:71,684,545...71,787,694

G

receptor accessory protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP2 mRNA

NCBI chr18:34,973,642...34,980,516
Ensembl chr18:34,973,642...34,980,516

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

REV1, DNA directed polymerase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REV1 mRNA

NCBI chr 1:38,091,867...38,169,191
Ensembl chr 1:38,091,867...38,168,882

G

regulator of G-protein signaling 11

increases expression

benz(a)anthracene results in increased expression of RGS11 mRNA

NCBI chr17:26,421,500...26,430,295
Ensembl chr17:26,421,925...26,430,298

G

regulator of G-protein signaling 12

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RGS12 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RGS12 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:35,106,273...35,196,988
Ensembl chr 5:35,106,789...35,196,988

G

regulator of G-protein signaling 2

increases expression

benz(a)anthracene results in increased expression of RGS2 mRNA

NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899

G

regulator of G-protein signaling 3

increases expression

benz(a)anthracene results in increased expression of RGS3 mRNA

NCBI chr 4:62,478,079...62,621,256
Ensembl chr 4:62,478,084...62,622,238

G

regulator of G-protein signalling 7 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RGS7BP mRNA

NCBI chr13:105,082,412...105,191,438
Ensembl chr13:105,082,412...105,191,438

G

regulator of G-protein signaling 9

increases expression

benz(a)anthracene results in increased expression of RGS9 mRNA

NCBI chr11:109,116,174...109,189,013
Ensembl chr11:109,116,181...109,188,955

G

ras homolog family member B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RHOB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RHOB mRNA

PMID:26377693 PMID:27858113

NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009

G

ras homolog family member C

increases expression

benz(a)anthracene results in increased expression of RHOC mRNA

NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775

G

ras homolog family member U

decreases expression

benz(a)anthracene results in decreased expression of RHOU mRNA

NCBI chr 8:124,380,609...124,390,622
Ensembl chr 8:124,380,668...124,390,623

G

reproductive homeobox 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RHOX8 mRNA

NCBI chr X:36,963,657...36,979,643
Ensembl chr X:36,963,655...36,967,821

G

Ras and Rab interactor 2

decreases expression

benz(a)anthracene results in decreased expression of RIN2 mRNA

NCBI chr 2:145,613,647...145,729,536
Ensembl chr 2:145,517,135...145,729,536

G

RHO family interacting cell polarization regulator 2

increases expression

benz(a)anthracene results in increased expression of RIPOR2 mRNA

NCBI chr13:24,685,513...24,917,789
Ensembl chr13:24,685,508...24,917,799

G

ripply transcriptional repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RIPPLY3 mRNA

NCBI chr16:94,129,281...94,137,794
Ensembl chr16:94,129,279...94,137,794

G

regulator of microtubule dynamics 1

increases expression

benz(a)anthracene results in increased expression of RMDN1 mRNA

NCBI chr 4:19,575,036...19,606,932
Ensembl chr 4:19,575,162...19,606,932

G

RNA component of mitochondrial RNAase P

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RMRP mRNA
benz(a)anthracene results in decreased expression of RMRP mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:43,492,785...43,493,059
Ensembl chr 4:43,492,788...43,493,058
Ensembl chr 4:43,492,788...43,493,058

G

4.5S RNA

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RN4.5S mRNA

NCBI chr 6:47,631,855...47,632,028

G

ribonuclease, RNase A family, 10 (non-active)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNASE10 mRNA

NCBI chr14:51,245,208...51,248,218
Ensembl chr14:51,245,208...51,248,215

G

ribonuclease H2, subunit B

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RNASEH2B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNASEH2B mRNA

PMID:26377693 PMID:27858113

NCBI chr14:62,569,517...62,610,445
Ensembl chr14:62,530,038...62,610,441

G

ring finger protein 144A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNF144A mRNA

NCBI chr12:26,356,796...26,465,296
Ensembl chr12:26,350,963...26,465,253

G

ring finger protein 169

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNF169 mRNA

NCBI chr 7:99,569,461...99,630,537
Ensembl chr 7:99,569,461...99,629,655

G

U1b6 small nuclear RNA

affects expression

benz(a)anthracene affects the expression of RNU1B6 mRNA

NCBI chr 3:96,367,340...96,367,505
Ensembl chr 3:96,367,340...96,367,505

G

U2 small nuclear RNA 10

affects expression
multiple interactions

benz(a)anthracene affects the expression of RNU2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNU2-10 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:101,549,064...101,549,250
Ensembl chr11:101,549,064...101,549,254

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ROCK2 mRNA

NCBI chr12:16,944,808...17,038,275
Ensembl chr12:16,944,896...17,037,824

G

RAR-related orphan receptor gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RORC mRNA

NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583

G

RNA polymerase II associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPAP2 mRNA

NCBI chr 5:107,745,239...107,809,719
Ensembl chr 5:107,745,239...107,809,704

G

reprimo, TP53 dependent G2 arrest mediator candidate

increases expression

benz(a)anthracene results in increased expression of RPRM mRNA

NCBI chr 2:53,974,105...53,975,564
Ensembl chr 2:53,974,105...53,975,564

G

ribosomal protein S27-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPS27L mRNA

NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798

G

ribonucleotide reductase M1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM1 mRNA

NCBI chr 7:102,090,902...102,118,978
Ensembl chr 7:102,090,902...102,118,978

G

ribonucleotide reductase M2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM2 mRNA

NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145

G

RRN3 RNA polymerase I transcription factor homolog (yeast)

increases expression

benz(a)anthracene results in increased expression of RRN3 mRNA

NCBI chr16:13,598,563...13,632,705
Ensembl chr16:13,598,572...13,632,703

G

ribosomal RNA processing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RRP1 mRNA

NCBI chr10:78,236,196...78,248,877
Ensembl chr10:78,236,218...78,248,877

G

ribosomal RNA processing 12 homolog

decreases expression

benz(a)anthracene results in decreased expression of RRP12 mRNA

NCBI chr19:41,847,922...41,884,592
Ensembl chr19:41,851,290...41,884,612

G

retinoschisis (X-linked, juvenile) 1 (human)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS1 mRNA

NCBI chr X:159,548,815...159,584,800
Ensembl chr X:159,551,009...159,582,659

G

5.8S ribosomal RNA

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS5-8S1 mRNA

G

radical S-adenosyl methionine domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of RSAD2 mRNA

NCBI chr12:26,492,742...26,506,451
Ensembl chr12:26,492,745...26,506,451

G

regulator of telomere elongation helicase 1

increases expression

benz(a)anthracene results in increased expression of RTEL1 mRNA

NCBI chr 2:180,961,504...180,998,409
Ensembl chr 2:180,961,532...180,998,409

G

receptor transporter protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RTP3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RTP3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:110,814,003...110,818,781
Ensembl chr 9:110,814,003...110,819,651

G

RUN and FYVE domain-containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RUFY2 mRNA

NCBI chr10:62,815,947...62,852,988
Ensembl chr10:62,816,002...62,852,989

G

RUN and FYVE domain containing 4

increases expression

benz(a)anthracene results in increased expression of RUFY4 mRNA

NCBI chr 1:74,163,768...74,187,389
Ensembl chr 1:74,164,700...74,187,382

G

RWD domain containing 3

increases expression

benz(a)anthracene results in increased expression of RWDD3 mRNA

NCBI chr 3:120,949,046...120,965,427
Ensembl chr 3:120,949,047...120,965,344

G

S100 calcium binding protein A14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A14 mRNA

NCBI chr 3:90,434,156...90,436,144
Ensembl chr 3:90,434,163...90,436,144

G

S100 calcium binding protein A6 (calcyclin)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A6 mRNA

NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488

G

sphingosine-1-phosphate receptor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of S1PR1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S1PR1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721

G

serum amyloid A 1

increases expression

benz(a)anthracene results in increased expression of SAA1 mRNA

NCBI chr 7:46,389,921...46,392,404
Ensembl chr 7:46,389,921...46,392,404

G

serum amyloid A 2

increases expression

benz(a)anthracene results in increased expression of SAA2 mRNA

NCBI chr 7:46,401,257...46,403,737
Ensembl chr 7:46,401,214...46,403,737

G

serum amyloid A 3

increases expression

benz(a)anthracene results in increased expression of SAA3 mRNA

NCBI chr 7:46,361,422...46,365,100
Ensembl chr 7:46,361,422...46,365,124

G

SAC3 domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SAC3D1 mRNA

NCBI chr19:6,166,025...6,168,689
Ensembl chr19:6,166,030...6,168,680

G

sterile alpha motif domain containing 9-like

decreases expression

benz(a)anthracene results in decreased expression of SAMD9L mRNA

NCBI chr 6:3,372,257...3,399,458
Ensembl chr 6:3,372,257...3,399,572

G

sin3 associated polypeptide

increases expression

benz(a)anthracene results in increased expression of SAP25 mRNA

NCBI chr 5:137,639,735...137,641,164
Ensembl chr 5:137,639,596...137,641,164

G

stabilizer of axonemal microtubules 2

increases expression

benz(a)anthracene results in increased expression of SAXO2 mRNA

NCBI chr 7:82,282,166...82,297,777
Ensembl chr 7:82,282,168...82,297,736

G

stearoyl-Coenzyme A desaturase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

sodium channel, voltage-gated, type III, beta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SCN3B mRNA

NCBI chr 9:40,180,512...40,202,914
Ensembl chr 9:40,180,513...40,202,914

G

sodium channel, type IV, beta

increases expression

benz(a)anthracene results in increased expression of SCN4B mRNA

NCBI chr 9:45,049,922...45,065,453
Ensembl chr 9:45,049,693...45,065,450

G

short coiled-coil protein

decreases expression

benz(a)anthracene results in decreased expression of SCOC mRNA

NCBI chr 8:84,161,121...84,185,055
Ensembl chr 8:84,156,713...84,185,020

G

SCY1-like 3 (S. cerevisiae)

increases expression

benz(a)anthracene results in increased expression of SCYL3 mRNA

NCBI chr 1:163,756,669...163,782,695
Ensembl chr 1:163,756,669...163,782,695

G

stromal cell derived factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SDF4 mRNA

NCBI chr 4:156,077,300...156,098,067
Ensembl chr 4:156,077,329...156,098,067

G

secretory blood group 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEC1 mRNA

NCBI chr 7:45,327,110...45,343,825
Ensembl chr 7:45,327,110...45,343,826

G

selectin, lymphocyte

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SELL mRNA

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEMA3C mRNA

NCBI chr 5:17,779,814...17,935,266
Ensembl chr 5:17,779,279...17,935,266

G

septin 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN11 mRNA

NCBI chr 5:93,227,445...93,329,237
Ensembl chr 5:93,241,296...93,324,306

G

septin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN3 mRNA

NCBI chr15:82,153,003...82,178,775
Ensembl chr15:82,153,003...82,178,775

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERP2 mRNA

NCBI chr14:76,770,252...76,794,518
Ensembl chr14:76,770,254...76,794,329

G

serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10

increases expression

benz(a)anthracene results in increased expression of SERPINA10 mRNA

NCBI chr12:103,582,934...103,597,681
Ensembl chr12:103,581,045...103,597,703

G

serine (or cysteine) peptidase inhibitor, clade A, member 3F

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SERPINA3F mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINA3F mRNA

PMID:26377693 PMID:27858113

NCBI chr12:104,180,803...104,187,388
Ensembl chr12:104,180,803...104,187,388

G

serine (or cysteine) peptidase inhibitor, clade A, member 3G

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SERPINA3G mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINA3G mRNA

PMID:26377693 PMID:27858113

NCBI chr12:104,202,406...104,208,198
Ensembl chr12:104,202,504...104,208,198

G

serine (or cysteine) peptidase inhibitor, clade A, member 3H

increases expression

benz(a)anthracene results in increased expression of SERPINA3H mRNA

NCBI chr12:104,214,155...104,220,664
Ensembl chr12:104,216,411...104,219,928
Ensembl chr12:104,216,411...104,219,928

G

serine (or cysteine) peptidase inhibitor, clade A, member 3I

increases expression

benz(a)anthracene results in increased expression of SERPINA3I mRNA

NCBI chr12:104,229,304...104,235,768
Ensembl chr12:104,229,381...104,235,631

G

serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB10 mRNA

NCBI chr 1:107,456,724...107,488,469
Ensembl chr 1:107,456,757...107,477,001

G

serine (or cysteine) peptidase inhibitor, clade B, member 1a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB1A mRNA

NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

SERTA domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SERTAD2 mRNA

NCBI chr11:20,493,166...20,603,023
Ensembl chr11:20,493,253...20,603,021

G

sestrin 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SESN2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SESN2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

SET domain containing 1B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SETD1B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SETD1B mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:123,280,109...123,306,693
Ensembl chr 5:123,280,256...123,306,692

G

SET domain containing 4

increases expression

benz(a)anthracene results in increased expression of SETD4 mRNA

NCBI chr16:93,380,345...93,401,693
Ensembl chr16:93,380,345...93,400,951

G

Sfi1 homolog, spindle assembly associated (yeast)

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SFI1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFI1 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:3,081,850...3,153,344
Ensembl chr11:3,081,850...3,143,463

G

stratifin

decreases expression

benz(a)anthracene results in decreased expression of SFN mRNA

NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479

G

secreted frizzled-related protein 2

decreases expression

benz(a)anthracene results in decreased expression of SFRP2 mRNA

NCBI chr 3:83,673,628...83,681,621
Ensembl chr 3:83,673,628...83,681,623

G

sideroflexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFXN2 mRNA

NCBI chr19:46,561,798...46,585,340
Ensembl chr19:46,561,804...46,586,505

G

sphingomyelin synthase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SGMS1 mRNA

NCBI chr19:32,100,127...32,367,285
Ensembl chr19:32,100,127...32,367,114

G

SH3 domain protein D19

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SH3D19 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3D19 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:85,878,112...86,037,833
Ensembl chr 3:85,878,416...86,037,833

G

SH3 and PX domains 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA

NCBI chr19:47,248,613...47,453,053
Ensembl chr19:47,248,613...47,452,840

G

src homology 2 domain-containing transforming protein C3

decreases expression

benz(a)anthracene results in decreased expression of SHC3 mRNA

NCBI chr13:51,577,422...51,724,909
Ensembl chr13:51,585,077...51,723,523

G

SHC (Src homology 2 domain containing) family, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SHC4 mRNA

NCBI chr 2:125,469,359...125,566,085
Ensembl chr 2:125,469,367...125,566,068

G

shisa family member 2

increases expression

benz(a)anthracene results in increased expression of SHISA2 mRNA

NCBI chr14:59,862,730...59,869,109
Ensembl chr14:59,862,757...59,869,109

G

shieldin complex subunit 2

decreases expression

benz(a)anthracene results in decreased expression of SHLD2 mRNA

NCBI chr14:33,958,905...34,032,528
Ensembl chr14:33,958,990...34,032,450

G

sialic acid binding Ig-like lectin G

increases expression

benz(a)anthracene results in increased expression of SIGLECG mRNA

NCBI chr 7:43,057,623...43,067,773
Ensembl chr 7:43,057,628...43,067,782

G

sialic acid binding Ig-like lectin H

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SIGLECH mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SIGLECH mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:55,417,916...55,429,196
Ensembl chr 7:55,417,926...55,428,673

G

signal-induced proliferation-associated 1 like 2

increases expression

benz(a)anthracene results in increased expression of SIPA1L2 mRNA

NCBI chr 8:126,144,807...126,296,602
Ensembl chr 8:126,144,802...126,296,547

G

sirtuin 4

increases expression

benz(a)anthracene results in increased expression of SIRT4 mRNA

NCBI chr 5:115,616,065...115,628,322
Ensembl chr 5:115,616,069...115,622,784

G

src family associated phosphoprotein 1

increases expression

benz(a)anthracene results in increased expression of SKAP1 mRNA

NCBI chr11:96,355,396...96,650,448
Ensembl chr11:96,355,419...96,649,956

G

solute carrier family 15 (H+/peptide transporter), member 2

affects expression

benz(a)anthracene affects the expression of SLC15A2 mRNA

NCBI chr16:36,570,523...36,605,506
Ensembl chr16:36,570,539...36,605,324

G

solute carrier family 19 (thiamine transporter), member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC19A2 mRNA

NCBI chr 1:164,076,615...164,092,954
Ensembl chr 1:164,076,615...164,092,954

G

solute carrier family 22, member 28

decreases expression

benz(a)anthracene results in decreased expression of SLC22A28 mRNA

NCBI chr19:8,039,323...8,109,346
Ensembl chr19:8,039,574...8,109,346

G

solute carrier family 25, member 33

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC25A33 mRNA

NCBI chr 4:149,828,493...149,858,746
Ensembl chr 4:149,828,493...149,858,734

G

solute carrier family 25, member 45

increases expression

benz(a)anthracene results in increased expression of SLC25A45 mRNA

NCBI chr19:5,927,828...5,935,796
Ensembl chr19:5,927,836...5,935,906

G

solute carrier family 26, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A10 mRNA

NCBI chr10:127,007,262...127,016,690
Ensembl chr10:127,007,262...127,016,514

G

solute carrier family 26, member 11

increases expression

benz(a)anthracene results in increased expression of SLC26A11 mRNA

NCBI chr11:119,246,328...119,271,902
Ensembl chr11:119,246,383...119,271,905

G

solute carrier family 26, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A4 mRNA

NCBI chr12:31,569,813...31,610,054
Ensembl chr12:31,569,826...31,609,968

G

Slc2a4 regulator, pseudogene

affects expression

benz(a)anthracene affects the expression of SLC2A4RG-PS mRNA

NCBI chr 2:181,026,043...181,029,389
Ensembl chr 2:181,026,204...181,028,992
Ensembl chr 2:181,026,204...181,028,992

G

solute carrier family 2 (facilitated glucose transporter), member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A6 mRNA

NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010

G

solute carrier family 2 (facilitated glucose transporter), member 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A9 mRNA

NCBI chr 5:38,506,616...38,660,488
Ensembl chr 5:38,506,616...38,660,486

G

solute carrier family 30 (zinc transporter), member 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SLC30A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC30A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359

G

solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter), member D1

decreases expression

benz(a)anthracene results in decreased expression of SLC35D1 mRNA

NCBI chr 4:103,027,846...103,078,208
Ensembl chr 4:103,027,846...103,072,361

G

solute carrier family 35, member G2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA

NCBI chr 9:100,431,178...100,453,138
Ensembl chr 9:100,434,241...100,453,143

G

solute carrier family 36 (proton/amino acid symporter), member 2

increases expression

benz(a)anthracene results in increased expression of SLC36A2 mRNA

NCBI chr11:55,049,294...55,075,924
Ensembl chr11:55,049,296...55,075,903

G

solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2

increases expression

benz(a)anthracene results in increased expression of SLC3A2 mRNA

NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733

G

solute carrier family 43, member 3

decreases expression

benz(a)anthracene results in decreased expression of SLC43A3 mRNA

NCBI chr 2:84,766,943...84,788,853
Ensembl chr 2:84,766,923...84,788,853

G

solute carrier family 45, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC45A4 mRNA

NCBI chr15:73,449,267...73,517,606
Ensembl chr15:73,449,273...73,517,611

G

solute carrier family 46, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA

NCBI chr 5:147,812,707...147,831,670
Ensembl chr 5:147,815,247...147,831,625

G

solute carrier family 49 member 4

decreases expression

benz(a)anthracene results in decreased expression of SLC49A4 mRNA

NCBI chr16:35,514,432...35,589,740
Ensembl chr16:35,514,432...35,589,726

G

solute carrier family 50 (sugar transporter), member 1

increases expression

benz(a)anthracene results in increased expression of SLC50A1 mRNA

NCBI chr 3:89,175,553...89,177,878
Ensembl chr 3:89,175,553...89,177,877

G

solute carrier family 5 (sodium/glucose cotransporter), member 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A12 mRNA

NCBI chr 2:110,427,644...110,479,690
Ensembl chr 2:110,427,643...110,478,124

G

solute carrier family 5 (inositol transporters), member 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SLC5A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:91,855,210...91,884,361
Ensembl chr16:91,855,210...91,884,361

G

solute carrier family 66 member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC66A3 mRNA

NCBI chr12:17,038,649...17,050,385
Ensembl chr12:17,038,649...17,050,409

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

decreases expression

benz(a)anthracene results in decreased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

increases expression

benz(a)anthracene results in increased expression of SLC7A5 mRNA

NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433

G

solute carrier family 8 (sodium/calcium exchanger), member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC8A1 mRNA

NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806

G

solute carrier organic anion transporter family, member 2b1

increases expression

benz(a)anthracene results in increased expression of SLCO2B1 mRNA

NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547

G

SNF2 related chromatin remodeling ATPase 5, pseudogene

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SMARCA5-PS mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SMARCA5-PS mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:145,190,780...145,194,531
Ensembl chr 4:145,190,868...145,193,990

G

SMG1 nonsense mediated mRNA decay associated PI3K related kinase

affects expression

benz(a)anthracene affects the expression of SMG1 mRNA

NCBI chr 7:117,730,531...117,843,026
Ensembl chr 7:117,730,531...117,842,893

G

sphingomyelin phosphodiesterase 2, neutral

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SMPD2 mRNA

NCBI chr10:41,363,168...41,366,410
Ensembl chr10:41,361,638...41,366,365

G

SMAD specific E3 ubiquitin protein ligase 2

decreases expression

benz(a)anthracene results in decreased expression of SMURF2 mRNA

NCBI chr11:106,710,887...106,811,544
Ensembl chr11:106,710,892...106,811,541

G

snail family zinc finger 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]

NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734

G

synaptosomal-associated protein 23

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SNAP23 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNAP23 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:120,398,137...120,436,829
Ensembl chr 2:120,398,152...120,431,736

G

synaptosomal-associated protein, 47

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SNAP47 mRNA

NCBI chr11:59,297,967...59,340,868
Ensembl chr11:59,297,960...59,342,012

G

sushi, nidogen and EGF-like domains 1

affects expression

benz(a)anthracene affects the expression of SNED1 mRNA

NCBI chr 1:93,163,563...93,228,787
Ensembl chr 1:93,163,563...93,228,787

G

small nucleolar RNA host gene 11

affects expression

benz(a)anthracene affects the expression of SNHG11 mRNA

NCBI chr 2:158,217,633...158,228,394
Ensembl chr 2:158,217,558...158,228,071

G

small nucleolar RNA, H/ACA box 47

decreases expression

benz(a)anthracene results in decreased expression of SNORA47 mRNA

NCBI chr13:95,467,119...95,467,244
Ensembl chr13:95,467,108...95,467,245

G

small nucleolar RNA, H/ACA box 74A

decreases expression

benz(a)anthracene results in decreased expression of SNORA74A mRNA

NCBI chr18:35,690,083...35,690,280
Ensembl chr18:35,690,085...35,690,280
Ensembl chr18:35,690,085...35,690,280

G

small nucleolar RNA, C/D box 123

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNORD123 mRNA

NCBI chr15:32,241,991...32,242,078
Ensembl chr15:32,241,999...32,242,069

G

small nucleolar RNA, C/D box 3B1

decreases expression

benz(a)anthracene results in decreased expression of SNORD3B1 mRNA

NCBI chr11:87,334,063...87,334,277
Ensembl chr11:87,334,063...87,334,277
Ensembl chr11:87,334,063...87,334,277

G

small nuclear ribonucleoprotein 70 (U1)

decreases expression

benz(a)anthracene results in decreased expression of SNRNP70 mRNA

NCBI chr 7:45,025,878...45,045,177
Ensembl chr 7:45,025,877...45,045,166

G

syntrophin, basic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNTB1 mRNA

NCBI chr15:55,499,784...55,770,707
Ensembl chr15:55,499,784...55,770,345

G

sorbitol dehydrogenase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SORD mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SORD mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821

G

SRY (sex determining region Y)-box 17

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SOX17 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:4,561,154...4,567,624
Ensembl chr 1:4,561,154...4,567,577

G

SRY (sex determining region Y)-box 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SOX4 mRNA

NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696

G

spermatogenesis associated 1

increases expression

benz(a)anthracene results in increased expression of SPATA1 mRNA

NCBI chr 3:146,162,955...146,205,548
Ensembl chr 3:146,162,951...146,205,508

G

spermatogenesis associated 22

decreases expression

benz(a)anthracene results in decreased expression of SPATA22 mRNA

NCBI chr11:73,217,416...73,237,447
Ensembl chr11:73,220,567...73,236,870

G

spermatogenesis associated 2-like

increases expression

benz(a)anthracene results in increased expression of SPATA2L mRNA

NCBI chr 8:123,958,994...123,962,997
Ensembl chr 8:123,956,540...123,962,972

G

spermatogenesis associated 7

increases expression

benz(a)anthracene results in increased expression of SPATA7 mRNA

NCBI chr12:98,594,169...98,636,078
Ensembl chr12:98,594,416...98,636,074

G

SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SPC25 mRNA

NCBI chr 2:69,009,753...69,036,583
Ensembl chr 2:69,024,239...69,036,538

G

signal peptidase complex subunit 2 homolog (S. cerevisiae)

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPCS2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPCS2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:99,486,775...99,512,576
Ensembl chr 7:99,486,776...99,512,669

G

sperm flagellar 2

increases expression

benz(a)anthracene results in increased expression of SPEF2 mRNA

NCBI chr15:9,578,279...9,748,954
Ensembl chr15:9,578,279...9,748,954

G

Spi-B transcription factor (Spi-1/PU.1 related)

increases expression

benz(a)anthracene results in increased expression of SPIB mRNA

NCBI chr 7:44,175,419...44,181,511
Ensembl chr 7:44,175,417...44,181,495

G

spindlin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:51,254,523...51,306,588
Ensembl chr13:51,254,916...51,306,582

G

spondin 2, extracellular matrix protein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPON2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPON2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:33,370,862...33,375,596
Ensembl chr 5:33,355,528...33,375,799

G

speckle-type BTB/POZ protein

decreases expression

benz(a)anthracene results in decreased expression of SPOP mRNA

NCBI chr11:95,304,909...95,384,236
Ensembl chr11:95,304,906...95,384,232

G

spectrin alpha, non-erythrocytic 1

decreases expression

benz(a)anthracene results in decreased expression of SPTAN1 mRNA

NCBI chr 2:29,855,572...29,921,463
Ensembl chr 2:29,855,572...29,921,463

G

spectrin beta, non-erythrocytic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPTBN1 mRNA

NCBI chr11:30,049,395...30,218,384
Ensembl chr11:30,049,395...30,218,175

G

serglycin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRGN mRNA

NCBI chr10:62,329,612...62,363,224
Ensembl chr10:62,329,612...62,363,230

G

serine/arginine-rich protein specific kinase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRPK3 mRNA

NCBI chr X:72,818,011...72,822,531
Ensembl chr X:72,818,011...72,822,531

G

serine/arginine repetitive matrix 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SRRM2 mRNA

NCBI chr17:24,009,501...24,043,715
Ensembl chr17:24,009,506...24,043,715

G

serine and arginine-rich splicing factor 11

decreases expression

benz(a)anthracene results in decreased expression of SRSF11 mRNA

NCBI chr 3:157,716,552...157,742,304
Ensembl chr 3:157,716,110...157,742,276

G

serine and arginine-rich splicing factor 5

affects expression

benz(a)anthracene affects the expression of SRSF5 mRNA

NCBI chr12:80,992,308...80,997,277
Ensembl chr12:80,992,278...80,997,281

G

serine and arginine-rich splicing factor 6

increases expression

benz(a)anthracene results in increased expression of SRSF6 mRNA

NCBI chr 2:162,773,428...162,779,041
Ensembl chr 2:162,773,448...162,779,041

G

small RNA binding exonuclease protection factor La

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SSB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSB mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:69,691,963...69,702,185
Ensembl chr 2:69,691,906...69,702,190

G

sarcospan

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SSPN mRNA

NCBI chr 6:145,860,423...145,910,951
Ensembl chr 6:145,877,367...145,910,949

G

signal sequence receptor, gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSR3 mRNA

NCBI chr 3:65,287,078...65,299,974
Ensembl chr 3:65,287,076...65,300,044

G

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ST6GALNAC1 mRNA

NCBI chr11:116,655,851...116,666,333
Ensembl chr11:116,655,851...116,666,333

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ST8SIA4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ST8SIA4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:95,515,407...95,595,473
Ensembl chr 1:95,515,407...95,595,296

G

signal transducing adaptor family member 2

increases expression

benz(a)anthracene results in increased expression of STAP2 mRNA

NCBI chr17:56,304,074...56,315,558
Ensembl chr17:56,304,077...56,312,584

G

signal transducer and activator of transcription 2

decreases expression

benz(a)anthracene results in decreased expression of STAT2 mRNA

NCBI chr10:128,106,367...128,128,722
Ensembl chr10:128,106,428...128,128,718

G

staufen double-stranded RNA binding protein 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of STAU2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of STAU2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:16,299,027...16,591,228
Ensembl chr 1:16,298,898...16,590,336

G

stefin A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of STFA1 mRNA

NCBI chr16:36,097,510...36,105,733
Ensembl chr16:36,097,313...36,105,735

G

serine/threonine kinase 35

increases expression

benz(a)anthracene results in increased expression of STK35 mRNA

NCBI chr 2:129,642,437...129,674,207
Ensembl chr 2:129,642,437...129,674,207

G

storkhead box 2

decreases expression

benz(a)anthracene results in decreased expression of STOX2 mRNA

NCBI chr 8:47,633,083...47,866,943
Ensembl chr 8:47,633,083...47,899,397

G

syntaxin 17

increases expression

benz(a)anthracene results in increased expression of STX17 mRNA

NCBI chr 4:48,124,912...48,186,507
Ensembl chr 4:48,124,915...48,186,507

G

sulfatase 1

decreases expression

benz(a)anthracene results in decreased expression of SULF1 mRNA

NCBI chr 1:12,762,421...12,946,090
Ensembl chr 1:12,762,501...12,931,416

G

spectrin repeat containing, nuclear envelope 1

decreases expression

benz(a)anthracene results in decreased expression of SYNE1 mRNA

NCBI chr10:4,970,192...5,501,013
Ensembl chr10:4,970,917...5,501,482

G

spectrin repeat containing, nuclear envelope 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SYNE2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYNE2 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:75,865,092...76,157,702
Ensembl chr12:75,864,908...76,157,700

G

synaptojanin 2 binding protein

affects expression

benz(a)anthracene affects the expression of SYNJ2BP mRNA

NCBI chr12:81,538,968...81,579,685
Ensembl chr12:81,544,715...81,579,685

G

synaptotagmin X

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT10 mRNA

NCBI chr15:89,657,221...89,726,181
Ensembl chr15:89,666,596...89,726,063

G

synaptotagmin XV

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT15 mRNA

NCBI chr14:33,941,915...33,952,378
Ensembl chr14:33,941,552...33,952,377

G

synovial apoptosis inhibitor 1, synoviolin

decreases expression

benz(a)anthracene results in decreased expression of SYVN1 mRNA

NCBI chr19:6,096,586...6,103,748
Ensembl chr19:6,096,606...6,103,742

G

SZT2 subunit of KICSTOR complex

increases expression

benz(a)anthracene results in increased expression of SZT2 mRNA

NCBI chr 4:118,219,937...118,266,483
Ensembl chr 4:118,219,940...118,266,470

G

brachyury 2

increases expression

benz(a)anthracene results in increased expression of T2 mRNA

NCBI chr17:8,574,590...8,661,323
Ensembl chr17:8,574,824...8,642,345

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAB2 mRNA

NCBI chr10:7,781,412...7,832,039
Ensembl chr10:7,781,417...7,831,994

G

TATA-box binding protein associated factor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TAF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:100,576,335...100,644,635
Ensembl chr X:100,576,279...100,644,640

G

transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TAP1 mRNA

NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199

G

TatD DNase domain containing 3

increases expression

benz(a)anthracene results in increased expression of TATDN3 mRNA

NCBI chr 1:190,778,023...190,795,373
Ensembl chr 1:190,778,023...190,795,129

G

TBC1 domain family, member 10c

increases expression

benz(a)anthracene results in increased expression of TBC1D10C mRNA

NCBI chr19:4,234,356...4,241,194
Ensembl chr19:4,233,410...4,241,283

G

TBC1 domain family, member 2

increases expression

benz(a)anthracene results in increased expression of TBC1D2 mRNA

NCBI chr 4:46,604,390...46,650,396
Ensembl chr 4:46,604,390...46,650,209

G

T-box 21

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TBX21 mRNA

NCBI chr11:96,988,833...97,006,157
Ensembl chr11:96,988,897...97,006,157

G

T-box 3

increases expression

benz(a)anthracene results in increased expression of TBX3 mRNA

NCBI chr 5:119,808,600...119,822,789
Ensembl chr 5:119,808,734...119,822,789

G

TRPM8 channel-associated factor 1

decreases expression

benz(a)anthracene results in decreased expression of TCAF1 mRNA

NCBI chr 6:42,644,933...42,687,065
Ensembl chr 6:42,644,936...42,687,022

G

transcription elongation factor A (SII), 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCEA3 mRNA

NCBI chr 4:135,975,253...136,002,214
Ensembl chr 4:135,975,040...136,002,209

G

transcription elongation factor A (SII) N-terminal and central domain containing 2

increases expression

benz(a)anthracene results in increased expression of TCEANC2 mRNA

NCBI chr 4:106,991,352...107,035,563
Ensembl chr 4:106,991,352...107,036,313

G

transcription factor 12

decreases expression

benz(a)anthracene results in decreased expression of TCF12 mRNA

NCBI chr 9:71,751,534...72,019,611
Ensembl chr 9:71,749,970...72,019,153

G

transcription factor 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TCF19 mRNA

NCBI chr17:35,823,627...35,827,730
Ensembl chr17:35,823,631...35,827,721

G

transcription factor 7 like 2, T cell specific, HMG box

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCF7L2 mRNA

NCBI chr19:55,730,227...55,922,091
Ensembl chr19:55,730,252...55,922,086

G

treacle ribosome biogenesis factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCOF1 mRNA

NCBI chr18:60,946,827...60,982,055
Ensembl chr18:60,946,827...60,982,043

G

testis development related protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TDRP mRNA

NCBI chr 8:14,002,008...14,025,484
Ensembl chr 8:14,002,008...14,025,032

G

tec protein tyrosine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEC mRNA

NCBI chr 5:72,913,061...73,025,997
Ensembl chr 5:72,913,059...73,025,826

G

tectonin beta-propeller repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TECPR1 mRNA

NCBI chr 5:144,131,260...144,160,433
Ensembl chr 5:144,131,260...144,160,433

G

thyrotroph embryonic factor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TEF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEF mRNA

PMID:26377693 PMID:27858113

NCBI chr15:81,686,874...81,711,064
Ensembl chr15:81,686,622...81,711,064

G

testis expressed gene 11

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TEX11 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEX11 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:99,882,254...100,103,245
Ensembl chr X:99,882,254...100,103,273

G

transcription factor CP2-like 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TFCP2L1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TFCP2L1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:118,555,646...118,612,898
Ensembl chr 1:118,555,675...118,612,898

G

trefoil factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TFF1 mRNA; benz(a)anthracene results in increased expression of TFF1 protein
2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]]; [rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]]; fulvestrant inhibits the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]; fulvestrant inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; Go 6976 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]

PMID:22643241 PMID:26377693

NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251

G

trefoil factor 3, intestinal

decreases expression

benz(a)anthracene results in decreased expression of TFF3 mRNA

NCBI chr17:31,344,280...31,348,585
Ensembl chr17:31,344,280...31,348,620

G

tissue factor pathway inhibitor 2

decreases expression

benz(a)anthracene results in decreased expression of TFPI2 mRNA

NCBI chr 6:3,962,589...3,988,977
Ensembl chr 6:3,962,595...3,988,919

G

transforming growth factor, beta 1

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of TGFB1 mRNA

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

THAP domain containing 7

increases expression

benz(a)anthracene results in increased expression of THAP7 mRNA

NCBI chr16:17,345,823...17,349,975
Ensembl chr16:17,345,846...17,349,000

G

thrombospondin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of THBS1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THBS1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614

G

thyroid hormone receptor associated protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of THRAP3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THRAP3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:126,057,875...126,096,548
Ensembl chr 4:126,057,875...126,096,553

G

thrombospondin, type I, domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD4 mRNA

NCBI chr 9:59,874,214...60,429,394
Ensembl chr 9:59,874,214...60,429,329

G

thrombospondin, type I, domain containing 7A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD7A mRNA

NCBI chr 6:12,311,607...12,749,252
Ensembl chr 6:12,311,609...12,749,409

G

thymocyte nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of THYN1 mRNA

NCBI chr 9:26,910,950...26,918,632
Ensembl chr 9:26,911,006...26,918,632

G

TRAF-interacting protein with forkhead-associated domain

increases expression

benz(a)anthracene results in increased expression of TIFA mRNA

NCBI chr 3:127,582,524...127,592,043
Ensembl chr 3:127,583,454...127,625,813

G

tissue inhibitor of metalloproteinase 1

increases expression

benz(a)anthracene results in increased expression of TIMP1 mRNA

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

timeless interacting protein

increases expression

benz(a)anthracene results in increased expression of TIPIN mRNA

NCBI chr 9:64,188,776...64,212,704
Ensembl chr 9:64,188,863...64,212,706

G

TLC domain containing 3B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TLCD3B mRNA

NCBI chr 7:126,413,213...126,429,391
Ensembl chr 7:126,396,840...126,429,391

G

transducin-like enhancer of split 1

decreases expression

benz(a)anthracene results in decreased expression of TLE1 mRNA

NCBI chr 4:72,028,182...72,124,575
Ensembl chr 4:72,036,042...72,119,130

G

transducin-like enhancer of split 2

decreases expression

benz(a)anthracene results in decreased expression of TLE2 mRNA

NCBI chr10:81,410,573...81,435,018
Ensembl chr10:81,410,395...81,426,679

G

transducin-like enhancer of split 6

increases expression

benz(a)anthracene results in increased expression of TLE6 mRNA

NCBI chr10:81,426,738...81,437,021
Ensembl chr10:81,426,738...81,436,907

G

talin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TLN1 mRNA

NCBI chr 4:43,531,513...43,562,583
Ensembl chr 4:43,531,519...43,562,691

G

talin 2

decreases expression

benz(a)anthracene results in decreased expression of TLN2 mRNA

NCBI chr 9:67,124,371...67,541,357
Ensembl chr 9:67,124,369...67,466,985

G

toll-like receptor 1

increases expression

benz(a)anthracene results in increased expression of TLR1 mRNA

NCBI chr 5:65,082,023...65,090,945
Ensembl chr 5:65,082,022...65,090,906

G

toll-like receptor 12

increases expression

benz(a)anthracene results in increased expression of TLR12 mRNA

NCBI chr 4:128,509,239...128,512,412
Ensembl chr 4:128,509,236...128,512,412

G

transmembrane channel-like gene family 4

decreases expression

benz(a)anthracene results in decreased expression of TMC4 mRNA

NCBI chr 7:3,668,790...3,680,522
Ensembl chr 7:3,668,789...3,680,552

G

transmembrane protein with EGF-like and two follistatin-like domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEFF2 mRNA

NCBI chr 1:50,951,946...51,226,429
Ensembl chr 1:50,939,806...51,226,429

G

transmembrane protein 141

decreases expression

benz(a)anthracene results in decreased expression of TMEM141 mRNA

NCBI chr 2:25,510,078...25,512,059
Ensembl chr 2:25,510,079...25,512,017

G

transmembrane protein 150A

affects expression

benz(a)anthracene affects the expression of TMEM150A mRNA

NCBI chr 6:72,332,466...72,336,745
Ensembl chr 6:72,332,430...72,336,745

G

transmembrane protein 171

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM171 mRNA

NCBI chr13:98,822,744...98,832,142
Ensembl chr13:98,822,743...98,831,342

G

transmembrane protein 245

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TMEM245 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM245 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:56,866,923...56,947,456
Ensembl chr 4:56,866,923...56,947,437

G

transmembrane protein 25

decreases expression

benz(a)anthracene results in decreased expression of TMEM25 mRNA

NCBI chr 9:44,705,069...44,710,821
Ensembl chr 9:44,705,066...44,710,604

G

transmembrane protein 42

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM42 mRNA

NCBI chr 9:122,850,072...122,852,556
Ensembl chr 9:122,850,391...122,852,770

G

transmembrane protein 44

increases expression

benz(a)anthracene results in increased expression of TMEM44 mRNA

NCBI chr16:30,330,673...30,369,643
Ensembl chr16:30,330,673...30,369,660

G

transmembrane protein 80

decreases expression

benz(a)anthracene results in decreased expression of TMEM80 mRNA

NCBI chr 7:140,908,046...140,917,069
Ensembl chr 7:140,907,652...140,917,069

G

transmembrane protein 82

increases expression

benz(a)anthracene results in increased expression of TMEM82 mRNA

NCBI chr 4:141,341,544...141,345,944
Ensembl chr 4:141,340,687...141,345,944

G

tropomodulin 4

decreases expression

benz(a)anthracene results in decreased expression of TMOD4 mRNA

NCBI chr 3:95,030,110...95,036,520
Ensembl chr 3:95,031,787...95,036,520

G

tenascin C

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TNC mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TNC mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:63,878,022...63,965,554
Ensembl chr 4:63,878,022...63,965,252

G

tumor necrosis factor

multiple interactions
increases expression

[benz(a)anthracene co-treated with TNF protein] results in increased activity of AHR protein; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CCL2 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CXCL8 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CYP1B1 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of NEDD9 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of PTGS2 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of TGFB1 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of TNF mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein; [benz(a)anthracene co-treated with TNF protein] results in increased secretion of IL6 protein; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Curcumin inhibits the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA]; RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]
benz(a)anthracene results in increased expression of TNF mRNA

PMID:23396138 PMID:25433334

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 13b

increases expression

benz(a)anthracene results in increased expression of TNFRSF13B mRNA

NCBI chr11:61,017,567...61,040,435
Ensembl chr11:61,017,581...61,040,198

G

tumor necrosis factor receptor superfamily, member 13c

increases expression

benz(a)anthracene results in increased expression of TNFRSF13C mRNA

NCBI chr15:82,105,943...82,108,581
Ensembl chr15:82,105,944...82,108,570

G

tumor necrosis factor receptor superfamily, member 4

increases expression

benz(a)anthracene results in increased expression of TNFRSF4 mRNA

NCBI chr 4:156,098,049...156,101,070
Ensembl chr 4:156,098,300...156,101,069

G

tumor necrosis factor (ligand) superfamily, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFSF10 mRNA

NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576

G

tumor necrosis factor (ligand) superfamily, member 13, opposite strand

increases expression

benz(a)anthracene results in increased expression of TNFSF13OS mRNA

NCBI chr11:69,572,858...69,581,967
Ensembl chr11:69,572,842...69,590,215

G

TOG array regulator of axonemal microtubules 2

increases expression

benz(a)anthracene results in increased expression of TOGARAM2 mRNA

NCBI chr17:71,980,153...72,036,666
Ensembl chr17:71,980,256...72,036,664

G

TOX high mobility group box family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TOX4 mRNA

NCBI chr14:52,516,603...52,532,966
Ensembl chr14:52,516,603...52,533,858

G

thiamine pyrophosphokinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPK1 mRNA

NCBI chr 6:43,316,510...43,644,726
Ensembl chr 6:43,321,935...43,643,212

G

translocated promoter region, nuclear basket protein

decreases expression

benz(a)anthracene results in decreased expression of TPR mRNA

NCBI chr 1:150,268,544...150,325,686
Ensembl chr 1:150,268,589...150,325,686

G

tryptase beta 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPSB2 mRNA

NCBI chr17:25,585,282...25,587,070
Ensembl chr17:25,585,170...25,588,079

G

TRAF3 interacting protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRAF3IP3 mRNA

NCBI chr 1:192,857,812...192,883,854
Ensembl chr 1:192,857,761...192,884,011

G

tribbles pseudokinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRIB2 mRNA

NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923

G

tripartite motif-containing 11

increases expression

benz(a)anthracene results in increased expression of TRIM11 mRNA

NCBI chr11:58,865,054...58,882,288
Ensembl chr11:58,868,919...58,882,284

G

tripartite motif-containing 12A

decreases expression

benz(a)anthracene results in decreased expression of TRIM12A mRNA

NCBI chr 7:103,949,100...103,964,765
Ensembl chr 7:103,949,101...103,964,673

G

tripartite motif-containing 2

decreases expression

benz(a)anthracene results in decreased expression of TRIM2 mRNA

NCBI chr 3:84,067,746...84,215,659
Ensembl chr 3:84,067,746...84,214,184

G

tripartite motif-containing 35

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TRIM35 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRIM35 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:66,534,474...66,548,873
Ensembl chr14:66,534,480...66,548,873

G

transformation related protein 53

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRP53 mRNA; benz(a)anthracene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 protein]
benz(a)anthracene results in increased expression of TRP53 protein

PMID:22120587 PMID:27858113

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transformation related protein 53 inducible nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRP53INP1 mRNA

NCBI chr 4:11,156,441...11,174,379
Ensembl chr 4:11,156,431...11,174,379

G

transient receptor potential cation channel, subfamily C, member 3

increases expression

benz(a)anthracene results in increased expression of TRPC3 mRNA

NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316

G

transient receptor potential cation channel, subfamily C, member 6

increases expression

benz(a)anthracene results in increased expression of TRPC6 mRNA

NCBI chr 9:8,543,868...8,680,753
Ensembl chr 9:8,544,143...8,680,742

G

transient receptor potential cation channel, subfamily M, member 6

increases expression

benz(a)anthracene results in increased expression of TRPM6 mRNA

NCBI chr19:18,707,566...18,869,885
Ensembl chr19:18,727,347...18,869,875

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRPV4 mRNA

NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482

G

TruB pseudouridine (psi) synthase family member 2

increases expression

benz(a)anthracene results in increased expression of TRUB2 mRNA

NCBI chr 2:29,651,235...29,677,697
Ensembl chr 2:29,651,236...29,678,514

G

TSC22 domain family, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSC22D1 mRNA

NCBI chr14:76,652,401...76,745,205
Ensembl chr14:76,652,401...76,745,205

G

teashirt zinc finger family member 2

decreases expression

benz(a)anthracene results in decreased expression of TSHZ2 mRNA

NCBI chr 2:169,474,430...169,914,671
Ensembl chr 2:169,474,933...169,913,736

G

tsukushi, small leucine rich proteoglycan

increases expression

benz(a)anthracene results in increased expression of TSKU mRNA

NCBI chr 7:97,999,875...98,010,602
Ensembl chr 7:97,999,875...98,010,535

G

tetraspanin 1

increases expression

benz(a)anthracene results in increased expression of TSPAN1 mRNA

NCBI chr 4:116,019,078...116,024,818
Ensembl chr 4:116,019,066...116,024,798

G

tetraspanin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN17 mRNA

NCBI chr13:54,936,915...54,944,588
Ensembl chr13:54,937,190...54,944,589

G

tetraspanin 18

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TSPAN18 mRNA

NCBI chr 2:93,032,105...93,164,898
Ensembl chr 2:93,032,105...93,164,850

G

tetraspanin 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TSPAN4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:141,055,194...141,073,340
Ensembl chr 7:141,055,153...141,073,340

G

TSPY-like 3

increases expression

benz(a)anthracene results in increased expression of TSPYL3 mRNA

NCBI chr 2:153,064,290...153,067,361
Ensembl chr 2:153,064,290...153,067,361

G

tetratricopeptide repeat domain 16

increases expression

benz(a)anthracene results in increased expression of TTC16 mRNA

NCBI chr 2:32,647,038...32,665,688
Ensembl chr 2:32,647,038...32,665,645

G

tetratricopeptide repeat domain 19

decreases expression

benz(a)anthracene results in decreased expression of TTC19 mRNA

NCBI chr11:62,172,256...62,208,611
Ensembl chr11:62,172,299...62,219,277

G

tetratricopeptide repeat domain 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTC7 mRNA

NCBI chr17:87,590,328...87,689,197
Ensembl chr17:87,590,314...87,689,197

G

tubulin tyrosine ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTL mRNA

NCBI chr 2:128,907,867...128,938,203
Ensembl chr 2:128,907,862...128,938,203

G

tubulin tyrosine ligase-like family, member 6

increases expression

benz(a)anthracene results in increased expression of TTLL6 mRNA

NCBI chr11:96,015,283...96,057,008
Ensembl chr11:96,024,612...96,056,277

G

tubulin, beta 2A class IIA

decreases expression

benz(a)anthracene results in decreased expression of TUBB2A mRNA

NCBI chr13:34,258,261...34,261,991
Ensembl chr13:34,258,257...34,261,990

G

tubulin, gamma complex component 3

increases expression

benz(a)anthracene results in increased expression of TUBGCP3 mRNA

NCBI chr 8:12,664,277...12,722,141
Ensembl chr 8:12,664,277...12,722,248

G

taurine upregulated gene 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TUG1 mRNA

NCBI chr11:3,589,313...3,599,021
Ensembl chr11:3,589,785...3,599,673

G

TUB like protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TULP4 mRNA

NCBI chr17:6,156,528...6,290,912
Ensembl chr17:6,156,712...6,301,403

G

taxilin alpha

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TXLNA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TXLNA mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:129,519,870...129,534,867
Ensembl chr 4:129,519,871...129,534,858

G

tRNA-yW synthesizing protein 5

increases expression

benz(a)anthracene results in increased expression of TYW5 mRNA

NCBI chr 1:57,427,394...57,445,833
Ensembl chr 1:57,427,396...57,446,260

G

ubiquitin-conjugating enzyme E2G 1

increases expression

benz(a)anthracene results in increased expression of UBE2G1 mRNA

NCBI chr11:72,498,087...72,577,307
Ensembl chr11:72,498,109...72,577,307

G

ubiquitin family domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of UBFD1 mRNA

NCBI chr 7:121,666,318...121,681,422
Ensembl chr 7:121,666,398...121,681,417

G

ubiquilin 1

decreases expression

benz(a)anthracene results in decreased expression of UBQLN1 mRNA

NCBI chr13:58,323,970...58,363,467
Ensembl chr13:58,323,970...58,363,467

G

uncoupling protein 1 (mitochondrial, proton carrier)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of UCP1 mRNA

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

G

UDP glucuronosyltransferase 1 family, polypeptide A6A

decreases expression

benz(a)anthracene results in decreased expression of UGT1A6A mRNA

NCBI chr 1:88,062,531...88,147,724
Ensembl chr 1:88,062,531...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

multiple interactions
increases expression

Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of UGT1A6 mRNA]

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UPF3 regulator of nonsense transcripts homolog B (yeast)

affects expression

benz(a)anthracene affects the expression of UPF3B mRNA

NCBI chr X:36,355,331...36,374,124
Ensembl chr X:36,355,331...36,373,975

G

uroplakin 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK1A mRNA

NCBI chr 7:30,302,517...30,312,159
Ensembl chr 7:30,302,517...30,312,272

G

uroplakin 3A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK3A mRNA

NCBI chr15:84,901,342...84,906,761
Ensembl chr15:84,901,342...84,906,748

G

uroplakin 3B

decreases expression

benz(a)anthracene results in decreased expression of UPK3B mRNA

NCBI chr 5:136,067,350...136,073,847
Ensembl chr 5:136,067,350...136,075,341

G

USH1 protein network component harmonin binding protein 1

decreases expression

benz(a)anthracene results in decreased expression of USHBP1 mRNA

NCBI chr 8:71,836,918...71,848,480
Ensembl chr 8:71,836,916...71,848,446

G

ubiquitin specific peptidase 18

decreases expression

benz(a)anthracene results in decreased expression of USP18 mRNA

NCBI chr 6:121,222,865...121,247,876
Ensembl chr 6:121,222,865...121,247,876

G

ubiquitin specific peptidase 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of USP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of USP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:43,978,318...44,006,924
Ensembl chr 9:43,978,318...44,006,924

G

UTP14A small subunit processome component

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of UTP14A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTP14A mRNA

PMID:26377693 PMID:27858113

NCBI chr X:47,345,811...47,371,326
Ensembl chr X:47,345,739...47,371,330

G

utrophin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of UTRN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTRN mRNA

PMID:26377693 PMID:27858113

NCBI chr10:12,257,931...12,745,632
Ensembl chr10:12,257,932...12,745,109

G

vesicle-associated membrane protein 2

increases expression

benz(a)anthracene results in increased expression of VAMP2 mRNA

NCBI chr11:68,979,354...68,983,207
Ensembl chr11:68,979,316...68,983,210

G

vasohibin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VASH1 mRNA

NCBI chr12:86,725,474...86,742,462
Ensembl chr12:86,725,474...86,738,865

G

vav 3 oncogene

decreases expression

benz(a)anthracene results in decreased expression of VAV3 mRNA

NCBI chr 3:109,247,757...109,593,010
Ensembl chr 3:109,247,969...109,593,014

G

VSP16 CORVET/HOPS core subunit

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of VPS16 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VPS16 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:130,265,744...130,286,189
Ensembl chr 2:130,266,259...130,286,189

G

VPS39 HOPS complex subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VPS39 mRNA

NCBI chr 2:120,146,942...120,183,618
Ensembl chr 2:120,146,942...120,183,618

G

vaccinia related kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VRK2 mRNA

NCBI chr11:26,421,398...26,544,006
Ensembl chr11:26,421,322...26,543,999

G

V-set and immunoglobulin domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of VSIG2 mRNA

NCBI chr 9:37,450,551...37,455,501
Ensembl chr 9:37,450,551...37,455,501

G

V-set immunoregulatory receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VSIR mRNA

NCBI chr10:60,182,630...60,266,073
Ensembl chr10:60,182,630...60,208,463

G

von Willebrand factor A domain containing 3A

increases expression

benz(a)anthracene results in increased expression of VWA3A mRNA

NCBI chr 7:120,336,554...120,404,769
Ensembl chr 7:120,338,541...120,404,965

G

WASP like actin nucleation promoting factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of WASL mRNA

NCBI chr 6:24,613,809...24,665,185
Ensembl chr 6:24,613,804...24,665,008

G

WEE 1 homolog 1 (S. pombe)

increases expression
multiple interactions

benz(a)anthracene results in increased expression of WEE1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WEE1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493

G

WAP four-disulfide core domain 12

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of WFDC12 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WFDC12 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:164,031,151...164,032,528
Ensembl chr 2:164,031,151...164,032,528

G

WAS/WASL interacting protein family, member 3

increases expression

benz(a)anthracene results in increased expression of WIPF3 mRNA

NCBI chr 6:54,406,206...54,480,753
Ensembl chr 6:54,406,588...54,480,753

G

WT1 transcription factor

decreases expression

benz(a)anthracene results in decreased expression of WT1 mRNA

NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961

G

XIAP associated factor 1

decreases expression

benz(a)anthracene results in decreased expression of XAF1 mRNA

NCBI chr11:72,192,229...72,204,560
Ensembl chr11:72,192,455...72,204,559

G

X-box binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XBP1 mRNA

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

G

X-linked Kx blood group related, X-linked

increases expression

benz(a)anthracene results in increased expression of XKRX mRNA

NCBI chr X:133,049,786...133,086,747
Ensembl chr X:133,049,792...133,062,825

G

X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XPNPEP2 mRNA

NCBI chr X:47,195,790...47,225,859
Ensembl chr X:47,197,602...47,225,858

G

5'-3' exoribonuclease 2

increases expression

benz(a)anthracene results in increased expression of XRN2 mRNA

NCBI chr 2:146,854,672...146,919,922
Ensembl chr 2:146,854,916...146,919,920

G

Y box protein 1

increases expression

benz(a)anthracene results in increased expression of YBX1 mRNA

NCBI chr 4:119,134,524...119,153,462
Ensembl chr 4:119,135,178...119,151,801

G

yippee like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of YPEL5 mRNA

NCBI chr17:73,143,623...73,157,439
Ensembl chr17:73,143,448...73,158,190

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of YWHAZ mRNA

NCBI chr15:36,770,505...36,803,228
Ensembl chr15:36,771,014...36,797,173

G

zinc finger and BTB domain containing 11, opposite strand 1

increases expression

benz(a)anthracene results in increased expression of ZBTB11OS1 mRNA

NCBI chr16:55,793,631...55,794,980
Ensembl chr16:55,786,468...55,794,980

G

zinc finger and BTB domain containing 16

decreases expression

benz(a)anthracene results in decreased expression of ZBTB16 mRNA

NCBI chr 9:48,563,097...48,747,525
Ensembl chr 9:48,565,597...48,747,522

G

zinc finger and BTB domain containing 20

affects expression

benz(a)anthracene affects the expression of ZBTB20 mRNA

NCBI chr16:42,728,008...43,462,981
Ensembl chr16:42,696,244...43,462,965

G

zinc finger and BTB domain containing 38

decreases expression

benz(a)anthracene results in decreased expression of ZBTB38 mRNA

NCBI chr 9:96,564,820...96,613,728
Ensembl chr 9:96,564,823...96,634,884

G

zinc finger CCCH type containing 6

increases expression

benz(a)anthracene results in increased expression of ZC3H6 mRNA

NCBI chr 2:128,809,285...128,860,483
Ensembl chr 2:128,809,322...128,860,483

G

zinc finger CCCH type containing 7 A

increases expression

benz(a)anthracene results in increased expression of ZC3H7A mRNA

NCBI chr16:10,954,458...10,994,257
Ensembl chr16:10,954,456...10,994,257

G

zinc finger, CCHC domain containing 12

increases expression

benz(a)anthracene results in increased expression of ZCCHC12 mRNA

NCBI chr X:35,459,553...35,462,817
Ensembl chr X:35,459,557...35,462,811

G

zinc finger, DHHC-type containing 22

decreases expression

benz(a)anthracene results in decreased expression of ZDHHC22 mRNA

NCBI chr12:87,027,537...87,037,604
Ensembl chr12:87,027,537...87,037,204

G

zyg-11 related, cell cycle regulator

increases expression

benz(a)anthracene results in increased expression of ZER1 mRNA

NCBI chr 2:29,987,295...30,016,299
Ensembl chr 2:29,987,295...30,014,597

G

zinc finger, C3H1-type containing

affects expression

benz(a)anthracene affects the expression of ZFC3H1 mRNA

NCBI chr10:115,220,691...115,268,677
Ensembl chr10:115,220,864...115,268,677

G

zinc finger protein 280D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP280D mRNA

NCBI chr 9:72,181,900...72,271,061
Ensembl chr 9:72,182,142...72,271,059

G

zinc finger protein 33B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ZFP33B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP33B mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:104,718,441...104,734,141
Ensembl chr 5:104,719,508...104,732,487

G

zinc finger protein 346

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ZFP346 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP346 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:55,253,079...55,282,884
Ensembl chr13:55,253,124...55,282,638

G

zinc finger protein 365

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP365 mRNA

NCBI chr10:67,721,935...67,748,492
Ensembl chr10:67,721,933...67,748,492

G

zinc finger protein 367

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP367 mRNA

NCBI chr13:64,280,836...64,301,013
Ensembl chr13:64,280,832...64,301,016

G

zinc finger protein 36, C3H type-like 1

decreases expression

benz(a)anthracene results in decreased expression of ZFP36L1 mRNA

NCBI chr12:80,154,534...80,159,787
Ensembl chr12:80,154,528...80,159,787

G

zinc finger protein 511

increases expression

benz(a)anthracene results in increased expression of ZFP511 mRNA

NCBI chr 7:139,616,302...139,620,519
Ensembl chr 7:139,616,304...139,620,515

G

zinc finger protein 512B

increases expression

benz(a)anthracene results in increased expression of ZNF512B mRNA

NCBI chr 2:181,223,925...181,234,572
Ensembl chr 2:181,223,896...181,234,596

G

zinc finger protein 62

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ZFP62 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP62 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:49,093,556...49,109,643
Ensembl chr11:49,094,119...49,109,643

G

zinc finger protein 628

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP628 mRNA

NCBI chr 7:4,918,221...4,925,001
Ensembl chr 7:4,918,216...4,925,001

G

zinc finger protein 641

increases expression

benz(a)anthracene results in increased expression of ZFP641 mRNA

NCBI chr15:98,183,466...98,194,395
Ensembl chr15:98,183,466...98,194,042

G

zinc finger protein 664

decreases expression

benz(a)anthracene results in decreased expression of ZFP664 mRNA

NCBI chr 5:124,939,758...124,965,694
Ensembl chr 5:124,939,755...124,979,757

G

zinc finger protein 692

affects expression

benz(a)anthracene affects the expression of ZFP692 mRNA

NCBI chr11:58,197,883...58,205,971
Ensembl chr11:58,197,895...58,205,453

G

zinc finger protein 704

increases expression

benz(a)anthracene results in increased expression of ZFP704 mRNA

NCBI chr 3:9,492,070...9,675,145
Ensembl chr 3:9,492,080...9,675,145
Ensembl chr 3:9,492,080...9,675,145

G

zinc finger protein 710

increases expression

benz(a)anthracene results in increased expression of ZFP710 mRNA

NCBI chr 7:79,674,581...79,742,498
Ensembl chr 7:79,674,562...79,743,921

G

zinc finger protein 760

decreases expression

benz(a)anthracene results in decreased expression of ZFP760 mRNA

NCBI chr17:21,926,412...21,944,616
Ensembl chr17:21,926,723...21,944,617

G

zinc finger protein 783

increases expression

benz(a)anthracene results in increased expression of ZFP783 mRNA

NCBI chr 6:47,920,109...47,931,483
Ensembl chr 6:47,922,363...47,929,076
Ensembl chr 6:47,922,363...47,929,076

G

zinc finger protein 809

decreases expression

benz(a)anthracene results in decreased expression of ZFP809 mRNA

NCBI chr 9:22,136,980...22,165,413
Ensembl chr 9:22,137,010...22,154,650

G

zinc finger protein 930

decreases expression

benz(a)anthracene results in decreased expression of ZFP930 mRNA

NCBI chr 8:69,661,701...69,683,188
Ensembl chr 8:69,661,690...69,683,188

G

zinc finger protein 961

increases expression

benz(a)anthracene results in increased expression of ZFP961 mRNA

NCBI chr 8:72,704,910...72,724,177
Ensembl chr 8:72,704,882...72,747,636

G

zinc finger, FYVE domain containing 21

increases expression

benz(a)anthracene results in increased expression of ZFYVE21 mRNA

NCBI chr12:111,780,600...111,794,822
Ensembl chr12:111,780,604...111,798,626

G

zinc finger with KRAB and SCAN domains 3

decreases expression

benz(a)anthracene results in decreased expression of ZKSCAN3 mRNA

NCBI chr13:21,571,174...21,586,942
Ensembl chr13:21,571,173...21,586,925

G

zinc finger matrin type 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZMAT3 mRNA

NCBI chr 3:32,388,941...32,419,814
Ensembl chr 3:32,388,941...32,420,163

G

zinc finger, MYM-type 3

increases expression

benz(a)anthracene results in increased expression of ZMYM3 mRNA

NCBI chr X:100,447,990...100,464,986
Ensembl chr X:100,447,990...100,464,455

G

zinc finger, MYM-type 6

decreases expression

benz(a)anthracene results in decreased expression of ZMYM6 mRNA

NCBI chr 4:126,971,176...127,018,167
Ensembl chr 4:126,971,176...127,018,165

G

zinc finger, MYND domain containing 10

increases expression

benz(a)anthracene results in increased expression of ZMYND10 mRNA

NCBI chr 9:107,424,067...107,428,520
Ensembl chr 9:107,424,497...107,428,518

G

zinc finger, MYND-type containing 15

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ZMYND15 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND15 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:70,350,259...70,357,028
Ensembl chr11:70,350,259...70,357,028

G

zinc finger, MYND-type containing 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND8 mRNA

NCBI chr 2:165,626,072...165,740,896
Ensembl chr 2:165,626,072...165,740,936

G

zinc finger and SCAN domain containing 26

increases expression

benz(a)anthracene results in increased expression of ZSCAN26 mRNA

NCBI chr13:21,626,344...21,637,901
Ensembl chr13:21,626,350...21,637,900

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22355
role	22341
biological role	22340
aetiopathogenetic role	21309
carcinogenic agent	19735
polycyclic arene	17734
ortho-fused polycyclic arene	10092
tetraphene	1323
7-bromomethyl-12-methyltetraphene	0
benz[a]anthracene 5,6-oxide	0
tetraphen-1-ol	0
Path 2
Term	Annotations
CHEBI ontology	22355
subatomic particle	22350
composite particle	22350
hadron	22350
baryon	22350
nucleon	22350
atomic nucleus	22350
atom	22350
main group element atom	22239
main group molecular entity	22239
s-block molecular entity	21861
hydrogen molecular entity	21779
hydrides	20817
organic hydride	20365
organic fundamental parent	20365
hydrocarbon	19923
cyclic hydrocarbon	17967
arene	17948
polycyclic arene	17734
ortho-fused polycyclic arene	10092
tetraphene	1323
7-bromomethyl-12-methyltetraphene	0
benz[a]anthracene 5,6-oxide	0
tetraphen-1-ol	0

paths to the root